var title_f37_13_38096="Timolol: Patient drug information";
var content_f37_13_38096=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Timolol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/13/30932?source=see_link\">",
"       Timolol (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/60/22469?source=see_link\">",
"       Timolol (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11885 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38096=[""].join("\n");
var outline_f37_13_38096=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/13/30932?source=related_link\">",
"      Timolol (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/60/22469?source=related_link\">",
"      Timolol (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_13_38097="Seborrheic keratosis temple";
var content_f37_13_38097=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76720&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 229px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADlAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzmw1ELcS2luhjiiY77pVPB+h71mT6tFbs0lrNcvdbjmWWTOfXAPSqFxdqTNHDDJOEJJlB2r1+8TVJITsW4uIEnnl+WCAMef8AaNc6ir3ZvzNaIuRXEs12sdnm4nZssWbaOfc12NtobJ4aurzUpDLq1+4jtlMzRpEM9eDyPeuS0exjjKWw3tK0gMmxclyf4V+ldjcww6prMP2trkaPp6iNEcYYuOp9wKmpLlVkNRvLcZAZdJlS0Sdw8AxJOj5hT/d7k1zWr6yZtS3vJLOqE7Y1bHmE98VN4k1iOUP5OBAp2xpnBP19qo6TYai4F+YBZ2ZO37VcAhCD12f3sVMI/akXUnb3UdJprXVvpVxqk0clzdxjmFZCohXtuPTHtVvRdXsvDoj1OS2k1PUp15DE+WCem09vpWdqktlc/YdO8OXVzdyZEl2bhTHFn1AHWn6NZTaprMi3Nw0wjJZii4y3oD3AqV5lO60aNeLSL3UNUbUI3VdYl/eTWUufIjT03f3sdDXQnX7eRVtbBp4bm34m3jeyf7I/vfXtWbr+qWWkaYNOsHE19LxlxtZD/eb2rMsVs7SdI1ivZdc2g28kfCqfVj1P09Kxb5v0LjFL1O2sb9vKR9RYfMwMMcR+fPozd6m1CV7q52NeLNcyMMxq2Gij74HciuUkRowLjxW7SXErgwpFgRSH+7uXkNnsa6Tw5pRSNRPDCJ7xxugjP+q7je3c+1Qot7l3UV7upo2msXsF1DpFhaO9qGzBqF8xTb6hh3NX9UitreWFtYu59V1GR8QWpY7Sf9hBwB7mna7f20Fo9hpURu5mG25vH5XJ/gX39qZpNtY+ELIz6uTc6heARwyhPMZOPuPn7o/2hUtLVkpyRGLD7LJLe67diSaUALaxjEcXogx94j1qS6kmvSsIJjWQ/LCrY2D/AGz1z7VSvpJr2SKR1lmklIjWSNQEX2T1+vWuk/sSbStGjmvbqyitpFKmSIYmBPILE/yrNKTTk9jaUoxtFdSzaQJDHC087FoxsV5GCrHn/GriXkke0aeiTNgjzJRhR9W61jafp326S1leMxRBsRecSzyH+8x6Aelat8IrBxbSymSYrkpEm8sPUHpik22r9Cba2JtMkaMiXUpmcsMExjaF+lSXT/K7wO8UWcAuOWP0qonmzXNrbRxrBMQHY58yRh6ccCr2oRTMzTvMttEhCLFLjzcdCVFLWwaX1IbmRLWNF3yPNKoKxqdzsfTFQ2sV5dCRMyRZOQqnO31yex9qnsPMguHNpEy+WMGS4++SemAavWETq0gkYxueXyefrWdrsvmstCtFEWtXtIkJjzueT29qSeQwW8SKgLOMIv41oK5ZFW1CeSqE78ck1jwA/bDLhSyHEZI6DvgUpSSHD3rsc4+zeZvIad/mkcnJz6CpSxZFcNiMptBJ6DvVfVBLKx2xpFJIfuqckL3JqdAZrS38lEQJwSeenfHbNZrV6mnRCnbsR8ts3Fc7sbvapp5f9FN1AqsqEKVXIyfUk9aZKEuI4gPm8knBY/L/AIU0Sb4GAUlVOMYxj60XtoiWr2bFuUhe1jkLMzE7myTt/LuaZukfMsrfvCMKenAqxAzLJ5RLltny7l4I9aiDqGIyqoAc4HpSbY4pIRAjxOs0jDjKKvVmqhJK6Yd5mHGCx559h3q0JXaDzlG1ZMqJZRgfRRVdIkOWkXcy/dz1FEn0NIJXZDcuXlXmUIvJjJBZj6n0+lSpO+0tsZW252njA9qI1luJhFFGQScs/p9ajunJLNI5Z1O0n2HcUFWWxVh3szBnZAxwMHk5qxqDyKBbEMhjweTkrTYFYzLOr7F/h9SfX2ovwrXAIyzBdzY559c01cbXvIrxtJKpaQnjpg8modzZVcsTnhSeMepq0u5olijXarDk98/XtUcMRVG3YL7uQOaEWR3quHQB1JIz8vA//VTMvEqllJ/3s0rKzL8zAKBnJH6VJMhFqMYHTG481VxbWK4IZ3yWA7AH7tQuzDOS30HenqwOOvHJIHU0rLvB5wMdaEymivukBDLuXdxyaZISdpDnLjHHanMxDBRyB3NMdNyM6H516+1UmFkU5mZZFTL8EE4NFNkj3yqzEk5FFaRE4o8I1xBZ2iwO24yMcCIYLc9Ko2d3CswWcNLdsuPKCn5F9Pb60urtNe62ZEBlu3BOVHyxjtV6xjNnZyxWEm+eUf6TdE8e6ivZ2Wp8+i34S02W41o3UkbyWsD5dIpNpXjgA/1FXPFupfYrZbZWCR8kIW3Pj+eTVRtem07Qha2SlRJlSbhDHu9SprF0K2eaSXUbmJnCn5XlyEX3/wBr8Khxu+ZlRfLotzR8PaDcahPC19IkFrKceQTtkZfXnpXbaitpbvb6fYxXGoXCAJELmTzfIQe/QflVLQ5rqxmt5bWOG91e5Jx9oQMEX6f3adqmqWmiWcq2LxG8l3NNtOdzE+o6D2rKo3J8qNKcVdyKFtEIbvU5rV3dUISSV1xk9wp6Z+lJpusrpdkz2aI16zE7mYbV9APVvas+zl1bUIItLdSlrM5lfZJkH3PpWhPpts+spo1kqSyAKwECBkA7ln6mqa11K5kloGh2f2u4fX9ZuGdSSsZKfM8noqdsV1q28VjYNeamPstqxH7pmzNOewZuuD6DFTC0RdRiW4aAWdshxJaqVGccjpwfesH7abm8OtXDyrpVu5jt97b5Lhu23PXHrWMnd2RcIu1+rOpsruzFl9uuLUSmRTGtv5e+C2j9Oud5/SoNGsdRuLmSfTjJYaDCN/lyvveUjqA3Y4+oFM0m3m1uaKfWFENoW/0a2Xl29se/fNbOoX9xfakmjw+UyW4HmWsXReOAzdAvqKybS8xpN7C6fd6bqd8GRbmG2jJa3guHCeWvdgRgOTW3bSx2AuHj0+eOzI2gkAySfiTwK5vXb6xktzZ3jLql1GoVYbRR5cBHfcfT2qlb6drWs2AiuZp4tLVgIonkBEh9iOSPaouzRRWx01neRWV+93AFFyqfJZb1eKMe/Pyn3HNRrqGs3fnX17pDwgcxztC1wi89kGMn3NaHhzTdN0q32xaSI8AF54B5pz6n+Ifka1ZteN/cpDZXsFxHH8vmS5jYY7A8En61EuW1i1z30MiG9vGMcqb9SuiuCbhDHGme5UY/LmtW3iuXCNdeSoxk7dxB+ijHHtUV/cJaENfTGAt8y+YwbP8Au471XbWVk2o9wLcyNtiPEkrj12jhPqazubqPU3LOZorlVa7CSTcR29tGIyR9OSPxrS+z2lk7yJALiZR/rJyWYH8aoaULa1kIheJJCMvK/wA0h/GppbpbiSYwo0kirnJUjB9MnrRJu1jLk5pGhpkf2hy8ysypliTzTZ7l4IztkDTvlUB5JHtVWz1C5gtpPLtg00o27C33fdvT6VbjgSCBry7kUyY4dhx9B3pdEQ92SSrOII98OFC434wOfT3rL1acWksEEKrJcheUU9B/eY9qt31zcTaevz/ZrUYzLK+Hb/dX/GsjUdR2wJFZxNLcMMLJIuCw+nUj3PFRLQqkrsmmVolIikF1dTLuKL973xnoKtWH/HikRADcb8ck+gqHToG0+yM08sTzSp++lI3tg9h7CmaVFJcyRmFyLSNiWkPDP7L6UWNZPRmnKk8Ki3j2CYkb954iU9/c+1Phh+wWr+S4EIbJLDlzUuoxJBCJkRWVmG0HOB+Pc+9UDOb3cFJfyhtIU8A0pe67GME5LmHktK/my7ueBg9v6Co5YxcITH8lvnDSDq/+77U6Etgxs7BCMGOM/e9mNV9TucIoj+XYAsadganQ1UW3ZFtoh9nRXVSUG9Ix0A7Z96prlpgMllIywHFOYsxKLIZAqgMxO35j2z6VHIoSbklmOAdvT/69JlwVgIC2zS7juJ+WNW7e9VVUM7NIQWHRV4C/WrdwflKqgBHAxxuqCAFQ7uVwPvhev0obLirasbDF+7aYofLXqff2p0KqEeYyFUwck9/YUx5TxDv/AHXcelLOuLZfusQeOOlHMO1yvAcSMpLbCOR/iaVPlmZoyFIIA5zxTgrRksQpRsZPUZqNIy7sCRuGfu8UJsqwyQ/6RlySzcZH3RSzPuTdks3T2FROGk27G+VDycd/SiVVV9uWbA+YnnHqMVSYWK+BIPlV9p7g0gTAOQu30qVgS2UyqKOAO9RSNlVbGCegFNbjZXeNi53EDHQD+L6UrsJACpBAG0hR/OljHmSsG2qAM+pFMlTGfKTdz61S3E+xFtUNxjOaKntg0bIXUfMeQBmitIkSbufPEEUdh9ogsH+UnbI5GTJz0Wop/Ljlje7RIn4WO1gY/m3v61WuZby1dlkfypSSPJhwxVc9z60unQ/Z3a+vJJ1ZCGSNF3M/+9npXtW6ngX0sO8WNPLJaR6hIhcD5IY+Aien1NaV1qEm21hWGX7FHt2WbfLk+rGsiSS1w96ZTc3cjFmd+RGPSorYSXd0s7DzrqRgsaZ3E+20U+VMd1F3O/hl0nQLR57+8a/1O4Ib7LC4KjPRdw5H0rl5fnuJ7mZM7vuxQjbHFnoOeuK6vTPC1xbxrJexoZyu7e6bGQegXt9apavCkS2Onou/L+bMWKgY9WJ4A9654vWy1NlG8dA0PRvJ0o6hqUxVCpPlqdoc9s49aveGol0jKRkQX10pZioJKR56KO5qK51r+0dYh0zw+Dd+XHktFFwrdlGeD35rUsbiXw1b32p3Nw0epgGONSiM4OOvPQfTpUvmXzGrNWRV8fa9EZ7bTbdJ7KyVR50bAee59OP7350LaSz2yalqzR2UIULaWUK7nTHf0BrldI1G/wBRuJJba2a/1Jn5uJG3KCe+favRNO8KRxqlzrF/DqUhG+SKPciRH/b9aUkoRLjLmehSt9Uv7tIrLSYZLOWc+W14QXYfU9FA9BzXT/2bFpFoLaaZNSuj923tOFmc9S3fb65qrZ3yK7f2QGGov8kbRuRDaRj+NscZ9q2NC0t7VLq+ll2wqpZrmcbJJeOWX0B/WsH2NUZKRPp9/Bauls19eZH2dI/kiUjk++BXTTmOysYokcJDF8qqq53f7o6k1wuha7cRXt/qtq/n3dyPIUTwFl2Dpt7/AIiuq02w1qWFbm6+zRyvkl1YlyP7vTCj6c1Ek2rGkJKLuyxb3KXEk7ajJLbxxp8sKkmeYep28j6VpfZL9I4iFt7aHGYUuEWSTb7dl/Gq9i72NpJCtvaQIwLTXJnHmvnsWI60+OW8hVmFpCwYZ+e5LHHtgVm1bY0Tcncjl06yt7YCfRIZGdstNJ+8xnuOmKuWtnpnmxBYIo1X/WEQsDz/AHj0pllfXuoywQ232JsSbtyqz4x1GTwcVpLqt1ctPZQ3srzOQGSFBGiL6MQOM+nWkkKUnsixAunWbpKLyKBS2EWKYDI/3etFxd21xdyFL64jsET94AFdmf29P50trp+m6PasrQpcX85zHFDEC59gWyfxNX9P0wbRPqUVv57H93CqDZAPr3b1NDvczcluyBryaWxgij1SOwhPz7SEeVvTPpx+NRz/AGYTRwwT6heyk+Y7E/w+ozgCtcrCA0oCKiDcXjjHIHasWSZpYvtTyss10dqBlx5MYON+O4qG7sIxRfNlPMv2pY4LTfy0mfNnC9sZ4BqsjWcfnoimWQHEjdXc/wC0T/Km32oi72WWn3W+2iAElwYTkEdk7EmpLN3giENlaqiL8zGUjJPqfU/Wk30LpwdrktvAJ1CyESjbtSJQdg+vqaktZo3vXtY3Q+TwQedx9OOn41Vjtbm8uREbll3LvkES7VUen1q5AIrYtDboiRjoEX9c/wBaV2kNq9yC7Se9yL18WoJHkIcAfWrNgkcVs77fKjHyxxqOp9fc064Dy28bRIFjB5/iLH0zTDIscCrKcEn5fm5U+1T1uCV42RBgraMgj2ksN8jjBHPrVNIke42SAl4gSRj+dXNslwhbEgT++wy34D196kSPZC2MkscEseW9z71Nr7msZcpDaAAsWz93PTP60u6JFUupzntzx9KlYCOJsMqY/I+1VfLeD94WYludzDA/CkG7CSEzA+VlYwc7m+8fb2+tFqdyyCEqgPDMBzj29ajIeaZQSUB7g9TUsSG3kdD8/bgYA+tC7ja03KdxEse5Y8smeC3GTU+C9uoDZcj5gtSC1SWEyshEecZz1NLbbpN6ABio5LHAUdqaWonLSyKhxJlEBwo+6eM+9QQsFRY9oCk4JC/MT/nvVnYZXkKtlQOrf0qHzY45AUTMWOCOpPpTsUncimRlKqNyr1G7vUG1fNUN8pJ5NTuWkViVIIOBzjFNJjAwVYscZLHr7CgvYY8YUsVbcq/xetUirM3y4QHgnPIHtV65YxnYoyTUKLuKjHB/MfhTegRbtcr+WFPHTGB60jlY1GzJ9cCpp2ZSVxwvXuR9KgjwVYsApHTORmmUtUB2hFKHndyDRTc/MOmc4PHOKK0iS0fNrYvLucWcF1HCXYMzYCx8/wB49TWtomjeH7qZ5LrWNTXTo+JJpLJch+4xv+Ye9UrS8CxSWsDy3M5JzuyIo/w/iqxrczrYWtjBBHNcgbmZR92vaba0PnrX1G3ljb3dw50+9eXTFYrC4tfL872wSSPqa7PwPodtpl/He3f2jzlOQbUKTGPx4JrkrOaLSPJ+0fvbtxwkZBxntitu61O9ttLiuLm4hSZx+7tbdsyH03AdKynKS0RooqR1XivWrU3JbF9d3THKW7SAPjuTiuE1Oa9h1CVpIVQCMoRt83KnnHHHTrTvD0sf2+7kukW+vnG6ZfNKxp9SO/bFZdk82sa95dkwt/LYkpknaB159Md6UIWbKlPSyNK21GKxgCLe3NvLPlmltk3yNxgLz0FV7Hw9da1fwWsto0EG4yNuJLFf7xJ7mtLToLa8uJ7u4YnyiEjVOQAOuSOfyrotHvXumk+wLsRmxLM2SpUdlz3pSlygk2jftLGxs0hgh8qOKJcGUjB/HHes7xNrDKLe2hDrZz5UyAZkl/2VA9elULzW9Ot1b7TcKcHCxu+QT2zj738qoeG31bV9c+26cIY7xef7QuULC1Qf884+gPpWMYuTvI3bUFZbnZWNvp+iaFFf61HBb2zY8uxLbHB7Ar/EfasPWdX1nxZfpo1rby2umyKHeLIEhT1kI+4uO1dDrUFh4etH1nUri41zWZBhbm+GWL448tRwopngLRrmCzmuNUllTVdQYMyRgY2k/dPfpSvdtjT5Y+Zt6JpdnYQRWkDLHFGNokjG8H6HvXRXOoLaaEbS2fzJWY/MFKEfX14qGPT4Ybe5KO0EqKAkTfM0nPpXPedLqlxcR4MWn24xcXQfhc/wr6t7VlKUi4KL1K7Il46SOP8AiX25yGbkzSd2PsKksrmbWlMdmTb6YGIe4Yczeqx+nuaguYrzWbqLT40+yaVGMbcYkmj759FPp1rp7WO3ZYkDNBYQDhwnLdtoHpWaZvKRoadpz6ja2dno8SW8FjE5MoUKMnsh6kn1NXLESWlgNO0yGJWDA3F453Rhvb++30rDKz67qQstJmFlp6RiOeQH94/P3Vx0rqNZFvoGkwpEmPJQqmXzj/69W3pc5bXlyojlaOwm2W8UNrPMAJZRlnc/U9/arLXBiSNDO0cZGc7BuY+tZOm2eLm2u7n55Nu6OPk+V/tNnq3tV6fyiktzM4tbWAMXmmbr6+wrOTui0lcytYnknng06N5d9x/Cp4255z9aQWo3XX2dghDeXPeYIGOnlxqf1NU9Nt4tfuW1m63R6VkrbptIedR/ET2X0x1rXupZBGuzEcQwqQlckj2HXms2rI3T5nZCTgW0EVtACiqAI1RgQR6t6GmzrOifLJ+9ZtqqGHL/AOApk9yS+y4XyHBCkAZH4052i+3rNbwtIyJgI3zFm9V9BUWe5d+VFiGM2dsVkmn3gHzZAwOW749qghdpgkhM7ROhxh8D2NR35kxFZfc8xfPn252ovp689Kp7FMLCPciKw/ehsDaOgx3qndjgk0XrmUvEokkMmOAm/wDnVmBljgUR7pDjJES8D8TVaziIXdJbIpjGUAXG0f3vc0s8nnSi3f5kZd7AZVce+OhqbWHvoi1HK53vKxIHAjXqT7nv+FKXV/ugRDrtz3qNG3sWVj5RGAP6CoPM/foAi4Pdm5BpMaitywqyBwGG7+LbmpWDrLiRyGYd+w9qZEhz5c0bicnIPYj61NevENiQOvOdwIPX0yaXLZXIbu7IgRovO+QgvEeo4J+tNnJuJWkfgngt7elVrQM1zceX8oOAfeppAoG3PbjHNTfQtxSeopG+HG8tHn5VyRimQA72AfEePmUDHFOfaoXIyo/Q04xuibWGCTkLjHH1oTYWSKzS7k2hsY6cZNVkQB1XKgM3pnBq1KFR9wwGUY4NRSjdtkyMDrk45qxplW8lijkdd27bgFiOtJNiNY2LBnYHCf3PTn1pl1blVSQlWYnoD1pyRmZgqjIHPqaV2aJIrb2MZ5PB9MmljYocbl6Z7Zq0xWGKXDFWYc571QZd3+r596WxSsx5iJl3NuY+5AFMuFw5BAyemOlSqFZArHeoAPbOfSorkEE8lmz0B6CrixWIkiAfLjIzxiinkEbOGZQQR2oqokyPmV9TNncudzrBuOWXjn0q5pj6pqdw7WckywyffldAAg/Glh8Of6VPc3lxHHYW/wC8bzf4j2GO5zVK612e7It4JPstspyzqCCVHoPWve30R86jc0+0SzvY4dPb7TdSPzLcMPKB7l/QVFqdxb24uJEkWN3JWa/QDMh7rCvp71z17eLMnk+S62nBBxh7j6mnJbG5ljkvYC0Q+WK2jJbA98dKOW2rK5uxr+GUvdStn+wQ2+n6WoK+c5wzDuS3c98V0mk6ba6Po80sd9tW8JCzEAMU7+/Pasm9kuLzT7FWENpbREAR7fLx+X3jUl7e20UsCIJLiWEZad2zx6AVlO8hwS6lm1MjtKumR3UNo2UVVT53x3z2+tQ6jNcjyrae4Eky42WVo+dv/XRx096qT6lcAiOWSU+cS8VvCScD1Y10OgaNEkLXOotHbRM2AkmWdz746+wqX7urNou+xFpXhqzZUmuZxPfn52lGDawjPRAfvNXexXk+j6JJJYQR2linzTXtyhEknptU8mqulTWdhArXFut1LIePMUFwP93oo+nNRR3V3rV2bidom0yB/wBzblSRvHcE9frXPKTkzSKUR2g2Nx4k1RNa1Z7h7WPmOCU4APY4HT6V263s9hOiwxCaaZ9kQi5Ofy4AqLTL2zsLNvOC+d955imQv9M1QGpvYXp1XZ52o3IMdhbkDhf+ejY+7+NRe702Hunc6DxLrr6Vbm0WQtq8yY82Nt4izwcDHXFYEFittaW89/GuyI5t7YfxyH+NwPvNUf2yS08uRHl1W9Z9pk2KsPmk9A38WO4HNXp7IWRkuNYmJuSuS6kbV/DtWc7t3RdPRFvTrKURzXEs0fmy/NcSmQAIPQDtU6mK8tY57gzxeHrfmW6bgyc42xg9v9qqKWrXtj9v1ALZ6Qi747b7rz4/jc9lPYVr6GW1OOyvtU06V4mfzLKGZiE2Afedf5Zpwj1FVldaG6l7p5tlNpaRW2dqqmPmZByGB+nesMNDrPiJ7srJ9ihcLChcjfJ/eNJrt0DeXcFssaX88gXyyuPLjI5c9hUe9yyWGnDfBCPLLjjdnqcnpUyfM7ipxSRr6lqItr3yUcOwTkggD/gR7D3rE1Kym8R3NraSPJJEzDfEvEYTryO4PqanZbTTYWlvWXYg3CPbne3oB1NMs9WWGN528+Pz/mMqARov+xubn8hUKOt2bvRaHQzReUm4QO7RYjiRTt6cAY9BWTrN6bXEssu24Y+Wg3bR9fwrG1K9vlZriWe30u0TADM++4mz/dUngf7RFc+1xC90JIlF/MCX3vmRT/u84Huabg2KMlHc7G3u4IbVzFcQkAkl5QfmPfAPWudvPGaWbvFoKhkAJlnmUs5cn+D0HtWPJ/ausxM9xY+WkfCFHwHB6knoMelZMz+XAJLg2kcEbFI1ALMT6mt4UdNTCpWV7Ikv/EmvTNIr3F23mEPOIBjcueFPt9Kq3OpKsebWK+jlLbnkkOQo7DFZ3hm5ivtSuQbxp7uJt6GNSdg/3ByRVnWJLi5e3vrcM8ZlIFxMpDN9EHUZ7GtXRRn9YktEXrLxhqek3cTR6hHeWzkL8xMjx59e34V0dr4tvGvnikkhnkcgAjAX8a4K51JNj3Wp+XC5+SMbBFvP94Y4Aqlp10m+WP7XbQrI27jBA+nvUSopmsMQ1uey2fiqC74lmaCVX2BV+4pq9DqVldXCC3uo2kz1dsZNeKvq0zssFuYJIiS2W4wR7ipLfUrgwSxXduGCLvHlP8m3uR3J+lZSwzOiOIW59BC5mhQmQN5ZXqT8uaQMrqFySTycjCj8a8H8Ma/rOm6hCsN+89lMNyRyuWXHYEHoa9g0fUU1KyaVZgrkjCv0z3rCpTcXZmsWmro1LVFW4cO/LDeox17VYDKEy5BY8BCOB+NVI5JBN8kheOVcDCjIx71MrBogW3kKceuRWVrDerGJg7lHQnLEDOPpUjNI6KoZ8IPlLc/nTLqUCNijOEHoP88UtuSIgS7BkG4kHg+1FrDa0uV5FXOGYlv73rUd3kRqGJ2lsdck+9Sb2DGSPO4fxNg8H0qtcO3lYlJ3KfWkWlqNljV1UKQQByT2pls6QFT5j5PA28c1G3zAEHjoM8CmRpskycs2fTgUrmnKSTRooPALN071GF2psBGPU1PcgmT+8Ooye1VmJU5jO8dwO3+NNhFaD1CxIx25x26VWnKhAVx8p4PQ1PEWlJAUnHZv8aikQCUnZnBIPoKaE99SFVzjcSpJ5JPJopSxTp/CRx2oq4vQUj5Y1nUv7Q1Kd5ZSqhywZuRj2HrWc2GmTyodzOfkBOWz9KtPZ3FzcSyKqQ2wcjzpBtB+gPWtbTZLbSH3wJHd379JZxgRD2Xv+NfQ/CrI+Z1ZFZ6RFFtfWm23Dn5VY4Ue/wD9aumgvray054NKhVVz885XaGP0PNYNzeT3sTpCn2m6k4kuZEwqj0X+6KgLNEnkX5aSNB+72fdz7kVDTluaK0Rup3Akvd2A7nChAxOT6j0rQhtr1pkSIx2qIu9yPnlcdyc9KisJRGhaOLbMxAWfO51X0Uf41syx3JljsbK0EE9ycmWV90h/wBo+gqXLoVGN02zXtjBplgk16WiRsMCxHmMOy475q5Z/atavhHFE2cbvOmOxY09Pc1oWug6d4ft1uLqQXt8qjzLqdshf9lQelF1dS21h9pu7VknunIihU/PIvbOOg9a5JNNnTG9iY2+wm1t5TPM5w88h2qg/wBkdzXTaVZwxpF5QjjtIvkTnLEnqcVzvh2xWANLdN5t1J1JGFQf3R6Vc8ReJH094dP0m2e61K4/dRW8QzjPfP65rOzeiK82SeILyNLlNJsp2mdnDvFG275+24Ece9C6dFpjy3GszR3V7sw9yx+VP9hR7dK0fDOh/wDCPW8skybdWuBuuZy2Qg7gev1rG1NotZlHlR77KKTCsxz5gHU59BSfZAnfXodJYTvbWUF350Eca7mjDD50GOXORx7VSgRtSlF7qKlNL3ZERGXmI6M/t7VnT3MV3eR20ayNalgqxxAs02B19lBqHXbvUNR1iPQdHnNnJgfaZRw6r2APO39KjluzVOx0Yvk8S6rL54ZdK08Bkt5FAMp7F/RR2HeurGsXX2SSV99rZv8AI15L/r5QP4Uj6KPeuW0a1jtrJbSaaOSKE79rHdHC39492Y/Wq+tTtLqEMdyplyAYIS3zv/tMOyin5Izsnqy5E39qa3MlvHPDbQEMsjkk5Pc5+99M1uraOIZPKlaRDnO5vLyO+cf40zw1p84tCiBJfNblnO1FP+yKw/E+o3Mrz6bpkMaLbsRdXKnd1/hHqaTXQqLuyK+8Sabp2oxvJp8t1NGNltbB/vP/AH2bnaKwdY1Wa6ctLG8upO2Qu/8AdxjsFHb61WtNJmmuY7SAw+ZLmRpHk2ybR79BT9G1+Maheh4WuYTmHbJEGJx/EGHOK1jTViJ1bPQxArR3/wBo1mK5u7ZAQ1vAwRnz2yefxqlYpdXWqW/9i2syRyOY2gNwQwHYfl3rbtkn1fXUsJrLZbkGSR2cMETOAGI6Zq1qGdOltordljYuUhbZvVUHYDrz3NaW0MXNsdaySXG/TsxyGP5Gtrh5EJ9T8v3gKoeIre2sLW1tI2e5jjJOMeWrMe2erL9cVo+JDHpy2t1Hf2s96iZaeE+WsZ/55deTXFahqc+sXbtbvNEQmf8ASWxGD6KepzWi1Rkou9zR8P6NFI17d6DfQ6ZPEm2SeViGL/3UUZOPc0+4udM+xmzutSvV1oOPL811WJ17g46H61peEPBElz4dW+GkQm7uHKyz3uopbRqv+winJHu3NW7fTdLi0ebSZbe0co5CyIqyM57jzP4lHbNTN23NEr7GA0Eli5FpBAbyM4YLJ5/mKeoBPaqkjxXH22GIG3hc5MbgK0bAckf4VJqp+yaMsU+oj/RXO2Fo8KFPTDDn8Kw47S61dC9qrNBHgyXpLCNB/dHc1UVzILWZo6YLQrdR3U7uuA0CqdsZHfd3q68vkaYkM0OyFiGQnG7jpj2qs6vMGecWuxQFVIiVVx60y4t5BcrbajlnZQ6MgxhO31qbXKTSI4dWtrNmSe2DwynbIC+1gD/Gv0rsLDWJ9OltktJma0ABWdlG1x6HHeuS0WO0lmm/tO2e5njVjDGBjC/3+ev40+O/srZvKxI8J5VZoyqhvX3qakFLY2pVGnqe9afqEOoXEYskkTcmSqnv369KmguEKuvMZ3HdkcD2zXlOleIFh8Pm5umEckZCbwpIPsK6HR9bea0Vnz5BBOA2c++K4Z02jvpNS1O9eVJUWMA4HLMG4NRN+73bi23PABrH0zVYyhVZCFxyH5x759K0FlK4cpnPI7g1g1c2UbEoIZ442Jw+cg/wj1qCc79yoNxzt3HjAp6RykNJt+eU4BxjFMn3Jj7ucc560rWGkJGoA8s+vGKbMW3lIgMDqzHGKkWPdD5u5wp9On096jdGDJkYUjPI7UnsNK7FneT7OHcqAo2oD3qvBIpK5QsR3Bwq/wCNTzhWT5mLBR04qtatiYjYpOQARnvSKS0ZelUxPtVlORVW4kVzyxwO+MfhjvUj7VgdXZTg43Y5xULqWjAK7G6gd8VfoQkQhduZGBClhtU8596KSIIzhCWBz36UVcVoKR8uptN1LLe3Tzck7A2zB9Af4fwpdJsW1K9MMAit4WwWeRv5nkmrWj6Idc1CRry6ESKxfCDO0f0/Gume8TT4/sWgpaxwYKy3gBaV/q3QfhXvTn0R81GLepiXZitmFrDDJJgfebhHPsOp/GqdlZSS3PllcKeSc4Cfh3qxPAzMoiiRGc4B3/O3qTWglnKIUtrBmluD9+TOFT1z6mlzWRpa5E1sdJuo10+RJHkU5V8cf7VbGg3iSahFkrHLHGxkkn5JPt64rPMVtZWZMkgW5Q8ueST7e1VjNJcB4SBPJOcuEPQ9hntWVuZNs0Wh08l7DquqKskhuI4jhVKgCV/QDsBXQQQyxWrXt66NdsCiEfdQf4D1rmNOsv7EVBE8bmQYkjf7xz/CDWrL4gOpapDa+XFYxwqP3lxzBb4H32xyx9B0rFxX2TTmfU2IJLye5ttJ8P2r3V/IMsSPlQd3kboqDrz1rqPD3hqPRQ96t/Z3F3ISkt8shyR3WP8AuIPXvVTSZYIrUWuj3tzFoLr5l3dGIrcX8nuQeI+30rE8QanZJbSSQt5WmBgp2/euG7Rp3xnvUN20ihRTluafi3WUktGjsfNa2Q7EZJS5uH9BkcKKzNPt5pbeK3bY6OwNzg4zj+BfX3rLd5xdW63Mfn6ncY2WcPSzj9D2B9+pqzr2pXGlTw6dbD7Zr18NgijwqQJ7DqMDv3pcrWiNL3sSatqty2pPpml3cgmI2zGMAJbxemR3xXQ6dawaJYLbWkCXLzIXeLzCGA/56zP12+i1ymmzQaTA9pYmJfKYyXE0wyjP3B7t9K1dPu21mUR6fK0MBcPdXcihRx3Y/oFoemw2b2i2q22nR3CRJNcBmaCBiQCx/wCWsv8AdX0XrV2DTodNspdR1G5Mjz8z3Trgt7eoHsKw4dbt5tYisdNt59UtrbOzdMI4w/8AFJJJ3HtUiQ3mqaqF1C9M9ty+5TsiHPSNeMj1Y0rEu5R8UeLftbLZ+Hi40rGHupMx+dgche+Peudmnuri2toRcXC20hyIICERfdu/4mqnj69toNXmt7aRJoVILzISwU46KRx9a5/S7yzkxDNaXjYySS2ctjjHStY07rmFKXLojotblurS2fT7e4+0w8OYsBmDDv5g/lXKtLPZL5yymKbDKHJ+6T1wOpqDULo+ZmMpAE6Av976gV0fwtsZY72fW72GZnhXbA0qlIYx3Oe9bqKirmLld2Nfwp4ok0fw3LF9oWJbj5J7gox3eikEZJpkGrWk2oObZvtLzrthWFyOOhwx4B9qn1vxLDdXZjljjmB/c8MTuJ53bRwf5URWsOvaXJEL28W3twFjdHiijic9cr12+vFZ3vqDVi7NZ6Bo9ys2qKuoSxxbo47WQOkjf7TdAfU+1c0dSkuYJIolhEk7H92EXKDPABH9aL+y06z1iO2a8l1CyKgpCD5ZkPc564rUu7mzxOlvp8VmGAWNiSCPU4HX6mmwStsU7HSdVmuJ20oSG7jiDTx20azrt/vEk4HHatOHyL1Zjp8aWkkYEbSajKfNc9yiDp+Fc3cajDYKhSaUC4Ox9jlTJ7DHX8av/wBlQappc9zd35sbpAPsscYzKw/2m/h+lTKNy4y5Sa8urXw3KZjeE62R+6u5I8xxZ64T+pqpNqM91eQx2tvcTXVwuPMRdgkJ6k44NVdEl0zRF1KLUzfSX8iARxSDPmk92ZuQK27ie/l0lGttRhdwuTGFAbOOit6Ad6rlSJcm2VLixe6lFoivJcRKRI7gIAcc47VmWlnc301raWUzCffjzXYMI1HU46mrJs760jT+0JbVJJh8sMNx5020+oHA/GqdvGYbhVgCRTIOChHy455Oaq1tgubV6LaO7P8AaTtLGhKO0YKAj+8e4yayLmU3CRQo8dxKhOxfM4RfQin3eoSTyytdyb/MUeYVGFIHtWHqZhlYf2eskbNwZj0PsMURXcE7HQWd1JDDHaz7WjkJJKcrmtnw/Iz/ALqJgJhkEKu5SPQVydnbWstiss95LbMpICFSdzeufSrfh69khu5CjiSVlPAXGB6is6sEddCq07HoqJfxRJGCiiU4Yqdxx6Edq7W0jO+JVTadgAxkk+9cJ4VaS5mWS5bbF2xwT7GvQbAeZLLPNGxzhI13FcYrzakdbHqSful65zEfKdmZ0X7pOMH1qB1jjtvMwxY/d3DhaSWNkbfkBj25JpGLbAN5+XtjjNZMmC0I2MrQFEKGNcEnGST6j0oztIZ+Tjg5yc0DLbu2eTjiljhc7W3rtH51KuzTRDkVCQCvX7xx2qO8VUkYwhUUYwpJ5pdwilbzJArgY6HmnxqC5dsg9FBqiNiOEEbjKF+b7oHOaa4Ij3Mu1R95vWpg4VHwMEd/Ws+cs6YQFmPIUf1o2BK40MBKm0EndwfWinREMpWQ5nyOF7D60U4hJHhms6hp+iwXGk6HHNMGf98+QGlbP970rHeWd9iSBVwMrGDkJ7tjrTLtlS5kMYIJJEat2XPU1mXcsuBZ2YeSV2zLMozu9hXvKJ843pZEzXgkkljtlLseJJ+wHfFbEN/HaWyQxK5aQjYvV3b39Kxo4/sjLawxM1w3VcYGfVqt2M1w101tZNE143E1ypyqD05pyjdDi7E2pWst7cx28bedqUxyD/BAuOR7mrWnXtrp0ZtfLhLw5U46yN6sf6VA895BcmzsJBLdP8hKxjcT65609dNtbLUY7WebdebCZJepjz1IHrUPaxW+psW0UuqSNFbNLZxrzdXs7AKo/uop5GfWuu0qx0G3tUtRd2v9nfeKyuC0z+rd8Vj6eyw6bJBZ6TBHE4zJqcqeZOwHcK3QVPJqVhBYKTIy2Y5ETIBPOewzgYXNYN9Imlm9WS6pd2Fz5pspLiOxiwpNsGJuCOiqp4x6mqNjFq99Mt5JbI90oKWtvMm1LYeq54Le9TQX00V3C9y8U2rzL+4svMxBZRj+I84z+uaksrvSNNkZL29M0krbp5I8yO+ecd8CpScTRu60LGnzDwrpNxqtzomoymY+X9qlZWM0vb8M+lc3DcXlrdXESJHLr96QZLgv/qEP8Az93itbxV4rm1fUoItPttUluo0xp9pKQIrePoXI/hb3NYy6aY43iW+e/vX4u3iOY4QeSobrI59uKtJpXZN2y1dx6izppVgkV9cxje5gBEUOezMTgt710ml6dKbJYtZvFkskXm0skEe8/wC8cn8apWmlxRWkRaxijsoCAsLvsRc/xSMOWb/ZrWkeGG3FzbiWOJxsWeWQxRlv7saH5jWcpdEVuRLp1pc+XBcP9ltV5kaScqkcXXHYGrdx/wATOeWXSbG3i0FUEPnzZbzsdQncgenSs/T/AAyJhLqPiS+uLiZVLwWoYFEPZmBq7597eBbTTdQkMUGDNcYjVFJ7Bjxge1TZDZx+v25hudzyDy1fMDbdsaf7qjpWHqdvdXJWWCdrxEG6Sf7qRn3Y8ZrvdanfRrQ26am97LKwIIhi2g/7B6t9a5XXYhqFsGvFvJJc7UhkkzGz+qooA/OtqcmtGTUSlqjn00xtYnjj0tpZ7ifqQmFX3B7j3ruNa8P6tpvhjT7OzMAjkG0yJKu6Ru56kgfWqOiRx2Np9gt5Fi1Sb5JrmZjHFGv90MOlV0WW6ubmy065S7mXJkkjbJAHVxwM1pNtnOkOtVgs71baPUJoQuCXcKCzdx9BS60l7eXWyyMTzkAGdFwir6sPWuZ1S0uraNUFyru8u2KNoishPc4PY+1adrp3iK2dG1FY0jSLzDGcjcf4QSKfL1GpK5a0/wCywQzzzTTHUd+yScoMuPQE/dH05ohvvMuEtbaKRSx+4Uxx6jPJqxoun2s+nwT3kckL7yzLDJlj/hUlzdw2okFnaOt1I2BKZCzhfbNQ2ikQTWMdtNLLcXarNKSqQpH82Mdz0/Km6Z/Y0Sy22tX9xlcGIR3AhCHthepP1qteRXc1u/kzr5+MvLM3A/8Ar1vWVrYWdjbaPp2kRXV8w3319dIXIU87i2ML7AHNVa61DRaE9wumJJLFbAXdjIgJa6XdclvdvT0rJvrqbCQB4hCPlihgUbxntn1qx5PmW8i2epJdSI2zZHaH92B2L55HvR9h2QJd2mpBtUiYhLYW+z68k8/WoWjsOytch1HQ7jSdKtpXljQ3A3TtlZpYz0VTjp9aqpZwW+l+ZJdRs+/LRiMncPcnpms62+1atORMNrwuWmZtwZMHv6j3qxqs8QlZJzcSxhQgcHbu9zWmxGrM+dmkbdFKhZmPy8YUdhSBbcCWZ0DSRrhUBODTp3aIxCEWsCngEjk/VvWpmgWPR7vzJWe8lYIkUf3VHrnvViSZRubhradY5QIUIHyBsgg+taOiRW8t0qxgQ7OcKSfy9qwZLN5pApO58g9OuBXb+D9HZ76KTrGOSMdfbFRVajA6MLCUp+SPSPB2lNdzQ+aBBbx8+ay/eNd0xCtvO0IchQOmP71Y+k2+yAAxCMbtwAXH14rYkUBFlY/uugJIJryJPqerJ3kQom/aocMG+8wBLAUspjbhBs7ZY1YWERRAsVMjchewpreX5SoyoARydvJrJBza6EPlosKv95V4LY71XXJY9flG7p0qSfdGmIkYgdNxwAPSmeXIY5POY/MOFRscfWgtakDyn5Zd5YnjHGanPmIQrbl75YVErRx7UAVdx64yfpUrzb3XgmNT0J6ikmUyNoyCpDBQPWo5XKyDCqcdabdsrABFcjsoORUKnMbKeGPPPb6U72BK43JaZdzbRu6oDgfjRUVzdStttyoEYION3eirRVmfMFxdXF1eyLACZGY5bP8ADnlia0opHf8A0ewcbV+/PngfSnQ6TafO1zr1taozHckNtJI7exIxxUlzP4dij+zWGqapdN/EIrFIVB74JYmvoLa6Hy8ShdyLCDa6ezfN/rp2PLH609b17GFI7WPa78KZBhm9SBSQfYrSGQo0j85Bcgn8ff3pmiiNpzqci7QG+Tc27P51PS49b6GzosU+n28t3eO0BYFmMfMv4HtWnoWnvfS21w9sY7OWTcyh8vJ7u39Kzxd3WtavCLiYQ2kYOQkQU4q/JdrPfRhJESGJsvnOMDpu96ykmapK2h0uqsTPv86GO2iHKg9PTp1+lYLapanVE3o95N0iVThUPqfU/wAqyVuNR8V3riIpaadA21pTwqc8kH1rrNHt7RUVbC2a2sEzvuW4kuDjnr0U+orF+4aX5th9p9gisrj+z4ESEDfcX06gjd6Lnl29qq6jfy2On2+kaPaCXWLn524BZY/7zHtUGq3ayxRyiL/R4W22NrtH72X+8fVRVe0vm0G3uZrWYPql1k3F44BDHHKqPQVUe4PyLFvaSaGB57tqmvXP+rhziNSehdu+PyNb/h3R7i6SbzLiOW4hTdczKQiRH/nnH2LewrnfD2gyXWdS1GRlts/LNLnDZ7Io5Yn8q3NV1CaKBNOsreaBOiWpUea/H3mP8I9utRN9ikuw+7vgLy3WQ/2jqX3bPSU4S3/6ayN0yepz0p0ljcNrtu10Z9X1aNS8uCFht/RFzwo/2utGkpF4e013ktvMv35dUbJGf7zHgCq7WV3rcH7u8khsZG33EkK7Q4/uqTy314FS/ItMv30/+kRreXcc8pzvsrGJnA9i55Y/kKx7m1fU9S3X9w2nWUYISIqspU+wHyr9eTWtZWJihZNLRbGzQgG4fkyAdl9/UmqNxOJVe0Uh2Xuq5Vfcmo5rPQ1jG61Me4EUWo/8SSKSe4Iw5lkwWx2yen4VS128uYyUMqvfuP3jq+Y7Yf3R/te9S6ldrZCKFbxsOcSOBhz7LgVjahK3yxINisceVnc5X1Y/0rqgm9Wc9RpbEWj6Hq2sxSQaYLoQbv3k27g/nzW3qqWvh7SobWXT57fWwRsmd+Wx0b/61XLe70P+zzb29vfxal1Wa2nY/N6sOgHsBVQXmpaG0st/E12tyB/pk6CRse2fu/hVt3djHlvqVrvXGlhsZNRAnuVbLTNxJj0B7Ct248Q3f2a2jt0WISjaMyqwQH1J5/OuN/tIvqO+FYy0J39RtA/2h0zSarqFzdSfaJHwJB91UwuPp3quQh7m2bPVNNaa4ijt3hOScSjec+mOK5ybxHKlxHtjAAyPLzlgatXGqyDSRDagxsRhi/LflWj4bm0/TbJgNPae/m+dp3UMFHoue9LlstUVfsLos8Op6hG2ux3UOmpygaIorn0JreufIEGwXV7JZ53IjP8AJjPpnkfWp7PWre8tJVnN8LUcOssgC49AKjistLuQ6wWkEVrIuEeRmMmfQAHHNZtopK+rMq71GyiuGWx+0kYAZ3XaPwXpitLQo7mW6S6M6WTOrbBcAEsO+PQGuajsHe+W0geS6AYtKTGQIEHQsR1q9O6gsoullOcF4xxj05puKEm0Xph5l813qOpMSEMaQwS7CB6M2OR7YqhLsmWMq7G2PBLDOR/sk8/jWZLKFnGYvMYHBJzkfQUPKYwH3RttOMZz+naq5bgmR3QtLUuthbsWJ5llk3tj0APApsDPH0byYyPvFN3P0qCaeFnklnZnDKdqKAMGr5065tLeG41BvLEq5jXOXz2yPSq0W4RTbuTWUNxO8alAYwCB5YAr2LwZolpa2MF3JcRblOPL+YNj1zXnXh7Ttk8JOZx95l6AmvZtIt4pru0kkePcsXzQxIY0Hp1615+KqXdj1qFPkhc20/eRpcyIY5mGAqt2Hc0jSs4jVyrKjZPAGRTzGPNVBmSU9s8Uycuj+Wyqig8oK5JSLik2SFtx3FSB+VMncJCxfAYHOCKajKIzJsGFbcDnqaryu00is3UnDL7etRfqVyjp5ioJEhYtj5QP60y4DIozn5xnHHFJdny42kdkbkKAOuKYHaWdIlUJkcsewpXNFHS6IIOJ9xZtwPJA6U27mZvlhUsNvpzUr4iDJEWA75PDH1plyRGoMaBDj5j60rFqz1K9uzBOTlxwvakJxFh1KyAn5ianGEtTuZdy8rjgn61XciVQAGL9AvUn6mmlpcrcrvieVGUcggDJ60VPIjeZDuIyp5C8AUVpFEykfKd9e3F7cvEpKoWwAmcke5qaOxFpbtJMQVBz5anqfc01pktbx47YhkLkM7cH8Kh1C6N3cx2yIgCnlFc8n3PpX0LPlExPOe7dIYkZ5JTtEUK5z6ADrXUyWSaLbR/2iynUcAraqwIgH+16t7VDBejw7CsOiCOfW7gfvLxlyYAf4Yz/AFrIuY4bRC95M8tw5LO7nLAnrUu8i1pqXEu7qRJZBJFHATukYnhR6Vu6ZG15olxLf3fkaSfk3ONgmH+z3cn1rL0nTomntrjW4pxEw32+nQrmS4H95h/CPrWpsvNVuzd6kyWlpBlY03YjtlHYep96iZcddTRi1CGaO1hks/8ARIB+40+A7D/vzH06UwTanrsVzf3Bf+w7N9k0qMEiLdo0P8VYep63a3YWx0yGWOw3bpplH76f1APvWlq2pS31rbi/iXSdEtABa6ZCc7jj77DuxqOS6L5raFuXXnwFsrWDzGxEqxqP++ST0HvXRaB4RSWF9e8UMksca70jK7Y0xzgD2qh4O0K3kRtZ1N0ttPhXf85wv0J9aPFerw695S3skth4cjOYockS3OPReyn1NZNdEWnfcludbuvEF0V0VbfyYB814xPlWq/3mPdvRRVu0u7PTYlTT4Z7u/f5pL26O6Sb1ZU/hX3NcxNrQuLeO2t4ktrCEkxwxcKP9p26E+/NaOiWb3i/arhvKsurEks0n4dx7mlJKxrEvXOrMsiGV4HR2y1vsysmPVsfN+FdJDa6lcael5fRiBX/ANRbOMKo7Hb1NV9OaGzEly25QBnzXwzKvoPT6CnSeIXvG8uygMs7D92JB29T6D3rCTL5dSc26ZWa/kknRBkZO2Mf8BHWj7HJrReDShDbQbATc3CbEPsijkn3PFECwW96txqt3HPcgfKjOAi/7q+n1rSPipLXdZ2m57mYcJbpl2X/AG2PCr6UrFO62PPNY8PxWVy8gMks4G2Vzli3oK5i4gkaRobVDJM/DqvIX6ntXrFxFfa67D7Oun6fEuH2DdNIe+W6D8K5fU9MtbHdHGyrGSSyodo9i5NbU6rWg3FSRgtpkGmWCW5vx50qbmaFcKG/u5PX61npEZvJh1hn+yD+GP75X1z2q6kK3k+2zJmCNyy5Ea/jzU0mjzx3AjuBJIWO5FiOQfq3X8K1Ul1M3S1sQ6gmmWwSLTrGFLUjDAuSz/U96x5bAGSNrZZFQ5xvfhfpXQ3Giy24VHCxlj8qqNzfSiLQ2Y+UkTO+cM7twPYe9NVFFXuJ0G9DnLWxe+1CK3jJkyQGZTwR3APrXV3UFna20cFujjIwWdMmI9z1q9qNpBa2Vna2MPlrCm1st99j/Fkc1lwqWi8pElaUH5mUkg/Wk6nOHsHHYv6fYQyy7dFeS5mKfvJZcbB67RVeSzQRMb69EUcbDMNtje3uD0AHeq+lXMkU8jRCSErkEAc5ps2ryLC9okSm1J3NG6glj65FKzbM3FxRLpaxWtveTWV/BHbsuyRZCTLJ6dOtY13GJsLCV2gbsqCD9TSPJLJEZozDbqoIEcSY3fWqTPeXMZ2QyqcZdsYT657VoomerLm1BPCliLhPlwZJMkk9z9Kq3ETl/wB2FBU8qvO4+ta9zPqFxa2scsr7gu0DPb2AqgFYOShChF5x1JqrhyMt2H2eHTC8kSNfznbIjjAVR3q9b6cNSjUIPKhXAABJ/LNP0fTGvoZL5slSwiXd1969L8LaBFCImkVmjX7oAwDXJWqqJ6WHoK15bEPg/wAObjFuzFBHgbs/eNehwwBYy9upBJK7GOeBTobJFIIfdCoyGUbQD6VYZotqiMAEZ34HU+tcEnfVm8p82i2I7eFlJkOFYnAHcfSo5VV7rMkhYKMke9TRBpYnKYA4wByTSwgR+Y0a/OeMNj8eayBOzKZ4UjGyM/dDdBUUijYrDOAcF1P6VPOxklCqTg8ZOOKguSgkWNMtGp/iPBPrQWitcsSxVVPqCegqWyWRV89WLbhhjSsHcFF5XOMk4PvT5dkaMI12oRxk5IpJXZTeliFkAkLnj0JqldbnUFVfaem48VbaQfZRtQ7s/MWOc1BKcIMKUY/f9BT9BxGzbdwHlnO3gJ3qv5wgt3YSbGH8I4alctcDgqMHH4VT1M/Jl1OU45pxfQu17IrpeFpFAYLlgSXHNFc5e757pAkzxMrDG00VvGncmWmh4vpGhNqTzT3l1DYWaOWMsjZZ+ekadSf0pk01uA9vp8SQ6fE/+tlTMsrepPr7VX1LUbm5nuMiMSSvyyLjA/uqP4R9KtaNps95HnhFTh53OI4h+PU17r01Z8siK3keSdbW0ic3EjAKuMk+5PapdStTpl2IpZIrvUl/gRt8UR9Tj+L2q1d3Gl2OnyQ6Qgmnl4kvnJEkh7hR0Qe9UtPWGIKzp5kh+7HGCQp9/wC8x9am/VFbLU1NJS4s2M584PKP3jzPh5fYdwParF3DPqVsHv5PI0yNtkdvBy8h/ugdSfftVaUNbsg1KVRcy4C6fAS0vsHb+DPp1q5qlsbExtFNH9vZQFjiPmeQvoD0B96mVt2UlpoZ/NnII1QvcA4S2iXcIh2DEdT6mut8GeE5r0NrPidzHZ2+WELMBjvgZ7n1qt4L0i3sydQ1zzRYKSTBE4Xzj/tv1IPpUvizxDN4luSsKRWGlxgIluoEcYA6YHU1nKTeiHGJa8QeJjqkwXT7WNLO3P7oTDMMR/vY/jb+VYMVgl5O13eXrTTYx9onf5V+i9/pULyQqETNzdzA/LEiBY1FVrq/na5WNZ1V1PEMCA7T6E+tCjbY2TSN+2ECSpLOZXs4fmUTBVEn0XoAK1tPm1vxBdldJDm0BzvaJdnHXBFZGk6ZaEm612OaUyD93G4J59/T+Vb154gurCwS3jzaQMCBFBIuX9M4rGfY2jqactnBGVFtPNeavnDG54t4foP4jS2+mxabDJeXdyVaQ5aSSXyw3sFHJrmbG91F4QZ7t7QN91II97tz0GR+tW7jRJri6t5JzNNP2W6kLSY9wPlUVlay95mqb6Gna3UEmoNFpdrZxpGu6a5kjzJz2VTzmr0V9YabIbq+hMYBDbLmVUaQ9t+eT9MVVt9K0+3dHupXkkJwlvat5ce72A5/M1vadpdkl4lxf2tmJIwH8gLuEfuScljUOSTsPlvqZ82qa7r9uJjLaaNZSfdfJeZwP7qY+Wi38M2cMgIjvdWkI3NcXXyIh9gePzrt9Y1q2aOOZSlraxqE3sOp9FI5z6AVgQW2oeJ5JP3o0jSE6tcgl7g+gXr+dRKTuVFJK5ns1xNafYrK5t7OwRsPOgyOe6MQAx+matDQbdNk2kQT2tptAlur47nlOOSq9RnrWxFZ2ulpE8qPeSZHlyMuTx/dUcL+VTzzXt9OiSjekPzRwscqhP8AE57/AEqHUvoaxh1Rj6XpMVxcCVAxiU4M8y5kcY7egrXudKgVQvkxhgRiMjA+pPap7eRlE0MAgeWPme8KMdmew7VaDzRxbMQOrch3Qlv581LfcaTb0MePwtZXNhNcSTv9qyNiIAUWua1Dwy1qjTqi4PTacFv8+1ehHzpWeCO42wSY3iOMKWPoPSrVzCl3cRpaWqK8ShS7HzCO+4npT57bC1i9UeMzaMcBfK8qVyWLAmse40e6tw8ishwcNnuPWvdr3SrY3Ijf9674ZcEYY/h0FYd7odlc7y0IiRJNjLu3byOo+lXHESRpywktTxiLTeGZYm+Zg3z9M+tah0lpIlYvLljtcDjb9PWvVItB0+dWa3WPdGu7ylOSn506LQo7cxT23M/3ssBxVPENiVOB5Vc6VHCRLBNKAowFdcnNUrLQ7y/bIjKSFv8AWen4d69ju/DsDMGuQDczDcQvAH1q5BpdtbKv2ONI3jwPmHzMe5FL6xJKyK9nT3Oa0vQIdPjtYZIWaOMZLFejn+LFdoI5bmSP7uMADAwMU+5EalUB7fOSOTUNqPKKwknJGVJOMrXO5dymrrQ1X/cR7JCSo7HpVWJ8hEG7LNweuKdJISwVtmxR90c/5NPiR1fzCD5Z4U5wR/hWbfYlKy1LDKkcYjUlec+5ql53mmTK/uycEgdKkid88KBgkZzk1DBJKJHVVAB/DPvQxxjYaWjUNtjwE6Kep96rtKSigrjn0p1znDZO/PAC9qbIi7YEJBlHc9aTNETQyhfNZQufujAqrcuWKhjtC8jtzViSN7dGd1XBO09s1WjZZLhmOCE+6h7e4FDvawRte5LMyLbKAMy9TITVIlpAsakeYTkA9KszzAAcrgHOagtD5czyMq7uq55OPWne1rDS0uZPjD+3NP0FX8K2Ru9R+0KJI3AKhMfNweoJ9OlQ3MF1LbQG+WCK5kiBmWFsrG/dQTXRTsxkPku5LHcuT0HtVGeIs7lwCx5Ld8+laOS5eWwoXUua5y2o2AaRPLjVCuDuUnBHrRXQrbq6HB/dggsO+fSiqjJ2NZSXU+ctG0CGZ3vtWZ7ay3EqGHzzkdlXrj61N4k1Tz44rSDy7TTwfltiCS49WA5NT3lxGlxLdavei9vnYsVj+4mTwo+lc5LqVy1+bi1KwPnChRlvz7V7jXM9T5NaLQ0mso7a1NxdFYRgENc/LJj/AGIxz+dS6ZNObn7PpcNyjTYWI7AZ5Sf7o6KKv6D4U1fVrgfYbB72advmuJjhN3pjq34V3Vh4d0zwDdLJ4w1bz9cuc7dM05BLckdApb7sY/Whysg3MHw94I1K41Kax0yyF/r5+a5mZwLexXvufoTW7eW3hD4f6fJFut/EWtHmSZ0KWqOT/CM5bHrWX4m8bSadbT2ljFHbbhtTT4X/AHUI/vTMOXb2rzV728uZnuXb7ROx4nkTCp/u54AFZqLmtS78r1N3U76/1y5NzflYrQHCBj5cKgf3U6moVvbNWMdqjancjopGIl9zWYYkucSTzXF9IT8xT7o9ix4x9K2NMtZ0iAjS0sYD1aX5mA/rV8qiik22QNbTywtPq94ltC4xtjPIHpVrSbhkfy9A011QDBnkGS3uM8VfgTSrc+a2+8mHPmsv8geAKtS6rLtC2VpJczk/JFu4T3J6AVnKV9LG0Ydblyy0xruM3Or3gQLztVvv/wC8x7ewq9FFaMRNZxQxKvym8uBkf8AU/wA6y49Iv75/N1fUFUJ0ggXCp/wKug0yzjUiSODauNpdzvdvpnoK5pvzNoqyLNtIZI0bRrV7y4Jwbljt4HUgnt+FSzJJboBJLzMdpgi6Oe+W7irq3dvbW/lzSRxBT/E2OPpWFc6yIppLzasblcW6sCzbP7wXt9TWWrNFodFYWNtp5EkwgWd/vf3U/wB0d6gn1R7y6bTPC9tJdXGAJbx12Rx574PWoNHhm1MrJM/2S2k+9NIP303tg/cH0rr7O2trHTmNvIkMH8ESHfJKfXPp7ms3pujSPmQaVosGmiK51e6k1PUlHy5HyoT2UdB9av3erCKJ41RUyfmUHdsPu3U/QVmfbZZoR5e1k5AVeCfbnoP51ZsBFaNFcTGIPF/q40GVyf7oPeobuzWyLFpHJcL57M6A8+fIMN9FHb8alhX7WGhUNb6dnDSZ+a4+nt70hvfOUq0Mk0xfLR7/AJFX1b+8fapJJZArtMWUfwogC/QCsZPU0jroXvPItTZl1hsR92BRy/oW70s++ZMxIVY8B2/oKba2sv7stEkUrjOXYsfzqV43aQoZTOzHkD5FA9z1qW7hFKLFW2hjt186Zg/cEdPr3olu5YADZZ24+9t4xVqPy04hTaem49Qfagru+eLOehJH3j6Y7VLb6FXV7yMVRLJGy8gH76r/AI1es4TPIVCKEQcBvpU5iAGAAVQ5OT/OlhcvMFtIzMc4znCj1571KUuppKcUtCpBolnbXX2xI2WfbtIU/ezWjJbbQoQnG3oeBVrZsnWNgC6DMhX7uewFNJRFzMuSM7UBrTYw5nLUzI1LPIVDHAwCV6n0qRkZZN5Rj5a5IPUn0q2S4iRYcbt3UH7oqvNOjzyoDIHJG3jg1LkWhzR+ZH5jKNoUMQeM+1VBbB+FUZJyeentWndwvDZqWC4JyR6VAgIjJ3LuPcjpUtjjLS5Flgu5QzEcZ9KUT5AMjHaeDnnJpY43eXYhG0jLHPUe1MkKmYEfKq8c9qFoVoxkmWyylti9h3qJvMTlBgdvarJdXULHnaOp7VXO9m2nbszxzinuNMVXPmoSw3t94gcUhj3T4G7cDnnsaZN8jAKDgdl60sEr7Q579QT82aL9B8umhLMWzh1VnI4zTY3t7eIFzyykOuO9EhXcxJ+cjO0c5qhcPIYzJCpLr95fQVXNYShfQYjeZIYo02/NkFhxV+WFoVCiRCxXkgdR6VT01Sw+0N8pbjb3qxe3DJbFNq7Qc9P60o66sqataKEuXIiURhYyF7DnFV8s+GOBH0wTyamDLcW+9pNpVeV29aRszsv7tcqM7lOPzqt9RIiiYhRGfljY8j0opjAfaFVSdh5x3NFaR2JaR836hp5dZBFt5JCpuBkJ/wB3tV/SdPs7KSIXK2sV2Bu8tsu5/wCAjv8AWsDVNWnW9me32WkWTtEWDK4Pfd1qbw/bNLFcXU13/Zts/wArXL/NJJ6qD1z717zTtqfMI37nWdd128bT9CCabCpKyTI5EgA6kn+EfTFZqXtv4cEsGhPFc6hICLjU5l3EHuIwe3vVbUtTjgtjZ6YvkaaSPMeU4kuT6k9T9KoxtdyShoII4Aw4Mi7j+A7ChJ2K2ECzAea6PKzNnzbj5EX3ANTxxm6YSSxmRR0C52/gvT8adlLU+df3Uc8695SXA+ijg1NHqc8+XH2e1h6+bKPmA/2VH8qNUNW6kk6iKIS3u22gUfKjvtyfZR1qOMzEiSWMKGxsiRcMfTnn9KjtcTym4aaPGRieaMlz/ur0FbUX2fTnwJrq8u25wqgqoPvUydjRK+w7T7KOPdNqjIkg5jgjOBn1dj1+grSh1GFBthPmHpiJeM1mARPNmVRGx6koXb8+lW0mjhVPKZyXPVxjHuAOTWMlc2grGlC1/OpdfJs4N2WlkBYj8OmauoZpFMn2hlg5zNMME+yisNtUj3OltC13cbvmkmG2KLHrUqG41C5URefdXMnH2iRNkMf/AFzTvjpmsXB9TZSNGSWK9uksdIgMsxw0tyw3sg9Bnoa6rSNG8q7trmXbPcu+IYM5Of7zHv8ATpVGwWHRLAxSGOM53Oc5klY+4/lWjZQT3q+fOrwHBJdDjyx2BP8ASsZNLYtal/W9Wig1J7JJDeXmfmEXzYPcA9KrXFijTb54/IUYISJvnPrubt9KbG9rZxbIYQ0hPzS7cH8cVVub+BG2r5juTiKKM/Mx9SPT3rLc3jC25tWqmJGNsFEQHCyfMPqT2FFjHNdkzCFJI87ftacLj+7Gv9aq2Wn3F2Fk1DPkj5ltlbAOP+eh71t2F2UmWJbRrqdzhERwqov94j+ED261L0KtctSSxWyrCkTI235IwvLH3IpYI0SRZHkieQkA8jCH2HWpFjuITKBHDlxmR2c/oe34VXEk6knyYAAfvKoJrBm0U7WNrEIyvm5OMllbB+gqM3cFs3zzxADtuBYfX1qgqxM3+leYVxwgG3+VXtMtbUQPJFFCijkl0JIH1osG24sOoLPIfs0M87D+LZhVNTpaXWyR7l9rE5Cl9q/kOTVnTbmzjc3Mz+VBH8xDjLuR6L6VDeX1tJcs6ucyHeEY5VR70KNtTPm5pcqQ9YIo40SXMu3nGdqg/SpjIO5UqnC44AP0rEkvrqZmkSNirHapZdo+oFW4i28KziRgPnBG0A96i76GnJbcvphY8DG8/M471EVDAlgQegJqGSVYiz7gQvJb19qhechUjBLOeQPb3pNjjBsvIxVcLjAqAt8wOAW68dqeoIjDsAoH86dmNYyOPm/E0gWgjmOVcMzNjqM8A06b7gzhFHXHRqhnYtgLgMcDJ71EUDE7t5xwQO9CYcpMjAksqhBgjAPUUkj94CQSvLf0qs+EChMqPQ+tOeVSFU8t049aLlcgW6mdnA3qSKgYEthiTs7+tWA3mZJDbh0Ipse0E+ZkMPyp3Y1oxI8paltvzOce4qFm3sO5znIq1cKr7VcgKo+QgVVQ7X2qwVRwWPrTsEWEq98BiRnp0poUIiguDIw5HfFTAyD77IVbjPeqiM6FGUfuwTubGc+1LbcdySVGKkkMQg6p0/GmlDJtQHcCcn2FKJXUEqSoakUFVLM201W49eok1wZoFiUrsThfUVWYiPO5fmJ4JqwyF1CRgZJzmo5lBxs3MF+Ug8kmna4rpDX+SaEgkY64IOaKhlJdlLL8qkAKO1FaRIkj5nsrWG0Z9RvPMWFsrHEoHmTe/oBTLzU59QdEW2WJV+VIkOdvuzVUvDJc3bz6jOI8nhZf5Kg5/Gph5jIEEnloOhx8xH0r6Fo+XQ2GBbbM088STNwMDc6/TPSnNJwWLtGTwAWy8n1xU1vaQI25F3Anknk5/GrqNa2/ZGkPRQO9JstK5nW2nOzrK0D89gP5k1qJbR2brLOlvHMcBVceYx/3Vpkl/KIg0QW3iPSWbj8geta3hayvNQuCuiRqJf8Alpf3LBVT8W6fhUSb6miS6li3tFEX2vWbpoMHCxbgGI9Qopsl7HGjtbQfY7Mcb34Zz75/pUN7bwabeTq2o299dKRma1/f8n/po3H5VETDF8906hz0d28x/pk/4Vla5qmkQrqDSPi3aWQ/88oVwPxY1OsTzK/2mWK2iA+cJksfYk9/aoJtRG1Y7dSSx4Qjr9asWenG8kxe3AZzyyE7Y4x/U1b0CN3oWLGdd6BPPFuo+WKOPc8x9h2HvXR2cd/gvujtC65Z5DvmAH8Kr0H1p2l2UcO2O0V1L/ec4AI9yegq89/DcP8A2bpG6TjbPdYyAO6qf61yVKmuh0QhbQNIsYyouLxJJHDkxrI2Wb3OOK25764urcQKY0hjbcSvyqv+8axL3UbSxjRGR7mbG1IYsk+3SqhttT1SQyaiwsrYfdt0bLD61i02tTogaF/exOCljM0hxgyhcA+yjrj3NXdLtZFjjklEFovrv8yY+pY9APaobOG1shLtj2AKDJIxyx9v/rCrkIe4BmYCG0B+TeOZD7iobsrI2tfVl1bwzSGHTAPJ4ElxIDx7IO5rYsY4rZSsAwijlx95vr61nzpi2hBZdhOc42gD+lNGprcMYbBWu5B8pYcKPxrJ+RSNSa5Gd0smI+xJxU8JXaNvCnqTwTWVZWcnmvcX4SafpGSMRw+yL6/7R5rWG2PG5g7DjcxH6VnJWLLUDxnA5z/eqKW9S2yJh5oPRTwopsvmtGog5A/AD6ms25hKhlkYOxOeOcVDNIQ5txlxfiaTGz5M8Jk4FWE+0SN5Z8vyu5VvlFVbi3lhX98jpu57cii0kAJOxY4lOdqk8n60XubOKWxtSXSRuphmZrvbtUKPlA/pSRz2yRylZpPNkQbncZO7PIFZM28Dykk8sy87iOcUiXYt5MxMsjY2gsOh9aDNQNC7lcxKHOI2cD5j82PXFXTIjtlThcAD1PtXLWVy00sjsAwLFc/z+lbFnNm12Enchx838Q9aiUbGnJY2VmaVxv4UDlfYVKJN6F3TA7fSoIlAgEmcl+nsKdvAAB+7+lJeZlZdCVZSHUYXnkA+lLuGTu69eKrLypLkYHc9aAx3nnIA9aBWGy5chjhVBzz1pSil0KqMk9e9RyMxKyNkseAM9fehWbG9gV9AaW5VtCzIN0hCnaex7moJiEkHO4rySehqNp1DDcRv9qkCeYC4+ZB146VS3Jt3HOzNIuCBnn6UmDIXySQOAO1I7Bdp6Y4ANRoztGc4Vt3GO9W/MVuwyWRkeRUwSOhPOPb60+2kGxS4IHJxVeIkysNvcnJ6ZqXzhIyRnI2c8cc1KdymrImfa65cNtP3aqSq68BvMQ++CtTzbHZAGyqnLAVXebfJui4xx61ZC1GsWB5xjtioVZhNhOAP7vTNSs24nCf0waAoGF5KY3E00VoMVg+3ON27J45opIgyXAOVKg9Woq4mcnY+VDOftUsjZZtxG5jljz609rvY3yRjd3LHOaKK+kPlh8U8jxvJK7N7KdtamkwrPY3k8AWHyAOMbi2fUmiioaNE7I07bxDa6JaollodhNqci7jf3oM7qT/dU8LWLqV802JL3zLqRvmPmSYXJ9gBgUUURSuHM7EEErybQCI1U5VEGFXPtXRaLp1rLoV7rd4sk5t3CJBv2jPqTgn8sUUVEl0NIblazvjJLK6wxxjHO0fMePWrelau91N5ZiCRIRwp5PuTjk0UUnFNFwk1sdRDItnon2rEks91u3M752qOwGKqeHL+bVriSyjY2dmvLpCfmk9i3pRRWLhFLRG8G29To4I7a0gItbZYlJOcHJ49zzUA1LdKcQLwcfMc0UVzuKO2LZPYyS6hElzO42RH91Cqjapz1PqfrTptSD3pi8jdIGwJJHLY/DgUUVm0rGsUm9TUit0uJozfGS5VgSUZsJgdsVpI8XlhYoFjjA+VVPSiiuaej0OiMUTQmMKoES49yTWmjIuB5SdOuKKKwe5pypj2JdSpJwOevWq0kw2uuzHuDRRU3Zagihd3RNvll3SNnDsc4HoKjurxYUiEcCABASM/eooq4as15EV0mMsUkjZzuwMnOKqSOYy6j+HJzRRVWVyoRRf0ZFjWMKBnBYnHJzWvZEbmOCNz880UVhMc0jShyAgHAOafJLiMIVB75ooqLuxzKKuM83HzFc+xNRNclIioUYPNFFK7K5Vca0/yp8vUDv0qVnyzDHGfWiii7BxQyZyqFhwad5hMeRuBxkc9KKKak7k8qFLecjM3VcVWDb9uRzn86KKUpMIpIBgIcDjOMf1qHz2jd4sZXv60UVUZOxXKrjI58iRduOcdae7DbkDqMcmiirTYSikIJt0akLgnrzVSW5ImA2jjJ470UVtFmbSF89vNUjq2CaKKKqLZMoI//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Seborrheic keratosis on the right temple of a 57-year-old man with verrucous (wart-like) texture and dark-brown coloration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38097=[""].join("\n");
var outline_f37_13_38097=null;
var title_f37_13_38098="Patient information: Leukemia in adults (The Basics)";
var content_f37_13_38098=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?13/12/13506\">",
"         Patient information: Hairy cell leukemia (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/40/24194\">",
"         Patient information: Leukemia in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/34/17955\">",
"         Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/30/34275\">",
"         Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/10/6309\">",
"         Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/60/37829\">",
"         Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Leukemia in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/leukemia-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H540870693\">",
"      <span class=\"h1\">",
"       What is leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Leukemia is a type of blood cancer. Blood is made up of different types of cells. These cells are made in the middle of your bones, in a part called the bone marrow.",
"     </p>",
"     <p>",
"      When people have leukemia, their bone marrow makes abnormal blood cells instead of normal blood cells. These abnormal blood cells grow out of control, get into the blood, and travel around the body. Sometimes, these cells collect in certain parts of the body.",
"     </p>",
"     <p>",
"      When the bone marrow makes abnormal blood cells, it does not make the normal blood cells a person&rsquo;s body needs. This can cause symptoms.",
"     </p>",
"     <p>",
"      There are different types of leukemia. Some types grow very slowly, and others grow much faster. Sometimes, people have a type of leukemia that is slow-growing at first and later becomes fast-growing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H540870700\">",
"      <span class=\"h1\">",
"       What are the symptoms of leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Leukemia does not always cause symptoms, especially at first. When it does cause symptoms, the most common ones include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling very tired and weak",
"       </li>",
"       <li>",
"        Bleeding more easily than normal",
"       </li>",
"       <li>",
"        Getting sick from infections more easily than normal",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not leukemia. But if you have these symptoms, you should let your doctor or nurse know.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H540870707\">",
"      <span class=\"h1\">",
"       Is there a test for leukemia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can use different tests to diagnose leukemia. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Bone marrow biopsy &ndash; A doctor will take a very small sample of the bone marrow. Then another doctor will look at the cells under a microscope to see if cancer cells are present.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor or nurse will also do an exam and ask about your symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H540870714\">",
"      <span class=\"h1\">",
"       How is leukemia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can treat leukemia in different ways. Sometimes, doctors treat leukemia right away. Other times, if the leukemia is slow-growing and not causing symptoms, doctors might watch it closely until treatment is needed.",
"     </p>",
"     <p>",
"      The right treatment for you will depend on the type of leukemia you have, where it has spread, your age, and your other health problems.",
"     </p>",
"     <p>",
"      Treatment for leukemia can include one or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Chemotherapy",
"        </strong>",
"        &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Radiation therapy",
"        </strong>",
"        &ndash; Radiation kills cancer cells.",
"       </li>",
"       <li>",
"        <strong>",
"         Bone marrow transplant",
"        </strong>",
"        &ndash; This treatment replaces cells in the bone marrow that are killed by chemotherapy or radiation. These &ldquo;donor&rdquo; cells can come from different places, including:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        You &ndash; your cells can be taken out of your bone marrow before your treatment is completed and put back in after you have completed chemotherapy or radiation treatment",
"       </li>",
"       <li>",
"        People who are related to you, and whose blood matches yours",
"       </li>",
"       <li>",
"        People who are not related to you, but whose blood matches yours",
"       </li>",
"       <li>",
"        Blood (which matches yours) from a newborn baby&rsquo;s umbilical cord",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Sometimes, treatment includes surgery to remove an organ called the spleen.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H540870721\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the leukemia comes back. Regular follow up tests include talking with your doctor, exams, and blood tests. Sometimes, the doctor will also do a bone marrow biopsy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H540870728\">",
"      <span class=\"h1\">",
"       What happens if the leukemia comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the leukemia comes back, you might have more chemotherapy, radiation, or bone marrow transplantation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H540870735\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctors&rsquo; instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for leukemia involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H540870742\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/40/24194?source=see_link\">",
"       Patient information: Leukemia in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/12/13506?source=see_link\">",
"       Patient information: Hairy cell leukemia (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=see_link\">",
"       Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=see_link\">",
"       Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=see_link\">",
"       Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=see_link\">",
"       Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/13/38098?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15491 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38098=[""].join("\n");
var outline_f37_13_38098=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870693\">",
"      What is leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870700\">",
"      What are the symptoms of leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870707\">",
"      Is there a test for leukemia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870714\">",
"      How is leukemia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870721\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870728\">",
"      What happens if the leukemia comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870735\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H540870742\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/10/6309?source=related_link\">",
"      Patient information: Chronic lymphocytic leukemia (CLL) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/12/13506?source=related_link\">",
"      Patient information: Hairy cell leukemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/40/24194?source=related_link\">",
"      Patient information: Leukemia in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_13_38099="Muscles obturator space";
var content_f37_13_38099=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Muscles of the obturator space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38099=[""].join("\n");
var outline_f37_13_38099=null;
var title_f37_13_38100="Echocardiogram five chamber view of AS";
var content_f37_13_38100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/80369/5chambas_conv.mp4?title=Echocardiogram+five+chamber+view+of+AS\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Five chamber echocardiographic view of a calcified aortic valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Five chamber view from a 2-D echocardiogram in a patient with aortic stenosis shows significant calcification of the aortic valve and lack of leaflet mobility. Moderate left ventricular hypertrophy is also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38100=[""].join("\n");
var outline_f37_13_38100=null;
var title_f37_13_38101="Didanosine: Patient drug information";
var content_f37_13_38101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Didanosine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     see \"Didanosine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/61/30680?source=see_link\">",
"     see \"Didanosine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Videx&reg;;",
"     </li>",
"     <li>",
"      Videx&reg; EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Videx&reg;;",
"     </li>",
"     <li>",
"      Videx&reg; EC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause irritation to the pancreas, liver problems, or change acid levels in the blood. Closely read the part in this leaflet which lists when to call your doctor. If you are pregnant you may have more chance of having high acid levels when taking stavudine and didanosine at the same time. Only use both drugs at the same time if the good effects outweigh the bad effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat HIV infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to didanosine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697233",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an irritated pancreas, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698527",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant and taking didanosine and stavudine, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697729",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy in HIV disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696711",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not breast-feed if you have HIV disease unless your doctor tells you to.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritated pancreas may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throwing up blood or throw up that looks like coffee grounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store children's liquid (suspension) in a refrigerator. Throw away any part not used after 30 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12377 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38101=[""].join("\n");
var outline_f37_13_38101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159665\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159666\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030814\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030816\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030815\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030820\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030821\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030823\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030818\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030819\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030824\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030825\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=related_link\">",
"      Didanosine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/61/30680?source=related_link\">",
"      Didanosine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_13_38102="High resolution manometry";
var content_f37_13_38102=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    High resolution manometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 574px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is a wet swallow captured by high resolution manometry. The colors represent pressure in the esophagus as shown on the y-axis. The x-axis is time. There are simultaneous contractions in the body of the esophagus. The LES relaxes incompletely. These findings are consistent with a diagnosis of achalasia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anthony J Lembo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38102=[""].join("\n");
var outline_f37_13_38102=null;
var title_f37_13_38103="Oxycodone and aspirin: Drug information";
var content_f37_13_38103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxycodone and aspirin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/48/32517?source=see_link\">",
"    see \"Oxycodone and aspirin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/18/18727?source=see_link\">",
"    see \"Oxycodone and aspirin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Endodan&reg;;",
"     </li>",
"     <li>",
"      Percodan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Endodan&reg;;",
"     </li>",
"     <li>",
"      Oxycodan&reg;;",
"     </li>",
"     <li>",
"      Percodan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F205041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Analgesic:",
"     </b>",
"     Oral: One tablet every 6 hours as needed for pain; maximum aspirin dose should not exceed 4 g/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F205049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/18/18727?source=see_link\">",
"      see \"Oxycodone and aspirin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Analgesic:",
"     </b>",
"     Oral (dose based on total oxycodone content): Oxycodone 0.1-0.2 mg/kg/dose (maximum oxycodone: 5 mg/dose; maximum aspirin: 4 g/day). Doses should be given every 4-6 hours as needed (American Pain Society, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F205042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10454538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Avoid use of aspirin in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F205043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Avoid use of aspirin-containing products in severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Oxycodone hydrochloride 4.8355 mg and aspirin 325 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endodan&reg;, Percodan&reg;: Oxycodone hydrochloride 4.8355 mg and aspirin 325 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F205058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10454539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of moderate- to moderately-severe pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Percodan&reg; may be confused with Decadron, Percocet&reg;, Percogesic&reg;, Periactin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Also see individual agents",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Circulatory depression, hypotension, shock",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, dysphoria, euphoria, lightheadedness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, respiratory arrest, respiratory depression",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxycodone, salicylates, other NSAIDs, or any component of the formulation; patients with the syndrome of asthma, rhinitis, and nasal polyps; inherited or acquired bleeding disorders (including factor VII and factor IX deficiency); do not use in children and teenagers in the presence of viral infections (chickenpox or flu symptoms), with or without fever, due to a potential association with Reye's syndrome; significant respiratory depression; hypercarbia; known or suspected paralytic ileus; acute or severe bronchial asthma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tinnitus: Discontinue use if tinnitus or impaired hearing occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction; acute pancreatitis may cause constriction of sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with platelet and bleeding disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Heavy ethanol use (&gt;3 drinks/day) can increase bleeding risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with erosive gastritis or peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; aspirin-containing products should be avoided in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obesity: Use with caution in patients who are morbidly obese.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychosis: Use with caution in patients with toxic psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; aspirin-containing products should be avoided in severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use oxycodone with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use with caution in patients with a history of seizure disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: ASA should be avoided (if possible) in surgical patients for 1-2 weeks prior to surgery, to reduce the risk of excessive bleeding (except in patients with cardiac stents that have not completed their full course of dual antiplatelet therapy [aspirin, clopidogrel]; patient specific situations need to be discussed with cardiologist; AHA/ACC/SCAI/ACS/ADA Science Advisory provides recommendations).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion: Healthcare provider should be alert to problems of abuse, misuse, and diversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F205050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of OxyCODONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of OxyCODONE. Management: A reduced oxycodone dose may be necessary with concurrent voriconazole.  Increased frequency and duration of monitoring for oxycodone-related adverse effects is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (oxycodone); D (aspirin) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F205045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F205033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F205034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5989445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Endodan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.8355-325 mg (100): $118.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oxycodone-Aspirin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.8355-325 mg (100): $113.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Percodan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.8355-325 mg (100): $162.48",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Percodan (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oxycodone, as with other narcotic (opiate) analgesics, blocks pain perception in the cerebral cortex by binding to specific receptor molecules (opiate receptors) within the neuronal membranes of synapses. This binding results in a decreased synaptic chemical transmission throughout the CNS, thus inhibiting the flow of pain sensations into the higher centers. Mu and kappa are the two subtypes of the opiate receptor to which oxycodone binds to cause analgesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aspirin inhibits prostaglandin synthesis by decreasing the activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors, acts on the hypothalamic heat-regulating center to reduce fever, blocks thromboxane synthetase action which prevents formation of the platelet-aggregating substance thromboxane A",
"     <sub>",
"      2",
"     </sub>",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/13/38103/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/13/38103/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/13/38103/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, &ldquo;New Approaches to Preventing and Treating Postoperative Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):26-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/13/38103/abstract-text/1619142/pubmed\" id=\"1619142\" target=\"_blank\">",
"        1619142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gobetti JP, &ldquo;Controlling Dental Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):47-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/13/38103/abstract-text/1619145/pubmed\" id=\"1619145\" target=\"_blank\">",
"        1619145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9731 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38103=[""].join("\n");
var outline_f37_13_38103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205038\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205039\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205056\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205041\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205049\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205042\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10454538\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205043\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205025\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205010\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205058\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10454539\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205027\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205064\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205054\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205030\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205014\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205050\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205018\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205020\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205032\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205045\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205033\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205034\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5989445\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038715\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205013\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205029\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9731\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9731|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/48/32517?source=related_link\">",
"      Oxycodone and aspirin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/18/18727?source=related_link\">",
"      Oxycodone and aspirin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_13_38104="Pathogenesis, clinical manifestations, and diagnosis of brain abscess";
var content_f37_13_38104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical manifestations, and diagnosis of brain abscess",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38104/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38104/contributors\">",
"     Frederick S Southwick, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38104/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38104/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38104/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38104/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/13/38104/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain abscess is a focal collection within the brain parenchyma, which can arise as a complication of a variety of infections, trauma, or surgery.",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of brain abscess will be presented here. The treatment and prognosis of this disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32438?source=see_link\">",
"     \"Treatment and prognosis of brain abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteria can invade the brain either by direct spread, which accounts for 20 to 60 percent of cases, or through hematogenous seeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/1\">",
"     1",
"    </a>",
"    ]. Bacteremic spread typically causes multiple lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Direct spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direct spread of organisms from a contiguous site usually causes a single brain abscess. Primary infections that can directly spread to the cerebral cortex include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subacute and chronic otitis media and mastoiditis (spread to the inferior temporal lobe and cerebellum)",
"     </li>",
"     <li>",
"      Frontal or ethmoid sinuses (spread to the frontal lobes)",
"     </li>",
"     <li>",
"      Dental infection (usually spreads to the frontal lobes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Brain abscess as a complication of ear infections has decreased in frequency, especially in developed countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. By contrast, brain abscess arising from a sinus infection remains an important consideration in both adults and children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/3,4,8\">",
"     3,4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bullet wounds to the brain can result in necrotic tissue and leave metal fragments that can serve as a nidus for infection. Other foreign bodies that have been associated with brain abscesses include a pencil tip lodged in the eye and a lawn dart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In these cases, brain abscess may develop many years after the injury. In addition, brain abscess can occasionally result from facial trauma.",
"   </p>",
"   <p>",
"    Brain abscess can also complicate neurosurgical procedures. Development of brain abscess after neurosurgery may be delayed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. For example, in one report of two cases of brain abscess following surgery for vestibular schwannoma (acoustic neuroma), one patient developed subtle neurologic findings three months after the surgery; the second presented with seizures 15 months after the original surgery, which had been complicated by a Pseudomonas aeruginosa meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hematogenous spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain abscesses associated with bacteremia usually result in multiple abscesses that are most commonly located in the distribution of the middle cerebral artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/2\">",
"     2",
"    </a>",
"    ]. Abscesses usually form at the grey-white matter junction where micro infarction damages the blood-brain barrier.",
"   </p>",
"   <p>",
"    Conditions that lead to hematogenous seeding of the brain include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/2,13-18\">",
"     2,13-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pulmonary infections, such as lung abscess and empyema, often in hosts with bronchiectasis or cystic fibrosis",
"     </li>",
"     <li>",
"      Skin infections",
"     </li>",
"     <li>",
"      Pelvic infections",
"     </li>",
"     <li>",
"      Intraabdominal infections",
"     </li>",
"     <li>",
"      Esophageal dilation and endoscopic sclerosis of esophageal varices",
"     </li>",
"     <li>",
"      Bacterial endocarditis (brain abscess complicates 2 to 4 percent of cases)",
"     </li>",
"     <li>",
"      Cyanotic congenital heart diseases (most common in children)",
"     </li>",
"     <li>",
"      Intrapulmonary right-to-left shunting in patients with pulmonary arteriovenous malformations. Up to 10 percent of patients with pulmonary arteriovenous malformations develop brain abscesses. Since 70 to 90 percent of patients with pulmonary arteriovenous malformations have underlying hereditary hemorrhagic telangiectasia, these patients often have a history of recurrent nosebleeds and visible mucocutaneous telangiectasias. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27656?source=see_link\">",
"       \"Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=see_link\">",
"       \"Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No primary site or underlying condition can be identified in 20 to 40 percent of patients with brain abscess depending upon the series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The location of a brain abscess reflects the site of the primary infection that spreads to the cerebral cortex. These locations in the brain in order of decreasing frequency are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frontal or temporal lobes",
"     </li>",
"     <li>",
"      Frontal-parietal",
"     </li>",
"     <li>",
"      Parietal",
"     </li>",
"     <li>",
"      Cerebellar",
"     </li>",
"     <li>",
"      Occipital",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may be features of the bacteria that contribute to the pathogenesis of brain abscess, although these have not been extensively explored. As an example, Citrobacter spp have been observed to cause both meningitis and brain abscess in neonates; in vitro, Citrobacter freundii was shown to be capable of invading human brain microvascular endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the pathology of brain abscess is required for the interpretation of computed tomographic (CT) scan and magnetic resonance imaging (MRI) findings. The histologic changes depend upon the age of the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/24\">",
"     24",
"    </a>",
"    ]. The early lesion (first one to two weeks) is poorly demarcated and is associated with localized edema. There is evidence of acute inflammation but no tissue necrosis. This early stage is commonly called cerebritis. After two to three weeks, necrosis and liquefaction occur, and the lesion becomes surrounded by a fibrotic capsule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports implicate a wide variety of organisms as the cause of brain abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/10,25-30\">",
"     10,25-30",
"    </a>",
"    ]. The pathogens involved differ depending upon the site of the primary infection, the age of the patient (with case series reflecting differences in infecting microorganisms between children and adults), and the immune status of the host [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Immunocompromised patients can have a broad array of organisms, including fungi, as the etiology of a brain abscess, whereas bacterial species are most common in immunocompetent individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The organism(s) recovered from a brain abscess frequently provide a clue about the primary site of infection and any potential undiagnosed underlying conditions in the host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98850357\">",
"    <span class=\"h2\">",
"     Source of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following primary sources of infection are associated with specific microorganisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Paranasal sinuses",
"      </strong>",
"      &ndash; Streptococcus spp (especially S. milleri), Haemophilus spp, Bacteroides spp, Fusobacterium spp",
"     </li>",
"     <li>",
"      <strong>",
"       Odontogenic sources",
"      </strong>",
"      &ndash; Streptococcus spp, Bacteroides spp, Prevotella spp, Fusobacterium spp, Haemophilus spp",
"     </li>",
"     <li>",
"      <strong>",
"       Otogenic sources",
"      </strong>",
"      &ndash; Enterobacteriaceae, Streptococcus spp, Pseudomonas aeruginosa, Bacteroides spp",
"     </li>",
"     <li>",
"      <strong>",
"       Lungs",
"      </strong>",
"      &ndash; Streptococcus spp, Fusobacterium spp, Actinomyces spp",
"     </li>",
"     <li>",
"      <strong>",
"       Urinary tract",
"      </strong>",
"      &ndash; Pseudomonas aeruginosa, Enterobacter spp",
"     </li>",
"     <li>",
"      <strong>",
"       Penetrating head trauma",
"      </strong>",
"      &ndash; Staphylococcus aureus, Enterobacter spp, Clostridium spp",
"     </li>",
"     <li>",
"      <strong>",
"       Neurosurgical procedures",
"      </strong>",
"      &ndash; Staphylococcus spp, Streptococcus spp, Pseudomonas aeruginosa, Enterobacter spp",
"     </li>",
"     <li>",
"      <strong>",
"       Endocarditis",
"      </strong>",
"      &ndash; Viridans streptococci, S. aureus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Congenital cardiac malformations (especially right-to-left shunts)",
"    </strong>",
"    &ndash; Streptococcus spp",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anaerobic pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaerobic bacteria are common constituents of brain abscesses. These organisms generally originate from the normal mouth flora and are most commonly associated with solitary brain abscesses originating from otorhinolaryngeal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/36\">",
"     36",
"    </a>",
"    ]. However, intraabdominal or pelvic infections can occasionally lead to bacteremia with an anaerobic organism that seeds the cerebral cortex. The anaerobes in such cases usually reflect colonic or female genital tract flora. The most frequent anaerobes cultured from a brain abscess include: anaerobic streptococci, Bacteroides spp. (including B. fragilis), Prevotella melaninogenica, Propionibacterium, Fusobacterium, Eubacterium, Veillonella, and Actinomyces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/31,36\">",
"     31,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aerobic pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerobic gram-positive cocci are also frequently encountered and include: viridans streptococci, Streptococcus milleri, microaerophilic streptococci, Streptococcus pneumoniae (rare), and Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/16,26\">",
"     16,26",
"    </a>",
"    ]. S. aureus is a frequent pathogen in brain abscess following trauma or a neurosurgical procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/19\">",
"     19",
"    </a>",
"    ]. Cases of community-acquired methicillin-resistant S. aureus brain abscess have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. milleri (also called S. anginosus) is particularly common; this organism possesses proteolytic enzymes that predispose to necrosis of tissue and the formation of abscesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/38\">",
"     38",
"    </a>",
"    ]. Rarely, the gram-positive rod Rhodococcus equi has been associated with brain abscesses, primarily in immunocompromised patients but also in one reported immunocompetent patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27080?source=see_link\">",
"     \"Group C and group G streptococcal infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37814?source=see_link\">",
"     \"Microbiology; pathogenesis; and epidemiology of Rhodococcus equi infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aerobic gram-negative rods can be recovered from a brain abscess following neurosurgery or head trauma or when an otogenic infection is the source. When gram-negative rods are isolated, Klebsiella pneumoniae, Pseudomonas spp., Escherichia coli, and Proteus spp. are most common. Less common pathogens include Haemophilus aphrophilus, Actinobacillus actinomycetemcomitans, Salmonella, and Enterobacter spp. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16600?source=see_link\">",
"     \"Epidemiology and clinical features of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Klebsiella pneumoniae brain abscess with or without meningitis can occur as a manifestation of metastatic infection that is associated with community-acquired primary liver abscess. This syndrome is primarily seen in Southeast Asia, particularly Taiwan. This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;The range of organisms, particularly opportunistic pathogens, is considerably broader in the immunocompromised host with a brain abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/32,42\">",
"     32,42",
"    </a>",
"    ]. Toxoplasma gondii can reactivate when the cell-mediated immune system becomes compromised. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Listeria can result in single or multiple brain or brainstem abscesses particularly in patients receiving corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/43\">",
"     43",
"    </a>",
"    ]. Mortality is three times higher in patients with Listeria as compared to those with brain abscesses caused by other bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/44/1736?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of Listeria monocytogenes infection\", section on 'CNS infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nocardia asteroides, a common soil organism, can enter the bloodstream via the lungs and seed the cerebral cortex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23991?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aspergillus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/46\">",
"     46",
"    </a>",
"    ], Cryptococcus neoformans, and Coccidioides immitis also can enter through the lungs and subsequently invade the cerebral cortex. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19494?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17271?source=see_link\">",
"     \"Coccidioidal meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other fungal pathogens causing brain abscess in the immunocompromised host include Candida spp, the fungi that cause zygomycosis (mucormycosis), Cladosporium trichoides and Curvularia spp, among others. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .) Fungal infections of the brain usually result in multiple brain abscesses, and the outcome is usually poor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     HIV-infected patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals infected with the human immunodeficiency virus (HIV) frequently develop infections of the cerebral cortex. The differential diagnosis of central nervous system infections in the HIV-infected patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41128?source=see_link\">",
"     \"Approach to HIV-infected patients with central nervous system lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Immigrants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasites are the most common etiology of brain abscess in individuals who previously lived outside the United States. Cysticercosis due to Taenia solium infection causes 85 percent of brain infections in Mexico City [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28232?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other parasites that can cause brain abscess or infection include: Entamoeba histolytica, Schistosoma japonicum, and Paragonimus species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Salmonella brain abscess has also been described in a traveler [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical features of schistosomiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=see_link&amp;anchor=H5#H5\">",
"     \"Paragonimiasis\", section on 'Cerebral infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33031?source=see_link&amp;anchor=H17#H17\">",
"     \"Extraintestinal Entamoeba histolytica amebiasis\", section on 'Brain abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of brain abscess initially tend to be nonspecific, resulting in a delay in establishing the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/8,19\">",
"     8,19",
"    </a>",
"    ]. The diagnosis is made at a mean of 13 to 14 days after the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/1\">",
"     1",
"    </a>",
"    ]. A number of other infectious and noninfectious entities are in the differential diagnosis of brain abscess (",
"    <a class=\"graphic graphic_table graphicRef61378 \" href=\"mobipreview.htm?1/52/1867\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headache is the most common symptom of a brain abscess although it is obviously also one of the most common medical complaints. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link\">",
"     \"Evaluation of headache in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pain is usually localized to the side of the abscess, and its onset can be gradual or sudden. The pain tends to be severe and not relieved by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other over-the-counter pain medications. In patients with cyanotic heart disease and headache, brain abscess must always be excluded.",
"   </p>",
"   <p>",
"    Neck stiffness occurs in 15 percent of patients with brain abscess. This complaint is most commonly associated with occipital lobe abscess or an abscess that has leaked into a lateral ventricle. Changes in mental status (lethargy progressing to coma) are indicative of severe cerebral edema and are a poor prognostic sign (see below). Vomiting generally develops in association with increased intracranial pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is not a reliable indicator of brain abscess since only 45 to 50 percent of patients have this sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/48\">",
"     48",
"    </a>",
"    ]. Focal neurologic deficits are observed in 50 percent of patients and generally occur days to weeks after the onset of headache (",
"    <a class=\"graphic graphic_table graphicRef69692 \" href=\"mobipreview.htm?5/50/5932\">",
"     table 2",
"    </a>",
"    ). Seizures develop in 25 percent of cases and can be the first manifestation of brain abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/48\">",
"     48",
"    </a>",
"    ]. Grand mal seizures are particularly common in frontal abscesses.",
"   </p>",
"   <p>",
"    Third and sixth cranial nerve deficits indicate raised intracranial pressure. Papilledema is a late manifestation of cerebral edema and usually takes several days to develop. This finding is observed in approximately 25 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of focal symptoms (eg, unilateral headache) or signs (eg, unilateral cranial nerve deficits, hemiparesis) or the finding of papilledema, a lumbar puncture (LP) is contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/49\">",
"     49",
"    </a>",
"    ]. Decompression of the cerebrospinal fluid (CSF) pressure below the tentorium in association with asymmetric cerebral edema results in brainstem herniation in 1.5 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/1,19,50-52\">",
"     1,19,50-52",
"    </a>",
"    ]. CT scan with contrast or MRI should be performed prior to LP in this circumstance to exclude a focal cerebral lesion. In patients presenting acutely or in whom meningitis is suspected, blood cultures can be drawn (positive in 15 percent of cases) and empiric parenteral antibiotic therapy initiated before CT scan or MRI. If the study is negative, an LP can then be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Computed tomographic scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scan is not as sensitive as MRI for the diagnosis of brain abscess but can frequently be obtained more easily on an emergent basis. When looking for a brain abscess, this study must be performed with a contrast agent. The lesion has different appearances depending upon its age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early cerebritis appears as an irregular area of low density that does not enhance following contrast injection.",
"     </li>",
"     <li>",
"      As cerebritis evolves, the lesion enlarges with thick and diffuse ring enhancement following contrast injection. The ring of contrast enhancement represents breakdown of the blood brain barrier and the development of an inflammatory capsule.",
"     </li>",
"     <li>",
"      The precontrast scan reveals a faint area of higher density than the surrounding edematous brain by the time the lesion has matured and become encapsulated. The contrast study for these late lesions demonstrates a thin ring which may not be uniform in thickness and is often less prominent on the medial surface, adjacent to the white matter, where vascularity is reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI should be performed with gadolinium diethylenetriamine peta-acetic acid. This agent increases the T1 intensity and causes more prominent enhancement of lesions than CT scan. Compared to CT scan, MRI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is more sensitive for early cerebritis",
"     </li>",
"     <li>",
"      Is more sensitive for detecting satellite lesions",
"     </li>",
"     <li>",
"      More accurately estimates the extent of central necrosis, ring enhancement, and cerebral edema",
"     </li>",
"     <li>",
"      Better visualizes the brainstem",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diffusion-weighted MR imaging (DWI) is capable of differentiating ring-enhancing lesions due to brain abscess from neoplastic lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/34\">",
"     34",
"    </a>",
"    ]. Abscesses are usually hyperintense on DWI (indicating restricted diffusion, characteristic of viscous materials, such as pus), while neoplastic lesions are hypointense or show variable hyperintensity that is lower than the intensity seen with an abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, this test is contraindicated in a patient with focal symptoms or signs. However, an LP has been inadvertently performed in a number of cases. In one study of 65 patients with brain abscess that underwent lumbar puncture, the CSF pattern was variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/52\">",
"     52",
"    </a>",
"    ]. The mean protein level was 250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (range 90 to 425",
"    <span class=\"nowrap\">",
"     mg/dL);",
"    </span>",
"    mean glucose level 39",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (range, 11 to 58",
"    <span class=\"nowrap\">",
"     mg/dL);",
"    </span>",
"    and mean white cell count 4407 per microL (range, 80 to 5006 per microL). Rarely, the CSF formula resembles bacterial meningitis, which indicates rupture of the abscess into the ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/54\">",
"     54",
"    </a>",
"    ]. When this occurs, the PMN count can be higher than",
"    <span class=\"nowrap\">",
"     150,000/microL",
"    </span>",
"    with accompanying hypoglycorrhachia and an elevated protein. In patients with presumed meningitis who respond poorly to antibiotics, MRI should be performed and may reveal an unsuspected brain abscess that has ruptured into the ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specimen obtained from stereotactic CT-guided aspiration or surgery should be sent for Gram's stain, aerobic, anaerobic, mycobacterial, and fungal culture. In addition, special stains including an acid-fast stain for mycobacteria, modified acid-fast stain for Nocardia, and fungal stains should be performed to aid in the identification of the etiologic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Toxoplasma immunoglobulin G (IgG) antibody in blood and anticysticercal antibodies on CSF specimens, can aid in the diagnosis of Toxoplasma gondii or neurocysticercosis infections, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28232?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cysticercosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of brain abscess and frequently the identification of the etiologic agent is made by pathologic examination of brain tissue obtained by open or stereotactic brain biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     16S ribosomal sequencing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In three studies, 16S ribosomal DNA polymerase chain reaction amplification increased the number of bacterial species isolated from brain abscesses as compared with standard culture; several species had not been identified previously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. Further studies will be required to determine the significance of the identification of these newly identified bacteria associated with brain abscesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38104/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Brain abscess is a focal collection within the brain parenchyma, which can arise as a complication of a variety of infections, trauma, or surgery. Bacteria can invade the brain either by direct spread or through hematogenous seeding. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The direct spread of organisms from a contiguous site usually causes a single brain abscess. Primary infections that can directly spread to the cerebral cortex include subacute and chronic otitis media and mastoiditis (spread to the inferior temporal lobe and cerebellum), frontal or ethmoid sinusitis (spread to the frontal lobes), and dental infection (usually spreads to the frontal lobes). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Direct spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Brain abscesses associated with bacteremia usually result in multiple abscesses that are most commonly located in the distribution of the middle cerebral artery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hematogenous spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide variety of organisms may cause brain abscess. The pathogens involved differ depending upon the site of the primary infection. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The manifestations of brain abscess initially tend to be nonspecific, resulting in a delay in establishing the diagnosis. In addition, a number of other infectious and noninfectious entities are in the differential diagnosis of brain abscess (",
"      <a class=\"graphic graphic_table graphicRef61378 \" href=\"mobipreview.htm?1/52/1867\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of focal symptoms (eg, unilateral headache) or signs (eg, unilateral cranial nerve deficits, hemiparesis) or the finding of papilledema, a lumbar puncture (LP) is contraindicated, as brainstem herniation may occur in 1.5 to 30 percent of cases when LP is performed in a patient with a brain abscess and substantial mass effect. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRI is the imaging study of choice in brain abscess as it is more sensitive than the CT scan. Diffusion-weighted MR imaging (DWI) is, in addition, more capable of differentiating ring-enhancing lesions due to brain abscess from neoplastic lesions. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Magnetic resonance imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The specimen obtained from stereotactic CT-guided aspiration or surgery should be sent for Gram's stain, aerobic, anaerobic, mycobacterial, and fungal cultures, special stains, and histopathology. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients at risk for parasitic brain abscess should have serology of blood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CSF sent for diagnostic testing. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/1\">",
"      Chun CH, Johnson JD, Hofstetter M, Raff MJ. Brain abscess. A study of 45 consecutive cases. Medicine (Baltimore) 1986; 65:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/2\">",
"      Bakshi R, Wright PD, Kinkel PR, et al. Cranial magnetic resonance imaging findings in bacterial endocarditis: the neuroimaging spectrum of septic brain embolization demonstrated in twelve patients. J Neuroimaging 1999; 9:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/3\">",
"      Gallagher RM, Gross CW, Phillips CD. Suppurative intracranial complications of sinusitis. Laryngoscope 1998; 108:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/4\">",
"      Giannoni C, Sulek M, Friedman EM. Intracranial complications of sinusitis: a pediatric series. Am J Rhinol 1998; 12:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/5\">",
"      Giannoni CM, Stewart MG, Alford EL. Intracranial complications of sinusitis. Laryngoscope 1997; 107:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/6\">",
"      Yen PT, Chan ST, Huang TS. Brain abscess: with special reference to otolaryngologic sources of infection. Otolaryngol Head Neck Surg 1995; 113:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/7\">",
"      Kangsanarak J, Fooanant S, Ruckphaopunt K, et al. Extracranial and intracranial complications of suppurative otitis media. Report of 102 cases. J Laryngol Otol 1993; 107:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/8\">",
"      Chalstrey S, Pfleiderer AG, Moffat DA. Persisting incidence and mortality of sinogenic cerebral abscess: a continuing reflection of late clinical diagnosis. J R Soc Med 1991; 84:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/9\">",
"      Foy P, Sharr M. Cerebral abscesses in children after pencil-tip injuries. Lancet 1980; 2:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/10\">",
"      Lew JF, Wiedermann BL, Sneed J, et al. Aerotolerant Clostridium tertium brain abscess following a lawn dart injury. J Clin Microbiol 1990; 28:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/11\">",
"      Staecker H, Nadol JB Jr, Ojeman R, McKenna MJ. Delayed intracranial abscess after acoustic neuroma surgery: a report of two cases. Am J Otol 1999; 20:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/12\">",
"      Hashmi S, Jones RA. Delayed recurrence of cerebellar abscess 20 years after excision of dermoid cyst and sinus. Br J Neurosurg 1998; 12:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/13\">",
"      Fischer EG, Shwachman H, Wepsic JG. Brain abscess and cystic fibrosis. J Pediatr 1979; 95:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/14\">",
"      Patel KS, Marks PV. Multiple brain abscesses secondary to bronchiectasis. A case of 34 discrete abscesses in one brain. Clin Neurol Neurosurg 1989; 91:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/15\">",
"      Kum N, Charles D. Cerebral abscess associated with an intrauterine contraceptive device. Obstet Gynecol 1979; 54:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/16\">",
"      Schlaeffer F, Riesenberg K, Mikolich D, et al. Serious bacterial infections after endoscopic procedures. Arch Intern Med 1996; 156:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/17\">",
"      Takeshita M, Kagawa M, Yato S, et al. Current treatment of brain abscess in patients with congenital cyanotic heart disease. Neurosurgery 1997; 41:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/18\">",
"      Cahill DP, Barker FG 2nd, Davis KR, et al. Case records of the Massachusetts General Hospital. Case 10-2010. A 37-year-old woman with weakness and a mass in the brain. N Engl J Med 2010; 362:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/19\">",
"      Schliamser SE, B&auml;ckman K, Norrby SR. Intracranial abscesses in adults: an analysis of 54 consecutive cases. Scand J Infect Dis 1988; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/20\">",
"      Ng PY, Seow WT, Ong PL. Brain abscesses: review of 30 cases treated with surgery. Aust N Z J Surg 1995; 65:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/21\">",
"      Yang SY, Zhao CS. Review of 140 patients with brain abscess. Surg Neurol 1993; 39:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/22\">",
"      Nielsen H, Gyldensted C, Harmsen A. Cerebral abscess. Aetiology and pathogenesis, symptoms, diagnosis and treatment. A review of 200 cases from 1935-1976. Acta Neurol Scand 1982; 65:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/23\">",
"      Badger JL, Stins MF, Kim KS. Citrobacter freundii invades and replicates in human brain microvascular endothelial cells. Infect Immun 1999; 67:4208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/24\">",
"      Britt RH, Enzmann DR. Clinical stages of human brain abscesses on serial CT scans after contrast infusion. Computerized tomographic, neuropathological, and clinical correlations. J Neurosurg 1983; 59:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/25\">",
"      Bonvin P, Ejlertsen T, Dons-Jensen H. Brain abscess caused by Salmonella enteritidis in an immunocompetent adult patient: successful treatment with cefotaxime and ciprofloxacin. Scand J Infect Dis 1998; 30:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/26\">",
"      Yamamoto M, Fukushima T, Ohshiro S, et al. Brain abscess caused by Streptococcus intermedius: two case reports. Surg Neurol 1999; 51:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/27\">",
"      Grigoriadis E, Gold WL. Pyogenic brain abscess caused by Streptococcus pneumoniae: case report and review. Clin Infect Dis 1997; 25:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/28\">",
"      Ba&ntilde;uelos AF, Williams PL, Johnson RH, et al. Central nervous system abscesses due to Coccidioides species. Clin Infect Dis 1996; 22:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/29\">",
"      Ohnishi K, Murata M, Kojima H, et al. Brain abscess due to infection with Entamoeba histolytica. Am J Trop Med Hyg 1994; 51:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/30\">",
"      Lakshmi V, Rao RR, Dinakar I. Bacteriology of brain abscess--observations on 50 cases. J Med Microbiol 1993; 38:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/31\">",
"      Brook I. Aerobic and anaerobic bacteriology of intracranial abscesses. Pediatr Neurol 1992; 8:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/32\">",
"      Hagensee ME, Bauwens JE, Kjos B, Bowden RA. Brain abscess following marrow transplantation: experience at the Fred Hutchinson Cancer Research Center, 1984-1992. Clin Infect Dis 1994; 19:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/33\">",
"      Baddley JW, Salzman D, Pappas PG. Fungal brain abscess in transplant recipients: epidemiologic, microbiologic, and clinical features. Clin Transplant 2002; 16:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/34\">",
"      Friedlander RM, Gonzalez RG, Afridi NA, Pfannl R. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 16-2003. A 58-year-old woman with left-sided weakness and a right frontal brain mass. N Engl J Med 2003; 348:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/35\">",
"      Arlotti M, Grossi P, Pea F, et al. Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis 2010; 14 Suppl 4:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/36\">",
"      Le Moal G, Landron C, Grollier G, et al. Characteristics of brain abscess with isolation of anaerobic bacteria. Scand J Infect Dis 2003; 35:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/37\">",
"      Sifri CD, Park J, Helm GA, et al. Fatal brain abscess due to community-associated methicillin-resistant Staphylococcus aureus strain USA300. Clin Infect Dis 2007; 45:e113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/38\">",
"      Jacobs JA, Pietersen HG, Stobberingh EE, Soeters PB. Bacteremia involving the \"Streptococcus milleri\" group: analysis of 19 cases. Clin Infect Dis 1994; 19:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/39\">",
"      Corne P, Rajeebally I, Jonquet O. Rhodococcus equi brain abscess in an immunocompetent patient. Scand J Infect Dis 2002; 34:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/40\">",
"      Brook I. Brain abscess in children: microbiology and management. J Child Neurol 1995; 10:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/41\">",
"      Rau CS, Chang WN, Lin YC, et al. Brain abscess caused by aerobic Gram-negative bacilli: clinical features and therapeutic outcomes. Clin Neurol Neurosurg 2002; 105:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/42\">",
"      Guppy KH, Thomas C, Thomas K, Anderson D. Cerebral fungal infections in the immunocompromised host: a literature review and a new pathogen--Chaetomium atrobrunneum: case report. Neurosurgery 1998; 43:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/43\">",
"      Eckburg PB, Montoya JG, Vosti KL. Brain abscess due to Listeria monocytogenes: five cases and a review of the literature. Medicine (Baltimore) 2001; 80:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/44\">",
"      Cone LA, Leung MM, Byrd RG, et al. Multiple cerebral abscesses because of Listeria monocytogenes: three case reports and a literature review of supratentorial listerial brain abscess(es). Surg Neurol 2003; 59:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/45\">",
"      Valarezo J, Cohen JE, Valarezo L, et al. Nocardial cerebral abscess: report of three cases and review of the current neurosurgical management. Neurol Res 2003; 25:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/46\">",
"      Erdogan E, Beyzadeoglu M, Arpaci F, Celasun B. Cerebellar aspergillosis: case report and literature review. Neurosurgery 2002; 50:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/47\">",
"      Correa D, Sarti E, Tapia-Romero R, et al. Antigens and antibodies in sera from human cases of epilepsy or taeniasis from an area of Mexico where Taenia solium cysticercosis is endemic. Ann Trop Med Parasitol 1999; 93:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/48\">",
"      Seydoux C, Francioli P. Bacterial brain abscesses: factors influencing mortality and sequelae. Clin Infect Dis 1992; 15:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/49\">",
"      Heilpern KL, Lorber B. Focal intracranial infections. Infect Dis Clin North Am 1996; 10:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/50\">",
"      Nielsen H. Cerebral abscess in children. Neuropediatrics 1983; 14:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/51\">",
"      Patir R, Sood S, Bhatia R. Post-traumatic brain abscess: experience of 36 patients. Br J Neurosurg 1995; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/52\">",
"      Tattevin P, Bruneel F, Clair B, et al. Bacterial brain abscesses: a retrospective study of 94 patients admitted to an intensive care unit (1980 to 1999). Am J Med 2003; 115:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/53\">",
"      Leuthardt EC, Wippold FJ 2nd, Oswood MC, Rich KM. Diffusion-weighted MR imaging in the preoperative assessment of brain abscesses. Surg Neurol 2002; 58:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/54\">",
"      Ferr&eacute; C, Ariza J, Viladrich PF, et al. Brain abscess rupturing into the ventricles or subarachnoid space. Am J Med 1999; 106:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/55\">",
"      Kamra P, Vatsal DK, Husain M, et al. MRI demonstration of unsuspected intraventricular rupture of pyogenic cerebral abscesses in patients being treated for meningitis. Neuroradiology 2002; 44:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/56\">",
"      Al Masalma M, Armougom F, Scheld WM, et al. The expansion of the microbiological spectrum of brain abscesses with use of multiple 16S ribosomal DNA sequencing. Clin Infect Dis 2009; 48:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/57\">",
"      Keller PM, Rampini SK, Bloemberg GV. Detection of a mixed infection in a culture-negative brain abscess by broad-spectrum bacterial 16S rRNA gene PCR. J Clin Microbiol 2010; 48:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/58\">",
"      Al Masalma M, Lonjon M, Richet H, et al. Metagenomic analysis of brain abscesses identifies specific bacterial associations. Clin Infect Dis 2012; 54:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38104/abstract/59\">",
"      DiGiulio DB, Relman DA. Majority rules? Tallying the microbial census in an abscess by means of molecular methods. Clin Infect Dis 2009; 48:1179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1297 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38104=[""].join("\n");
var outline_f37_13_38104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Direct spread",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hematogenous spread",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98850357\">",
"      Source of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anaerobic pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aerobic pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Immigrants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Computed tomographic scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      16S ribosomal sequencing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1297\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1297|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/52/1867\" title=\"table 1\">",
"      Ddx of brain abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/50/5932\" title=\"table 2\">",
"      Brain abscess neuro deficits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41128?source=related_link\">",
"      Approach to HIV-infected patients with central nervous system lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/44/1736?source=related_link\">",
"      Clinical manifestations and diagnosis of Listeria monocytogenes infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19494?source=related_link\">",
"      Clinical manifestations and diagnosis of cryptococcal meningoencephalitis in HIV seronegative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/36/28232?source=related_link\">",
"      Clinical manifestations and diagnosis of cysticercosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17271?source=related_link\">",
"      Coccidioidal meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16600?source=related_link\">",
"      Epidemiology and clinical features of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40919?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/38/15977?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33031?source=related_link\">",
"      Extraintestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27080?source=related_link\">",
"      Group C and group G streptococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/31/31226?source=related_link\">",
"      Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/31/29176?source=related_link\">",
"      Invasive liver abscess syndrome caused by Klebsiella pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23991?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37814?source=related_link\">",
"      Microbiology; pathogenesis; and epidemiology of Rhodococcus equi infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36967?source=related_link\">",
"      Paragonimiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/0/27656?source=related_link\">",
"      Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/43/32438?source=related_link\">",
"      Treatment and prognosis of brain abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_13_38105="Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults";
var content_f37_13_38105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38105/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38105/contributors\">",
"     Sunil G Sheth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38105/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38105/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38105/contributors\">",
"     Keith D Lindor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38105/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38105/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/13/38105/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis when no other causes for secondary hepatic fat accumulation (eg, heavy alcohol consumption) are present. NAFLD may progress to cirrhosis and is likely an important cause of cryptogenic cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, clinical features, and diagnosis of NAFLD. The pathogenesis, natural history, and treatment of NAFLD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16073?source=see_link\">",
"     \"Pathogenesis of nonalcoholic fatty liver disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=see_link\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nonalcoholic fatty liver disease (NAFLD) have hepatic steatosis, with or without inflammation and fibrosis. In addition, no secondary causes of hepatic steatosis are present. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). In NAFL, hepatic steatosis is present without evidence of significant inflammation, whereas in NASH, hepatic steatosis is associated with hepatic inflammation that may be histologically indistinguishable from alcoholic steatohepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Other terms that have been used to describe NASH include pseudoalcoholic hepatitis, alcohol-like hepatitis, fatty liver hepatitis, steatonecrosis, and diabetic hepatitis. (See",
"    <a class=\"local\" href=\"#H147562655\">",
"     'Histologic findings'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H147564559\">",
"     'NAFLD activity score'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242879713\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonalcoholic fatty liver disease (NAFLD) is seen worldwide and is the most common liver disorder in Western industrialized countries, where the major risk factors for NAFLD, central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/7\">",
"     7",
"    </a>",
"    ]. In the United States, studies report a prevalence of NAFLD of 10 to 46 percent, with most biopsy-based studies reporting a prevalence of NASH of 3 to 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Worldwide, NAFLD has a reported prevalence of 6 to 35 percent (median 20 percent).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 400 US military personnel and their families (mean age 55 years), the prevalence of NAFLD by ultrasound was 46 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/8\">",
"       8",
"      </a>",
"      ]. Factors associated with NAFLD included male sex, increasing age, and the presence of systemic hypertension, obesity, or diabetes.",
"     </li>",
"     <li>",
"      In a population-based sample that included 2133 subjects from the US who reported moderate or no alcohol intake, hepatic steatosis was present in 30 and 32 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Estimates of prevalence of NAFLD in Asia-Pacific regions range from 5 to 30 percent, depending upon the population studied [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the US, the prevalence of NAFLD has been increasing over time. This increase was demonstrated in a comparison of three cycles of the National Health and Nutrition Examination Survey (NHANES) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Between 1988 and 1994, the prevalence of NAFLD was 5.5 percent, between 1999 and 2004 it was 9.8 percent, and between 2005 and 2008 it was 11 percent, accounting for 47, 63, and 75 percent of chronic liver disease during those time periods, respectively. However, it should be noted that the definition of NAFLD used in the study (elevated serum aminotransferase levels in the absence of an alternative explanation) could lead to misclassification and likely underestimated the true prevalence of NAFLD, since patients with NAFLD may have normal serum aminotransferases.",
"      <br/>",
"      <br/>",
"      Over the same three time periods, the study also noted increases in the rates of other components of the metabolic syndrome (",
"      <a class=\"graphic graphic_table graphicRef53446 \" href=\"mobipreview.htm?30/44/31437\">",
"       table 1",
"      </a>",
"      ), including obesity (22, 30, and 33 percent, respectively), type 2 diabetes (6, 8, and 9 percent, respectively), and systemic hypertension (23, 33, and 34 percent, respectively). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242879720\">",
"    <span class=\"h2\">",
"     Patient demographics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients are diagnosed with NAFLD in their 40s or 50s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/12\">",
"     12",
"    </a>",
"    ]. Studies vary with regard to the sex distribution of NAFLD, with some suggesting it is more common in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/5,13-19\">",
"     5,13-19",
"    </a>",
"    ] and others suggesting it is more common in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/8,10,20-23\">",
"     8,10,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appear to be ethnic differences in the prevalence of NASH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/8,10,24\">",
"     8,10,24",
"    </a>",
"    ]. A study of hepatic triglyceride content in 2287 subjects from a US multiethnic, population-based sample found a higher prevalence of hepatic steatosis in Hispanics (45 percent) compared with whites (33 percent) or blacks (24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/10\">",
"     10",
"    </a>",
"    ]. The higher prevalence in Hispanics was explained by a greater prevalence of obesity, although the lower prevalence in blacks persisted after controlling for body mass index and insulin sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242879397\">",
"    <span class=\"h2\">",
"     Association with other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NAFLD (particularly those with NASH) often have one or more components of the metabolic syndrome (",
"    <a class=\"graphic graphic_table graphicRef53446 \" href=\"mobipreview.htm?30/44/31437\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/5,13-15,20,22,25-30\">",
"     5,13-15,20,22,25-30",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Systemic hypertension",
"     </li>",
"     <li>",
"      Dyslipidemia",
"     </li>",
"     <li>",
"      Insulin resistance or overt diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This association was demonstrated in a study of 304 patients with NAFLD but without overt diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/22\">",
"     22",
"    </a>",
"    ]. Liver biopsies were performed in 163 patients and revealed NASH in 120 (74 percent). Metabolic syndrome was seen in 53 percent of patients who did not undergo biopsy, in 67 percent of those with simple steatosis (NAFL) on biopsy, and in 88 percent of those with NASH on biopsy. After correcting for age, sex, and body mass index, metabolic syndrome was associated with an increased risk of severe fibrosis (odds ratio [OR] 3.5, 95% confidence interval 1.1-11.2).",
"   </p>",
"   <p>",
"    While the metabolic syndrome is a known risk factor for cardiovascular disease and is common in patients with NAFLD, NAFLD may be independently associated with cardiovascular disease. In a study using data from NHANES, NAFLD was associated with cardiovascular disease after controlling for older age, male sex, obesity, type 2 diabetes, smoking, and family history of early myocardial infarction (odds ratio 1.23; 95% confidence interval 1.04-1.44) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the study did not control for dyslipidemia or systemic hypertension, which could act as confounders, since hyperlipidemia is associated with both NAFLD and cardiovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated. The most widely supported theory implicates insulin resistance as the key mechanism leading to hepatic steatosis, and perhaps also to steatohepatitis. Others have proposed that a \"second hit\", or additional oxidative injury, is required to manifest the necroinflammatory component of steatohepatitis. Hepatic iron, leptin, antioxidant deficiencies, and intestinal bacteria have all been suggested as potential oxidative stressors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16073?source=see_link\">",
"     \"Pathogenesis of nonalcoholic fatty liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with nonalcoholic fatty liver disease (NAFLD) are asymptomatic, although some patients with nonalcoholic steatohepatitis (NASH) may complain of fatigue, malaise, and vague right upper abdominal discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients are more likely to come to attention because laboratory testing revealed elevated liver aminotransferases or hepatic steatosis was detected incidentally on abdominal imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331433\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NAFLD may have hepatomegaly on physical examination due to fatty infiltration of the liver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/5,13,16,17,32\">",
"     5,13,16,17,32",
"    </a>",
"    ]. In some patients, hepatomegaly is the presenting sign of NAFLD. The reported prevalence of hepatomegaly in patients with NAFLD is highly variable:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based study of 1168 participants from Mumbai, NAFLD was detected in 9 percent (19 percent of those older than 20 years of age) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/32\">",
"       32",
"      </a>",
"      ]. Among those with NAFLD, 5 percent had hepatomegaly.",
"     </li>",
"     <li>",
"      In a study of 12 patients with NASH who underwent CT scanning, 11 had hepatomegaly (defined as a liver span of &gt;18 cm), with a mean liver span for all 12 of 21 cm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 144 patients with NASH, 18 percent were noted to have hepatomegaly on examination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound, and there was a trend toward an increased rate of hepatomegaly among those with more advanced fibrosis (28 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The population-based study likely provides a better estimate of the prevalence of hepatomegaly in patients with NAFLD since it does not subject to referral bias. However, the study did not differentiate between patients with nonalcoholic fatty liver and those with NASH, and as suggested by the third study, it is possible that hepatomegaly is more prevalent in patients with more advanced disease.",
"   </p>",
"   <p>",
"    Patients who have developed cirrhosis may have stigmata of chronic liver disease (eg, palmar erythema, spider angiomata, ascites). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331440\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with NAFLD may have mild or moderate elevations in the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/20\">",
"     20",
"    </a>",
"    ], although normal aminotransferase levels do not exclude NAFLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The true prevalence of abnormal transaminases among patients with NAFLD is unclear, since many patients with NAFLD are diagnosed because they are noted to have abnormal aminotransferases. When elevated, the AST and ALT are typically two to five times the upper limit of normal, with an AST to ALT ratio of less than one (unlike alcoholic fatty liver disease, which typically has a ratio greater than two) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/12,37-39\">",
"     12,37-39",
"    </a>",
"    ]. The degree of aminotransferase elevation does not predict the degree of hepatic inflammation or fibrosis, and a normal alanine aminotransferase does not exclude clinically important histologic injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/20,30,34\">",
"     20,30,34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H34934589\">",
"     'Significant alcohol consumption'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The alkaline phosphatase may be elevated to two to three times the upper limit of normal. Serum albumin and bilirubin levels are typically within the normal range, but may be abnormal in patients who have developed cirrhosis. Other laboratory abnormalities that may be seen in patients who have developed cirrhosis include a prolonged prothrombin time and cytopenias. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with NAFLD may have an elevated serum ferritin concentration or transferrin saturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/16,20\">",
"     16,20",
"    </a>",
"    ]. There is evidence that a serum ferritin greater than 1.5 times the upper limit of normal in patients with NAFLD is associated with a higher nonalcoholic fatty liver disease activity score (and thus, NASH) and with advanced hepatic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients with NAFLD may also have positive serum autoantibodies (antinuclear antigen, antismooth muscle antibody), though the significance of these findings is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H147564559\">",
"     'NAFLD activity score'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331447\">",
"    <span class=\"h2\">",
"     Radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic findings in patients with NAFLD include increased echogenicity on ultrasound, decreased hepatic attenuation on computed tomography (CT), and an increased fat signal on magnetic resonance imaging (MRI). (See",
"    <a class=\"local\" href=\"#H19331226\">",
"     'Radiographic examinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147569346\">",
"    <span class=\"h2\">",
"     Associated disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the findings related to NAFLD, patients often have findings associated with the metabolic syndrome (",
"    <a class=\"graphic graphic_table graphicRef53446 \" href=\"mobipreview.htm?30/44/31437\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H242879397\">",
"     'Association with other disorders'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nonalcoholic fatty liver disease (NAFLD) requires all of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Demonstration of hepatic steatosis by imaging or biopsy",
"     </li>",
"     <li>",
"      Exclusion of significant alcohol consumption",
"     </li>",
"     <li>",
"      Exclusion of other causes of hepatic steatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In those undergoing a radiologic evaluation, radiologic findings are often sufficient to make the diagnosis if other causes of hepatic steatosis have been excluded. While not indicated for the majority of patients, a liver biopsy may be indicated if the diagnosis is not clear or to assess the degree of hepatic injury. In addition, liver biopsy is the only method currently available to differentiate nonalcoholic fatty liver (NAFL) from nonalcoholic steatohepatitis (NASH). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H34933599\">",
"     'Role of liver biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331410\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests, such as the serum aminotransferase and ferritin levels, are often abnormal in NAFLD. However, these abnormalities are neither required nor sufficient for making the diagnosis, as laboratory tests may be normal in patients with NAFLD and may be abnormal in patients with numerous other conditions. (See",
"    <a class=\"local\" href=\"#H19331440\">",
"     'Laboratory findings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, laboratory testing is required to evaluate for other conditions in the differential diagnosis of hepatic steatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150642167\">",
"    <span class=\"h2\">",
"     Rule out other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiating NAFLD from the other items in the differential diagnosis begins with a thorough history to identify potential causes such as significant alcohol use, starvation, medication use, and pregnancy-related hepatic steatosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We test all patients with hepatic steatosis for hepatitis C virus infection. We also test for hepatitis A and B. We do this to both to rule out these infections in patients with elevated aminotransferases and to determine immunity to guide future immunizations. We also rule out other chronic liver diseases such as autoimmune hepatitis and hemochromatosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7591?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of hepatitis A virus infection in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=see_link\">",
"     \"Immunizations for patients with chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We obtain the following tests in all patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anti-hepatitis C virus antibody &nbsp;",
"     </li>",
"     <li>",
"      Hepatitis A IgG",
"     </li>",
"     <li>",
"      Hepatitis B surface antigen, surface antibody, and core antibody",
"     </li>",
"     <li>",
"      Plasma iron, ferritin, and total iron binding capacity (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Routine iron studies'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum gammaglobulin level, antinuclear antibody, antismooth muscle antibody, and",
"      <span class=\"nowrap\">",
"       anti-liver/kidney",
"      </span>",
"      microsomal antibody-1 (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations and diagnosis of autoimmune hepatitis\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other disorders that should be considered based upon the patient's history, associated symptoms, and family history include Wilson disease, thyroid disorders, celiac disease, alpha-1 antitrypsin deficiency, HELLP, and Budd-Chiari syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=see_link\">",
"     \"Approach to the patient with abnormal liver biochemical and function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19331226\">",
"    <span class=\"h2\">",
"     Radiographic examinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various radiologic methods can detect NAFLD, but no imaging modality is able to differentiate between the histologic subtypes of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/42\">",
"     42",
"    </a>",
"    ]. Our approach in patients who have not already undergone imaging is to obtain an ultrasound. However, computed tomography (CT) and magnetic resonance imaging (MRI) can also detect hepatic steatosis.",
"   </p>",
"   <p>",
"    We consider a radiographic diagnosis to be sufficient for diagnosing NAFLD if all of the following conditions are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiographic imaging is consistent with fatty infiltration",
"     </li>",
"     <li>",
"      Other causes for the patient's liver disease have been excluded (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      The patient does not have signs or symptoms cirrhosis",
"     </li>",
"     <li>",
"      The patient is not at high risk for advanced fibrosis or cirrhosis (eg, a younger patient who does not have diabetes and has a normal serum ferritin is at lower risk for having fibrosis or cirrhosis) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=see_link&amp;anchor=H243002537#H243002537\">",
"       \"Natural history and management of nonalcoholic fatty liver disease in adults\", section on 'Risk factors for progression'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If these criteria are not met, patients will typically require a liver biopsy to make the diagnosis or to assess the degree of liver injury. (See",
"    <a class=\"local\" href=\"#H34933599\">",
"     'Role of liver biopsy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34934813\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography often reveals a hyperechoic texture or a bright liver because of diffuse fatty infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/43\">",
"     43",
"    </a>",
"    ]. A meta-analysis of 49 studies with 4720 patients found that the sensitivity and specificity for ultrasound were 85 and 94 percent, respectively, when using liver biopsy as the gold standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the sensitivity appears to be decreased in patients who are morbidly obese [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In a study of 187 morbidly obese patients undergoing bariatric surgery, hepatic steatosis was present histologically in 95 percent but was only detected by ultrasound in 49 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34934820\">",
"    <span class=\"h3\">",
"     CT, MRI, and magnetic resonance spectroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both CT and MRI can identify steatosis but are not sufficiently sensitive to detect inflammation or fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/47\">",
"     47",
"    </a>",
"    ]. Magnetic resonance spectroscopy (MRS) has the advantage of being quantitative rather than qualitative or semiquantitative, but it is not widely available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the difficulties in determining the sensitivity and specificity of CT and MRI for diagnosis of hepatic steatosis is that not all patients undergo confirmation by liver biopsy. In a study that did use histology as the gold standard, the sensitivity of CT scan for detecting hepatic steatosis was poor, whereas MRI had low specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/49\">",
"     49",
"    </a>",
"    ]. It included a total of 131 patients who had a radiologic evaluation with noncontrast CT, contrast-enhanced CT, or MRI before undergoing a partial hepatectomy, usually for malignancy. The sensitivities of noncontrast CT, contrast-enhanced CT, and MRI for detecting hepatic steatosis were 33, 50, and 88 percent, respectively. The specificities were 100, 83, and 63 percent, respectively. In addition, the accuracy of noncontrast CT fell with increasing body mass index.",
"   </p>",
"   <p>",
"    Unlike CT and MRI, MRS allows for quantification of hepatic fat, and may be particularly helpful in patients with small amounts of hepatic steatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/50\">",
"     50",
"    </a>",
"    ]. A study that compared MRS with liver biopsy in 12 patients found a close correlation between the measurement of intrahepatocellular lipid by MRS and the histologic assessment of cirrhosis (r = 0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/51\">",
"     51",
"    </a>",
"    ]. However, not all scanners have the capability of obtaining spectroscopic sequences, and it is not routinely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34933599\">",
"    <span class=\"h2\">",
"     Role of liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While liver biopsy is the gold standard for diagnosing NAFLD, in many cases a presumptive diagnosis can be made based upon the patient's history, laboratory tests, and imaging findings, provided other disorders have been excluded. However, some patients will continue to have an unclear diagnosis following a noninvasive evaluation. In such cases, a liver biopsy is indicated.",
"   </p>",
"   <p>",
"    In addition, imaging studies and laboratory tests do not reliably differentiate patients with NAFL from those with NASH, or predict the severity of liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/52\">",
"     52",
"    </a>",
"    ]. The only way to definitively confirm or exclude the diagnosis of NASH and to determine disease severity is with a liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/6,53\">",
"     6,53",
"    </a>",
"    ]. This information can be used to guide patient care and may motivate patients to enact lifestyle modifications. As examples, patients found to have cirrhosis will require screening for esophageal varices and hepatocellular carcinoma, whereas patients with early fibrosis may be motivated to lose weight to decrease the risk of progressing to cirrhosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=see_link&amp;anchor=H5#H5\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=see_link&amp;anchor=H150642859#H150642859\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\", section on 'Follow-up liver biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potentially useful non-invasive method for excluding advanced fibrosis is measurement of liver stiffness with transient elastography. However, the approach is not widely available and has not been extensively studied in NASH. Other indirect markers of cirrhosis such as the aspartate aminotransferase to platelet ratio index are also being studied to identify patients with fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=see_link\">",
"     \"Noninvasive assessment of hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147562648\">",
"    <span class=\"h3\">",
"     Which patients to biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear consensus about which patients require a liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/54\">",
"     54",
"    </a>",
"    ]. We obtain a liver biopsy in patients with suspected NAFLD if the diagnosis is unclear after obtaining standard laboratory tests and hepatic imaging, if there is evidence of cirrhosis, if the patient wants to know if inflammation or fibrosis is present, or if the patient is at increased risk for advanced fibrosis or cirrhosis. (See",
"    <a class=\"local\" href=\"#H19331440\">",
"     'Laboratory findings'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to the patient with cirrhosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=see_link&amp;anchor=H243002537#H243002537\">",
"     \"Natural history and management of nonalcoholic fatty liver disease in adults\", section on 'Risk factors for progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specifically, we obtain a biopsy if the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Has peripheral stigmata of chronic liver disease (suggestive of cirrhosis)",
"     </li>",
"     <li>",
"      Has splenomegaly (suggestive of cirrhosis)",
"     </li>",
"     <li>",
"      Has cytopenias (suggestive of cirrhosis)",
"     </li>",
"     <li>",
"      Has a serum ferritin &gt;1.5 times the upper limit of normal (suggestive of NASH and advanced fibrosis)",
"     </li>",
"     <li>",
"      Is &gt;45 years of age with associated obesity or diabetes (increased risk of advanced fibrosis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147562655\">",
"    <span class=\"h3\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic findings in NAFLD include steatosis, inflammation, cell injury, and fibrosis. The minimum criterion for a histologic diagnosis of NAFLD is &gt;5 percent steatotic hepatocytes in a liver tissue section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The extent of steatosis can be described as mild (5 to 33 percent of hepatocytes are steatotic), moderate (34 to 66 percent of hepatocytes), or severe (&gt;66 percent of hepatocytes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with NAFLD typically have macrovesicular steatosis, though mixed steatosis may also be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/56\">",
"     56",
"    </a>",
"    ]. Pure microvesicular steatosis is uncommon. In adults, steatosis is typically first seen in acinar zone 3, though when severe it may occupy the entire acinus.",
"   </p>",
"   <p>",
"    Patients with NAFL may have foci of lobular inflammation, mild portal inflammation, and lipogranulomas, but features of steatohepatitis (ie, hepatocellular injury and fibrosis) are absent by definition.",
"   </p>",
"   <p>",
"    Patients with NASH have liver biopsy findings that may be indistinguishable from those of alcoholic steatohepatitis. A diagnosis of NASH requires the findings of steatosis, hepatocyte injury (typically ballooning degeneration), and lobular inflammation (typically in acinar zone 3). Fibrosis is not a required diagnostic feature, but may be seen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28744?source=see_link&amp;anchor=H418822015#H418822015\">",
"     \"Alcoholic hepatitis: Clinical manifestations and diagnosis\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologic findings of NASH include (",
"    <a class=\"graphic graphic_picture graphicRef51497 graphicRef59170 graphicRef75188 \" href=\"mobipreview.htm?32/7/32890\">",
"     picture 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Steatosis",
"     </li>",
"     <li>",
"      Hepatocyte swelling or ballooning degeneration",
"     </li>",
"     <li>",
"      Apoptotic (acidophil) bodies",
"     </li>",
"     <li>",
"      Mild lobular inflammation (acute, and less often, chronic)",
"     </li>",
"     <li>",
"      Mild chronic portal inflammation (inflammation that is severe or is disproportionate to the acinar lesions is suggestive of concurrent hepatitis C)",
"     </li>",
"     <li>",
"      Perisinusoidal collagen deposition that may result in zone 3 accentuation in a \"chicken wire\" pattern (related to the deposition of collagen and other extracellular matrix fibers along the sinusoids of zone 3 and around hepatocytes)",
"     </li>",
"     <li>",
"      Portal fibrosis without perisinusoidal or pericellular fibrosis",
"     </li>",
"     <li>",
"      Cirrhosis, which is typically macronodular or mixed",
"     </li>",
"     <li>",
"      Mallory-Denk bodies (previously called Mallory bodies or Mallory's hyaline)",
"     </li>",
"     <li>",
"      Megamitochondria",
"     </li>",
"     <li>",
"      Glycogenated (vacuolated) nuclei in periportal hepatocytes (rarely seen in alcoholic steatohepatitis)",
"     </li>",
"     <li>",
"      Lobular lipogranulomas",
"     </li>",
"     <li>",
"      PAS-diastase-resistant Kupffer cells",
"     </li>",
"     <li>",
"      Hepatic siderosis (typically mild) involving periportal hepatocytes or panacinar reticuloendothelial cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As fibrosis progresses to cirrhosis, steatosis and inflammation may not be reliably identified, resulting in a diagnosis of \"cryptogenic\" cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/56\">",
"     56",
"    </a>",
"    ]. It is possible that portal fibrosis alone may represent a variant of NASH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/59\">",
"     59",
"    </a>",
"    ]. In biopsy specimens from children, portal inflammation may be more prominent than in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NASH may exist concurrently with other liver diseases, though diagnosing NASH in that setting can be difficult. As an example, patients with NASH may also have alcoholic liver disease, but there is no way to differentiate the relative contributions of the two processes from a liver biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/56\">",
"     56",
"    </a>",
"    ]. In a series of 3581 liver biopsies from patients with various chronic liver diseases, concurrent steatohepatitis was found in 5.5 percent of patients with hepatitis C (some with significant alcohol use) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/60\">",
"     60",
"    </a>",
"    ]. Among patients with other chronic liver diseases of nonalcoholic etiology, the prevalence ranged from 1.6 percent (autoimmune hepatitis) to 7.9 percent (alpha-1 antitrypsin deficiency). None of the patients with steatohepatitis with chronic liver disease from a cause other than hepatitis C had significant alcohol consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147564559\">",
"    <span class=\"h4\">",
"     NAFLD activity score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NAFLD activity score (NAS) is a validated score that is used to grade disease activity in patients with NAFLD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/61\">",
"     61",
"    </a>",
"    ]. The NAS is the sum of the biopsy's individual scores for steatosis (0 to 3), lobular inflammation (0 to 2), hepatocellular ballooning (0 to 2), and fibrosis (0 to 4). An NAS of 1 or 2 corresponds to NAFL, 3 to 4 corresponds to borderline NASH, and a score &ge;5 corresponds to NASH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=see_link&amp;anchor=H9#H9\">",
"     \"Histologic scoring systems for chronic liver disease\", section on 'Nonalcoholic fatty liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242879936\">",
"    <span class=\"h2\">",
"     Alternative causes of hepatic steatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple causes of hepatic steatosis that should be considered in a patient with suspected nonalcoholic fatty liver disease (NAFLD). Causes of hepatic steatosis in addition to NAFLD include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcoholic liver disease",
"     </li>",
"     <li>",
"      Hepatitis C (particularly genotype 3)",
"     </li>",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Lipodystrophy",
"     </li>",
"     <li>",
"      Starvation",
"     </li>",
"     <li>",
"      Parenteral nutrition",
"     </li>",
"     <li>",
"      Abetalipoproteinemia",
"     </li>",
"     <li>",
"      Medications (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , anti-retroviral agents for HIV)",
"     </li>",
"     <li>",
"      Reye syndrome",
"     </li>",
"     <li>",
"      Acute fatty liver of pregnancy",
"     </li>",
"     <li>",
"      HELLP (hemolytic anemia, elevated liver enzymes, low platelet count) syndrome",
"     </li>",
"     <li>",
"      Inborn errors of metabolism (LCAT deficiency, cholesterol ester storage disease, Wolman disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34934589\">",
"    <span class=\"h3\">",
"     Significant alcohol consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several definitions have been proposed for what constitutes significant alcohol consumption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/62\">",
"     62",
"    </a>",
"    ]. We define significant alcohol consumption as an average consumption of &gt;210 grams of alcohol per week in men or &gt;140 grams of alcohol per week in women over at least a two-year period, a definition that is consistent with a 2012",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     joint guideline",
"    </a>",
"    from the American Gastroenterological Association, the American Association for the Study of Liver Diseases, and the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A standard drink in the United States (12 oz [360 mL] of beer, 5 oz [150 mL] of wine, 1.5 oz [45 mL] of 80-proof spirits) contains approximately 14 grams of alcohol (",
"    <a class=\"graphic graphic_figure graphicRef56818 \" href=\"mobipreview.htm?20/18/20778\">",
"     figure 1",
"    </a>",
"    ), so the limits above roughly translate to &gt;15 drinks per week for men and &gt;10 drinks per week for women.",
"   </p>",
"   <p>",
"    One finding that suggests alcoholic fatty liver disease rather than NAFLD is an aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio &gt;2 (it is typically &lt;1 in patients with NAFLD). The alcoholic liver disease to NAFLD index (ANI) is a model that has been developed to predict the probability that steatohepatitis is due to alcoholic liver disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/63\">",
"     63",
"    </a>",
"    ]. The model is based upon aminotransferase levels, mean corpuscular volume (MCV), body mass index (BMI), and sex:",
"   </p>",
"   <p>",
"    ANI = -58.5 + 0.637 (MCV) + 3.91",
"    <span class=\"nowrap\">",
"     (AST/ALT)",
"    </span>",
"    &ndash; 0.406 (BMI) + 6.35 for men",
"   </p>",
"   <p>",
"    An ANI greater than zero favors a diagnosis of alcoholic liver disease, whereas an ANI less than zero favors a diagnosis of NAFLD. The probability of the patient having alcoholic liver disease rather than NAFLD is then calculated using the value obtained for the ANI:",
"   </p>",
"   <p>",
"    Probability =",
"    <span class=\"nowrap\">",
"     e",
"     <sup>",
"      ANI",
"     </sup>",
"     /(1+e",
"     <sup>",
"      ANI",
"     </sup>",
"     )",
"    </span>",
"   </p>",
"   <p>",
"    The ability of the model to accurately categorize patients ranged from good to excellent in validation cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38105/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/14/38114?source=see_link\">",
"       \"Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/47/12018?source=see_link\">",
"       \"Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis when no other causes for secondary hepatic fat accumulation (eg, heavy alcohol consumption) are present. NAFLD may progress to cirrhosis and is likely an important cause of cryptogenic cirrhosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      NAFLD is subdivided into nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). In NAFL, hepatic steatosis is present without evidence of significant inflammation, whereas in NASH, hepatic steatosis is associated with hepatic inflammation that may be histologically indistinguishable from alcoholic steatohepatitis.",
"     </li>",
"     <li>",
"      Most patients with NAFLD are asymptomatic, although some patients with NASH may complain of fatigue, malaise, and vague right upper abdominal discomfort. Patients are more likely to come to attention because laboratory testing revealed elevated liver aminotransferases or hepatic steatosis was detected incidentally on abdominal imaging. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with NAFLD may have mild or moderate elevations in the aspartate aminotransferase and alanine aminotransferase, although normal aminotransferase levels do not exclude NAFLD. (See",
"      <a class=\"local\" href=\"#H19331440\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic findings in patients with NAFLD include increased echogenicity on ultrasound, decreased hepatic attenuation on computed tomography, or an increased fat signal on magnetic resonance imaging. (See",
"      <a class=\"local\" href=\"#H19331447\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A definitive diagnosis of NAFLD requires all of the following (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Demonstration of hepatic steatosis by imaging or biopsy",
"     </li>",
"     <li>",
"      Exclusion of significant alcohol consumption",
"     </li>",
"     <li>",
"      Exclusion of other causes of hepatic steatosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other causes of hepatic steatosis include (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significant alcohol use",
"     </li>",
"     <li>",
"      Hepatitis C (particularly genotype 3)",
"     </li>",
"     <li>",
"      Wilson disease",
"     </li>",
"     <li>",
"      Lipodystrophy",
"     </li>",
"     <li>",
"      Starvation",
"     </li>",
"     <li>",
"      Parenteral nutrition",
"     </li>",
"     <li>",
"      Abetalipoproteinemia",
"     </li>",
"     <li>",
"      Medications",
"     </li>",
"     <li>",
"      Reye syndrome",
"     </li>",
"     <li>",
"      Acute fatty liver of pregnancy",
"     </li>",
"     <li>",
"      HELLP (hemolytic anemia, elevated liver enzymes, low platelet count) syndrome",
"     </li>",
"     <li>",
"      Inborn errors of metabolism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiologic findings are often sufficient to make a diagnosis of NAFLD, provided other causes of hepatic steatosis have been excluded. However, liver biopsy may be indicated if the diagnosis is not clear or to assess the degree of hepatic injury. (See",
"      <a class=\"local\" href=\"#H19331226\">",
"       'Radiographic examinations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34933599\">",
"       'Role of liver biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113848023\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's many contributions to our program, in particular, his work on this topic as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/1\">",
"      Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/2\">",
"      Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/3\">",
"      Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/4\">",
"      Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/5\">",
"      Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/6\">",
"      Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/7\">",
"      Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/8\">",
"      Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/9\">",
"      Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/10\">",
"      Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/11\">",
"      Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/12\">",
"      Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/13\">",
"      Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/14\">",
"      Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/15\">",
"      Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988; 95:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/16\">",
"      Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/17\">",
"      Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/18\">",
"      Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/19\">",
"      Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/20\">",
"      Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/21\">",
"      Arun J, Clements RH, Lazenby AJ, et al. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006; 16:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/22\">",
"      Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/23\">",
"      Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/24\">",
"      Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/25\">",
"      Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/26\">",
"      Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107:450.",
"     </a>",
"    </li>",
"    <li>",
"     Cello JP, Grendell JH. The liver in systemic conditions. In: Hepatology, Zakim D, Boyer TD (Eds), WB Saunders, Philadelphia 1990. p.1428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/28\">",
"      Pinto HC, Baptista A, Camilo ME, et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/29\">",
"      Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987; 82:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/30\">",
"      Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/31\">",
"      Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/32\">",
"      Amarapurkar D, Kamani P, Patel N, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007; 6:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/33\">",
"      Oliva MR, Mortele KJ, Segatto E, et al. Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 2006; 30:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/34\">",
"      Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/35\">",
"      Noguchi H, Tazawa Y, Nishinomiya F, Takada G. The relationship between serum transaminase activities and fatty liver in children with simple obesity. Acta Paediatr Jpn 1995; 37:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/36\">",
"      Charatcharoenwitthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci 2012; 57:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/37\">",
"      Cohen JA, Kaplan MM. The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci 1979; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/38\">",
"      Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999; 94:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/39\">",
"      McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/40\">",
"      Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/41\">",
"      Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/42\">",
"      Schwenzer NF, Springer F, Schraml C, et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009; 51:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/43\">",
"      Lonardo A, Bellini M, Tondelli E, et al. Nonalcoholic steatohepatitis and the \"bright liver syndrome\": should a recently expanded clinical entity be further expanded? Am J Gastroenterol 1995; 90:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/44\">",
"      Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/45\">",
"      Mottin CC, Moretto M, Padoin AV, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/46\">",
"      de Moura Almeida A, Cotrim HP, Barbosa DB, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol 2008; 14:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/47\">",
"      Rofsky NM, Fleishaker H. CT and MRI of diffuse liver disease. Semin Ultrasound CT MR 1995; 16:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/48\">",
"      Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288:E462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/49\">",
"      Cho CS, Curran S, Schwartz LH, et al. Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg 2008; 206:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/50\">",
"      Springer F, Machann J, Claussen CD, et al. Liver fat content determined by magnetic resonance imaging and spectroscopy. World J Gastroenterol 2010; 16:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/51\">",
"      Cowin GJ, Jonsson JR, Bauer JD, et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008; 28:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/52\">",
"      Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/53\">",
"      Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/54\">",
"      Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37:1202.",
"     </a>",
"    </li>",
"    <li>",
"     Brunt EM, Tiniakos DG. Alcoholic and nonalcoholic fatty liver disease. In: Surgical pathology of the GI tract, liver, biliary tract and pancreas, 2nd ed., Odze RD, Goldblum JR.  (Eds), Elsevier, Philadelphia 2009. p.1007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/56\">",
"      Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16:5286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/57\">",
"      Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001; 21:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/58\">",
"      Brunt EM. Pathology of fatty liver disease. Mod Pathol 2007; 20 Suppl 1:S40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/59\">",
"      Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 2004; 40:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/60\">",
"      Brunt EM, Ramrakhiani S, Cordes BG, et al. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod Pathol 2003; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/61\">",
"      Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/62\">",
"      Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol 2012; 107:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38105/abstract/63\">",
"      Dunn W, Angulo P, Sanderson S, et al. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 2006; 131:1057.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3625 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-4D580CFE0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38105=[""].join("\n");
var outline_f37_13_38105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242879713\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242879720\">",
"      Patient demographics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242879397\">",
"      Association with other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19331433\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19331440\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19331447\">",
"      Radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H147569346\">",
"      Associated disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19331410\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H150642167\">",
"      Rule out other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19331226\">",
"      Radiographic examinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34934813\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34934820\">",
"      - CT, MRI, and magnetic resonance spectroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34933599\">",
"      Role of liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147562648\">",
"      - Which patients to biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H147562655\">",
"      - Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H147564559\">",
"      NAFLD activity score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H242879936\">",
"      Alternative causes of hepatic steatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34934589\">",
"      - Significant alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H113848023\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3625|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/18/20778\" title=\"figure 1\">",
"      Standard alcoholic drink PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3625|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/57/7059\" title=\"picture 1A\">",
"      NASH Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/5/30806\" title=\"picture 1B\">",
"      NASH liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/52/34628\" title=\"picture 1C\">",
"      Mallory body alcohol hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3625|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/44/31437\" title=\"table 1\">",
"      Definition metabolic syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/4/28744?source=related_link\">",
"      Alcoholic hepatitis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/18/34090?source=related_link\">",
"      Approach to the patient with abnormal liver biochemical and function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23882?source=related_link\">",
"      Natural history and management of nonalcoholic fatty liver disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16073?source=related_link\">",
"      Pathogenesis of nonalcoholic fatty liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/47/12018?source=related_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/14/38114?source=related_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_13_38106="Clinical manifestations and diagnosis of the thalassemias";
var content_f37_13_38106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of the thalassemias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38106/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38106/contributors\">",
"     Edward J Benz, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38106/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38106/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/13/38106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/13/38106/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/13/38106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major hemoglobin in adults is hemoglobin A, a tetramer consisting of one pair of alpha globin chains and one pair of beta globin chains. In normal subjects, globin chain synthesis is very tightly controlled, such that the ratio of production of alpha to non-alpha chains is 1.00 &plusmn; 0.05. Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one or more globin chains, thus disrupting this closely-regulated ratio. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=see_link\">",
"     \"Molecular pathology of the thalassemic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of adult patients with alpha or beta thalassemia",
"      <strong>",
"       minor",
"      </strong>",
"      are asymptomatic, and may be diagnosed because of the presence of microcytic, hypochromic red cells, with or without minor degrees of anemia.",
"     </li>",
"     <li>",
"      Thalassemias of intermediate degrees of severity are common throughout the world, and may be due to the presence of more than one hemoglobin mutation in the same patient (eg, sickle cell thalassemia, hemoglobin",
"      <span class=\"nowrap\">",
"       E/beta",
"      </span>",
"      thalassemia) or to the presence of an abnormal hemoglobin with a reduced (ie, thalassemic) production rate (eg, hemoglobin Lepore, hemoglobin Constant Spring).",
"     </li>",
"     <li>",
"      Beta thalassemia and alpha thalassemia",
"      <strong>",
"       major",
"      </strong>",
"      are on the other end of this spectrum. The former is associated with life-long transfusion-dependent anemia, while the latter is incompatible with extra-uterine life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of the thalassemias will be reviewed here. The management of beta thalassemia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7802?source=see_link\">",
"     \"Treatment of beta thalassemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BETA THALASSEMIA MAJOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta thalassemia is due to impaired production of beta globin chains, leading to a relative excess of alpha globin chains. Excess alpha globin chains are unstable, incapable of forming soluble tetramers on their own, and precipitate within the cell, leading to a variety of clinical manifestations. The degree of alpha globin chain excess determines the severity of subsequent clinical manifestations, which are profound in patients homozygous for impaired beta globin synthesis (ie, beta thalassemia major) and much less pronounced in heterozygotes, who generally have minimal or mild anemia and no symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infants with severe beta thalassemia major (BTM) are well at birth, because the production of beta globin is not essential during fetal life or the immediate perinatal period. The major non-alpha globin produced at the time of birth is gamma globin, such that the major hemoglobin in early postnatal life is fetal hemoglobin (Hb F,",
"    <span class=\"nowrap\">",
"     alpha2/gamma2).",
"    </span>",
"   </p>",
"   <p>",
"    Symptoms emerge during the second six months of life when gamma globin chain production decreases and is normally replaced with the production of beta globin to form adult hemoglobin (Hb A,",
"    <span class=\"nowrap\">",
"     alpha2/beta2).",
"    </span>",
"    However, since newborns with BTM are unable to produce beta chains, they develop chronic anemia, the stigmata of profound hemolysis, and suffer the noxious effects of massive ineffective erythropoiesis upon the body. The clinical expression of the severe phenotype is remarkably heterogeneous, depending upon a variety of factors that alter the burden of alpha-globin inclusions in the individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When BTM becomes clinically apparent during the second six months of life, pallor, irritability, growth retardation, abdominal swelling due to hepatosplenomegaly, and jaundice reflect the onset and sequelae of severe hemolytic anemia. The symptoms associated with ineffective erythropoiesis (eg, bony abnormalities and abnormal skeletal development) soon follow. Eighty percent of untreated children will die within the first five years of life, due directly to the consequences of severe anemia, high output heart failure, inanition, and unusual susceptibility to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/3,6,7\">",
"     3,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features outlined below describe the most severe manifestations of BTM, most of which are rarely seen in the United States or other countries with highly developed medical care systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41783?source=see_link\">",
"     \"Community public health issues and the thalassemic syndromes: Lessons from other countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations of BTM are multifactorial. Even though the primary genetic defect resides in a single gene (ie, beta globin) expressed only during terminal maturation of red cell progenitors, many organ systems are affected. Understanding of the symptomatology of BTM requires recognition that patients suffer simultaneously from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The effects of severe and chronic anemia",
"     </li>",
"     <li>",
"      The stigmata of chronic hemolysis",
"     </li>",
"     <li>",
"      Organ damage from transfusional iron overload",
"     </li>",
"     <li>",
"      The profound local and systemic effects of a rapidly and relentlessly expanding mass of erythroid bone marrow progenitors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The application of modern forms of hypertransfusion therapy, which can suppress many of the adverse effects of anemia and extramedullary hematopoiesis, marked reduction in the risk of transfusion-associated hepatitis, rigorous use of iron chelation to reverse transfusion-related iron overload, and the use of hematopoietic cell transplantation have ameliorated most of these features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in many areas of the world where genetic counseling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intensive therapy are not available, patients with severe symptoms are still encountered. Indeed, management of the iron stores in these patients has become the overriding challenge, since most of the manifestations of anemia and hemolysis can be controlled by aggressive hypertransfusion regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The direct effects of BTM on other organs and tissues in the body are due to the deleterious effects of the profound anemia, the byproducts of hemolysis, and the intramedullary and extramedullary expansion of erythroid marrow progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1,3-5,9\">",
"     1,3-5,9",
"    </a>",
"    ]. However, in actual practice, patients exhibit both direct and indirect abnormalities of a number of organ systems. Indirect effects include the accumulation of end-organ damage due to iron overload either from blood transfusions or accelerated iron turnover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/10\">",
"     10",
"    </a>",
"    ], blood-borne infections (eg, viral hepatitis from blood transfusions), or progressive diversion of caloric resources to bone marrow expansion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Skeletal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skeletal abnormalities are dramatic in these patients and frequently lead to marked changes in the facial structure and body habitus, producing the characteristic \"chipmunk facies\" and delayed skeletal maturation. Skeletal changes are due largely to the expansion and invasion of erythroid bone marrow, which widen the marrow spaces, attenuate the cortex, and produce osteoporosis.",
"   </p>",
"   <p>",
"    The skull and facial bones are strikingly abnormal. Marrow expansion causes dramatic widening of the diploic spaces and produces a characteristic \"hair-on-end\" radiographic appearance of the skull [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, there is prominent frontal bossing, delayed pneumatization of the sinuses, and marked overgrowth of the maxillae. As a result, the upper incisors are \"jumbled\" and the malar eminences are especially prominent, producing malocclusion and the characteristic facies.",
"   </p>",
"   <p>",
"    The ribs and the bones of the extremities become box-like and eventually convex, due to expansion of the bone marrow. Premature fusion of the epiphyses can result in characteristic shortening of the limbs, particularly the arms. Of equal concern is the thinning of the cortices due to marrow expansion, which often results in pathologic fractures. Compression fractures of the spine, often with spinal cord compression and neurologic deficits, have been reported in these children.",
"   </p>",
"   <p>",
"    As children reach the end of the first decade of life, the greatly expanded hematopoietically active (\"red\") marrow is replaced at the periphery of the skeleton by inactive (\"yellow\") marrow as in unaffected preadolescent children. The changes in the hands and feet thus become somewhat less prominent in the second decade of life if the child survives. However, changes in the pelvis, skull and spine become more pronounced, due to the continuation of active erythropoiesis at these sites. It is often in the second decade of life, not surprisingly, that compression fractures and paravertebral expansion of extramedullary masses become particularly prominent. These changes may lead to complications such as back pain, spinal asymmetry and scoliosis, cord compression from intraspinal collections of hematopoietic tissue, and intervertebral disc degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteopenia with cortical thinning, increased trabeculation of the spine, severe osteoporosis with fractures, including vertebral fractures in adolescents and young adults, remain serious complications, even in well-transfused and iron-chelated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The mechanism(s) underlying this observation are unclear. Different studies have identified the following possible contributing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/12,16-22\">",
"     12,16-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Sp1 polymorphism of the COLIA1 collagen gene, which may predispose to vertebral osteoporosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/16\">",
"       16",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=see_link&amp;anchor=H14954217#H14954217\">",
"       \"Pathogenesis of osteoporosis\", section on 'Genetics'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased bone resorption that may be related to vitamin D deficiency of uncertain etiology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H10\">",
"       'Endocrine and metabolic abnormalities'",
"      </a>",
"      below). Bone formation may not be impaired [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Failure to progress normally through puberty [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/20\">",
"       20",
"      </a>",
"      ], most likely secondary to hypogonadism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H10\">",
"       'Endocrine and metabolic abnormalities'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      A direct effect of iron overload on bone, possibly due to iron-induced oxidative stress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/23\">",
"       23",
"      </a>",
"      ], along with a possible direct toxicity specific for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Liver and gallbladder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatomegaly is prominent early in the disease, due to increased red cell destruction as well as extramedullary erythropoiesis in this organ. Liver enlargement tends to be somewhat more prominent in children with BTM than in others with other causes for congenital hemolytic anemia. Later in the first decade of life, hepatomegaly becomes fixed and not reducible by blood transfusion, due to development of cirrhosis secondary to increased iron deposition.",
"   </p>",
"   <p>",
"    Even in the absence of transfusion, the accelerated rate of erythropoiesis enhances dietary iron absorption from the gut, resulting in a chronic state of iron overload. In the liver, iron first infiltrates Kupffer cells and then engorges hepatocytes, ultimately provoking fibrosis and, potentially, end-stage liver disease, in a manner analogous to that seen in hereditary hemochromatosis.",
"   </p>",
"   <p>",
"    A curious feature of deranged iron homeostasis in individuals with BTM is that hepcidin levels remain low despite massive iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/26\">",
"     26",
"    </a>",
"    ]. Such reduced hepcidin production enhances the absorption of iron from the diet, increasing the already high iron burden. Serum from thalassemic subjects blocks hepcidin synthesis in cultured liver cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/27\">",
"     27",
"    </a>",
"    ], suggesting that thalassemic serum contains a circulating repressor of hepcidin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H2#H2\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Anemia due to ineffective erythropoiesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=see_link&amp;anchor=H16#H16\">",
"     \"Regulation of iron balance\", section on 'Hepcidin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liver changes consistent with viral hepatitis, both hepatitis B and hepatitis C, are frequent, even in children who have received little or no transfusion therapy. While hepatitis as a complication of transfusion is readily understandable, the prevalence in non-transfused children suggests additional susceptibility factors. Iron overload is one situation thought to favor susceptibility to viral hepatitis.",
"   </p>",
"   <p>",
"    In view of the above, it is not surprising that liver function abnormalities are highly prevalent, but variable, given the multiplicity of underlying causes. Hyperbilirubinemia is nearly universal. Most affected children also have hypergammaglobulinemia and abnormal hepatocellular enzyme markers. In advanced stages of the disease, probably as the result of hemochromatosis and exposure to hepatitis B and C viruses through multiple blood transfusions, hypoalbuminemia, coagulation factor abnormalities, and other stigmata of end-stage liver disease (eg, hepatocellular carcinoma) may appear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prominent feature of children with chronic hemolytic anemia is the development of premature bilirubin gallstone disease and biliary tract inflammation. This is particularly true of children with BTM. Two-thirds of these patients have multiple calcified bilirubin stones by the age of 15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/30\">",
"     30",
"    </a>",
"    ]. Fortunately, true episodes of cholecystitis or cholangitis are rare. Gall bladder removal is thus rarely indicated in the absence of clear-cut symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive splenomegaly develops early in the course of BTM due to increased red cell destruction and the presence of splenic extramedullary hematopoiesis. Splenomegaly is progressive and can produce characteristic symptoms such as early satiety and hypersplenism. Shortened survival of transfused red cells or progressive worsening of the anemia or other cytopenias in non-transfused patients are indications that removal of the spleen may palliate symptoms by reducing splenic consumption of red cells. However, children often require splenectomy whether or not they are transfused. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=see_link&amp;anchor=H28#H28\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Extravascular nonimmune hemolysis due to hypersplenism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before and after splenectomy, children with BTM suffer immune deficits as the result of premature loss of splenic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1\">",
"     1",
"    </a>",
"    ]. Splenic monocytes and macrophage are particularly important for clearance of bacteria and other particulate matter, and splenic leukocytes appear to be important in early life for the maturation of the alternative pathway of complement activation. Iron overload within the spleen and engorgement of splenic reticuloendothelial cells are both thought to contribute to abnormal splenic function, even when the spleen is anatomically present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If splenectomy is performed, children with BTM, like all other splenectomized patients, are at considerable risk for overwhelming sepsis. Vaccination against pneumococcus and prophylactic use of antibiotics are essential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with BTM or thalassemia intermedia may also be at increased risk for developing thromboembolic phenomena, including stroke, following splenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Kidneys",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidneys are frequently enlarged in thalassemia, due to the presence of extramedullary hematopoiesis. Less well understood is the tendency for the renal tubules to be dilated. The urine is frequently dark, due to increased concentrations of bile pigments; large amounts of urate, uric acid, and oxalate are also seen.",
"   </p>",
"   <p>",
"    Because of the high rate of cellular turnover in this disease, hyperuricemia is encountered in children with BTM, and they are at risk for development of gouty nephropathy. However, true attacks of gouty arthritis are rare before the second or third decade of life. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=see_link\">",
"     \"Asymptomatic hyperuricemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Endocrine and metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endocrine and metabolic abnormalities are quite common in patients with BTM, attributable, at least in part, to chronic iron overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/34\">",
"     34",
"    </a>",
"    ]. In a study of 56 patients with transfusional iron overload (52 with either thalassemia major or intermedia), pituitary iron overload was detected by magnetic resonance imaging during the first decade of life, while clinically significant pituitary volume loss was not observed until the second decade of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/35\">",
"     35",
"    </a>",
"    ]. Both pituitary iron overload and volume loss were independently predictive of hypogonadism, which was defined clinically based upon the timing of secondary sexual characteristics or the need for sex hormone replacement therapy.",
"   </p>",
"   <p>",
"    In a study of 142 chronically transfused patients with hemoglobin E-beta thalassemia or BTM &ge;12 years of age and an average serum ferritin &ge;2000",
"    <span class=\"nowrap\">",
"     microg/L,",
"    </span>",
"    the following",
"    <span class=\"nowrap\">",
"     endocrine/metabolic",
"    </span>",
"    abnormalities were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypogonadism &mdash; 40 percent",
"     </li>",
"     <li>",
"      Growth failure &mdash; 33 percent",
"     </li>",
"     <li>",
"      Diabetes &mdash; 13 percent",
"     </li>",
"     <li>",
"      Hypothyroidism &mdash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Growth retardation is frequently profound in these children. This reflects, in part, the diversion of caloric resources for erythropoiesis, along with the effects of anemia, since hypertransfusion frequently restores growth rates to normal. However, the adolescent growth spurt is often delayed, even in children who are hypertransfused, unless intensive iron chelation therapy is instituted early in life.",
"   </p>",
"   <p>",
"    Primary and secondary characteristics of sexual development are usually delayed for both boys and girls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/21\">",
"     21",
"    </a>",
"    ]. While there is increasing evidence that hypogonadism may be primarily due to iron overload, zinc deficiency may also play a role.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Menarche is frequently delayed, breast development is often poor, and patients are frequently oligomenorrheic or amenorrheic, even if menarche occurs.",
"     </li>",
"     <li>",
"      Boys frequently develop no or sparse facial and body hair and tend to have decreased libido, even if sperm production does occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal carbohydrate metabolism is another major endocrine abnormality encountered in these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/36\">",
"     36",
"    </a>",
"    ]. Glucose intolerance usually develops during the second decade of life, even though baseline blood sugar levels are frequently normal. Interestingly, the early lesion appears to be related more to insulin resistance than to defective insulin production. The latter is a complication that occurs only during the late stages of development of hemosiderosis. More effective iron chelation appears to improve glucose intolerance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report from the Thalassemia Clinical Research Network reported on the following findings in 361 subjects with thalassemia (mean age 23, range: 6 to 75 years) living in North America and receiving current therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 25 percent of children and adults, regardless of their thalassemia syndrome, had short stature. Overall growth in children was mildly affected and final height was close to midparental height.",
"     </li>",
"     <li>",
"      Patients with beta thalassemia major had higher rates of multiple endocrinopathies, worse hyperglycemia, subclinical hypoparathyroidism, and hypercalciuria. All were found to correlate with higher ferritin concentrations.",
"     </li>",
"     <li>",
"      Hypogonadism, the most frequent endocrinopathy, was frequently undertreated. Among hypogonadal girls, menarche was delayed to 17 years.",
"     </li>",
"     <li>",
"      Low levels of vitamin D were common, especially among adolescents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cardiopulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac abnormalities are a major feature of BTM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Cardiac malfunction, including heart failure and fatal arrhythmias, are frequent causes of death, and cardiac dilatation secondary to anemia is nearly universal. Transfusion usually corrects the latter abnormality, but may lead to cardiac hemosiderosis due to myocardial iron deposition. Cardiomegaly, non-specific electrocardiographic changes (eg, bradycardia, repolarization abnormalities), and left ventricular dysfunction ensue in the untreated child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], leading to end-stage cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional risk factors for the development of cardiovascular complications may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vascular endothelial dysfunction and increased arterial stiffness have been found in children with hemoglobin E beta thalassemia despite treatment with periodic blood transfusions and iron chelation therapy, and have been attributed, at least in part, to the presence of oxidative stress markers and increased levels of non transferrin bound iron [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Presence of the epsilon-4 allele of apolipoprotein E [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/44\">",
"       44",
"      </a>",
"      ], which has decreased antioxidant and iron-binding activity compared with the epsilon-2 and epsilon-3 alleles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of the null (deleted) genotype for glutathione S-transferase M1, an enzyme which, when present, may help reduce some of the oxidant damage due to increased iron deposition in tissues [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A relationship among vitamin D deficiency, cardiac iron uptake, and ventricular dysfunction has been suggested, although the mechanism involved is not clear [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In an MRI-based study, there was a significant incidence of myocardial",
"      <span class=\"nowrap\">",
"       fibrosis/necrosis,",
"      </span>",
"      correlating best with presence of cardiovascular risk factors, a history of cardiac complications, and anti-HCV antibodies, rather than myocardial iron overloading [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of135 transfusion-dependent patients with beta thalassemia, eighteen (13 percent) satisfied MRI criteria for the rare cardiomyopathy left ventricular noncompaction (LVNC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/49\">",
"       49",
"      </a>",
"      ]. There were no statistically significant differences between patients with and without LVNC with respect to demographics, hemoglobin levels, splenectomy status, iron overload status, liver disease, infection, or iron chelator type. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41784?source=see_link\">",
"       \"Isolated left ventricular noncompaction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In transfused patients with BTM, cardiac hemosiderosis is the most feared complication. Without early institution of iron chelation therapy, a characteristic cardiomyopathy due to iron overload develops. These patients develop a sterile pericarditis, arrhythmias (both supraventricular and ventricular), poor exercise performance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/50\">",
"     50",
"    </a>",
"    ], and end-stage restrictive cardiomyopathy leading to heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fatal ventricular arrhythmias are a frequent cause of death. Rhythm disturbances begin with the characteristic prolongation of the PR interval, then first degree heart block, premature atrial beats, and, later, ST segment depression and ventricular ectopy.",
"   </p>",
"   <p>",
"    For poorly understood reasons, most patients with BTM have mild abnormalities of pulmonary function, including restrictive and small airway obstructive defects, hyperinflation, decreased maximal oxygen uptake, and abnormal anaerobic thresholds. These abnormalities are not corrected by transfusion and do not correlate with somatic iron burden, blood counts, or hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/53\">",
"     53",
"    </a>",
"    ]. After splenectomy, profound thrombocytosis places these patients at risk for pulmonary vascular obstruction.",
"   </p>",
"   <p>",
"    Although primary pulmonary symptoms are relatively infrequent, adult patients may develop pulmonary hypertension, the cause of which is not entirely clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/54\">",
"     54",
"    </a>",
"    ], but may be related to such factors as prior splenectomy, older age, chronic hemolysis, iron overload, platelet activation, and smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Aplastic crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parvovirus B19 infects erythroid precursor stem cells. In normal children, this results in a very mild transient erythrocytopenia because the impairment of marrow function is transitory and the 120-day survival of normal red blood cells protects them from acute drops in the red cell count. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with extremely shortened red cell survival, as in BTM, the effect is far more profound. These patients depend on very high rates of red cell production; moreover, the shortened red cell survival (four to eight days) causes the red cell count to fall rapidly when production is stopped. Children with BTM who develop B19 infection thus develop dramatic, often life threatening drops in hematocrit with reticulocyte counts of nearly zero. This \"aplastic crisis\" often requires emergent transfusion support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Milder decreases in rates of red cell production frequently accompany other infections (hypoplastic crises), probably due to the amplified effects of the short red cell survival on transient partial suppression of erythropoiesis occurring in association with infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19407982\">",
"    <span class=\"h3\">",
"     Chronic pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multicenter prospective study of 258 thalassemia patients (mean age 29; range 12 to 71) receiving care at 12 Thalassemia Clinical Research Network sites has revealed that 81 percent reported having pain for &ge;1 year, and 31 percent reported pain for &ge;5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients with pain reported an average number of four sites of pain, which included the lower back (82 percent), leg (56 percent), head (48 percent), and midback (47 percent). Of those questioned about pain during the prior four-week period, 36 percent had no pain, while it was considered mild, moderate, or severe in 36, 19, and 9 percent, respectively. Regression analysis demonstrated a significant correlation of increased age with increased pain, irrespective of the type of thalassemia, transfusion status, gender, bone density, chelator type, or degree of iron overload. Although this pain syndrome appears to be a major cause of morbidity, its etiology and predictors remain unexplained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Red blood cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profound hypochromic, microcytic anemia accompanied by bizarre red cell morphology is a hallmark of beta thalassemia major (BTM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The hemoglobin level may be as low as 3 to 4",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    Red cell morphology is dramatically abnormal in most patients, with extreme hypochromia and poikilocytosis, a predominance of microcytes, tear drop and target cells (",
"    <a class=\"graphic graphic_picture graphicRef76666 \" href=\"mobipreview.htm?26/29/27089\">",
"     picture 1",
"    </a>",
"    ), and the visibility, even in routine stains, of clumped inclusion bodies representing precipitates of alpha globin within the red cell. These precipitates (Heinz bodies) can be more readily appreciated by staining with methyl violet or other supravital stains.",
"   </p>",
"   <p>",
"    The white blood cell (WBC) count is often strikingly high, and the reticulocyte count surprisingly low. The latter reflects the severe degree of ineffective erythropoiesis underlying the disorder, resulting in many fewer than the expected number of reticulocytes being released from the bone marrow. The high white count may be misleading, since these patients release many nucleated red blood cells (NRBC) into the peripheral blood. Depending on the counting method used, NRBC can be miscounted as leukocytes. However, even when corrected for this phenomenon, a true neutrophilia is often encountered.",
"   </p>",
"   <p>",
"    The platelet count is usually normal. However, hypersplenism can lower both white cell and platelet counts. Splenectomy usually produces exaggerated rises in circulating NRBC, WBC, and platelets in the peripheral blood. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Splenomegaly'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Iron studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high rate of erythroid cell turnover, the serum iron level is usually elevated; the transferrin saturation, expressed as the ratio of serum iron to total iron binding capacity (or transferrin), is very high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum ferritin levels in those with thalassemia major may be quite elevated, reflecting the presence of iron overload primarily from multiple blood transfusions, but to a lesser extent from increased absorption of dietary iron from the gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H2#H2\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Anemia due to ineffective erythropoiesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9655434\">",
"    <span class=\"h3\">",
"     Other laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum is often icteric; increased concentrations of indirect (unconjugated) bilirubin and lactate dehydrogenase, and low levels of haptoglobin, findings typical of hemolytic disease, are usually present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin and mineral levels relevant to bone marrow homeostasis, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , vitamin B12, and pyridoxine, are usually normal. However, folic acid deficiency can develop in these patients, due to the high rate of cellular turnover. For unknown reasons, serum zinc levels tend to be particularly low in these patients. Serum and leukocyte ascorbic acid levels are reduced, possibly as a result of accelerated catabolism in the face of iron overload. Serum levels of Vitamin E are also sometimes low, perhaps for the same reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow examination reveals profound erythroid hyperplasia that is unusual for the degree of immaturity and bizarre morphology of the erythroid progenitors. Early erythroblasts are abundant, and often appear megaloblastic, likely reflecting limited supplies of folate and other nutrients. Later erythroid progenitors are less abundant than expected, due to their intramedullary destruction (ie, ineffective erythropoiesis), producing a marked \"left shift\" that was erroneously interpreted as leukemic in the late 19th and early 20th century descriptions of this disease. Alpha globin inclusions are readily apparent, particularly if supravital dyes are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4178107\">",
"    <span class=\"h4\">",
"     Extramedullary hematopoiesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A dramatic abnormality of the bone marrow, rarely seen in other forms of chronic anemia, is extramedullary erythropoiesis. In the most severely symptomatic children, erythroid bone marrow may invade the bony cortex and break through bone, setting up masses of ectopic erythroid cell colonies in the thoracic or pelvic cavities or sinuses (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53353 \" href=\"mobipreview.htm?34/13/35025\">",
"     image 1",
"    </a>",
"    ). These expanding masses can behave clinically like tumors, causing spinal cord compression and other abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Hemoglobin electrophoresis patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with homozygous beta (0) thalassemia are unable to make any Hb A. In untransfused patients only Hb F and Hb A2 are present on hemoglobin electrophoresis. When transfused, they will have variable amounts of Hb A from the transfused blood, but will still have increased amounts of Hb F and Hb A2 (",
"    <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"     table 1",
"    </a>",
"    ). Patients with combined heterozygosity for beta (0) and beta (+) thalassemia may produce small amounts of Hb A.",
"   </p>",
"   <p>",
"    A more complete discussion of hemoglobin separation techniques is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/968?source=see_link\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of beta thalassemia major will have been made in all patients at around 6 to 12 months of age due to the presence of pallor, irritability, growth retardation, abdominal swelling due to hepatosplenomegaly, and jaundice. The laboratory examination at that time will show severe anemia with markedly abnormal hypochromic, microcytic red cells (",
"    <a class=\"graphic graphic_picture graphicRef76666 \" href=\"mobipreview.htm?26/29/27089\">",
"     picture 1",
"    </a>",
"    ) and with all of the classical findings of severe hemolytic anemia (eg, increased indirect bilirubin and lactate dehydrogenase and reduced or absent haptoglobin).",
"   </p>",
"   <p>",
"    The diagnosis is confirmed on hemoglobin electrophoresis (",
"    <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"     table 1",
"    </a>",
"    ). Hemoglobin A is absent or severely reduced; only hemoglobins F and A2 are present. Variable amounts of hemoglobin A will be present in those who are subsequently treated with red cell transfusions, but levels of hemoglobins F and A2 will remain elevated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CLINICAL HETEROGENEITY OF BETA THALASSEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beta thalassemia syndromes are remarkable for their heterogeneity, particularly in terms of clinical severity (",
"    <a class=\"graphic graphic_table graphicRef69490 \" href=\"mobipreview.htm?27/53/28507\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some of the factors contributing to this variability have been identified on the basis of differences in the mutations producing the beta thalassemic lesion (eg, beta (+) or beta (0) mutations which produce some or no beta globin, respectively), as well as interactions which modify the alpha-globin inclusion burden (eg, an accompanying alpha thalassemia).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The genetic basis for the variability in clinical severity of homozygous beta (0) thalassemia was studied in a cohort of 316 Sardinian patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/60\">",
"       60",
"      </a>",
"      ]. Clinical severity was assessed via the age at first transfusion. Phenotypic severity (ie, earlier age at the time of first transfusion) was explained to a large extent by genetic variants affecting fetal hemoglobin production (HBG2:g.-158C&gt;T, BCL11A, HBS1L-MYB), with the remainder due to alpha globin gene defects and gender. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical variability in sickle cell anemia\", section on 'Fetal hemoglobin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients \"homozygous\" for beta thalassemia mutations (that is, inheriting a beta thalassemia mutation on each chromosome, even if they are not identical) usually exhibit some degree of alpha globin inclusion body formation, with consequent anemia, hemolysis, and varying degrees of ineffective erythropoiesis. The amount of alpha globin inclusion body formation and the degree of ineffective erythropoiesis correlate best with overall severity. The terms \"beta thalassemia minor\" and \"beta thalassemia intermedia,\" attempt to reflect the fact that individuals carrying beta thalassemia mutations exhibit considerable clinical heterogeneity, requiring differences in approach to management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link\">",
"       \"Pathophysiology of beta thalassemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The vast majority of heterozygotes for beta thalassemia (eg, beta thalassemia trait) are asymptomatic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1\">",
"       1",
"      </a>",
"      ]. This is thought to reflect the ability of the erythrocyte to catabolize some of the excess unpaired alpha-globin chains effectively; the burden is less because the patient is capable of producing approximately half the normal amount of beta globin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Beta thalassemia minor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms beta thalassemia minor, beta thalassemia trait, and silent carrier of beta thalassemia are used to describe heterozygotes who carry one normal beta globin allele and one beta globin thalassemic allele. The vast majority of these patients are entirely asymptomatic, but do present an abnormal blood picture that is sometimes erroneously diagnosed as iron deficiency anemia.",
"   </p>",
"   <p>",
"    Although the splenic volume, as assessed by ultrasonography, is 29 to 67 percent greater in those with thalassemia minor than in comparable controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], the spleen is palpable in less than 20 percent of subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/61,63\">",
"     61,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Typically, the blood count and peripheral blood film exhibit features similar to those seen in iron deficiency anemia (eg, hypochromia and microcytosis) (",
"    <a class=\"graphic graphic_picture graphicRef56728 \" href=\"mobipreview.htm?29/23/30071\">",
"     picture 2",
"    </a>",
"    ). However, as a rule, the microcytosis is much more profound, and the anemia much milder, than that seen in iron deficiency anemia. Patients with beta thalassemia",
"    <span class=\"nowrap\">",
"     minor/trait",
"    </span>",
"    also tend to have total red blood cell counts higher than normal, often into the \"polycythemic\" range.",
"   </p>",
"   <p>",
"    Patients with beta thalassemia trait almost always have a hematocrit &gt;30 percent, and a mean corpuscular volume of the red cells (MCV) &lt;75 fL. In contrast, patients with iron deficiency rarely become microcytic (MCV &lt;80 fL) until the hematocrit has dropped below 30. Another potentially useful indicator is the red cell distribution width (RDW). The RDW in patients with thalassemia trait tends to be normal, since virtually all cells are hypochromic and microcytic. In contrast, there is considerable heterogeneity in cell size in the early and intermediate stages of iron deficiency, producing an increased RDW. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=see_link\">",
"     \"Mean corpuscular volume\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The peripheral blood smear often reveals a large number of target cells, more dramatic than is seen in all but the most profound cases of iron deficiency, as well as tear drop shaped red cells (dacrocytes), which are not seen in iron deficiency. Red blood cell survival is either normal or only slightly shortened; reticulocyte counts are normal or only slightly increased, and overt hemolysis is generally not present.",
"   </p>",
"   <p>",
"    During pregnancy, women with beta thalassemia trait sometimes exhibit a tendency to develop a more profound \"physiologic\" anemia of pregnancy than normal mothers, and may require transfusion. However, pregnancy outcomes are generally favorable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some rare forms of heterozygous beta thalassemia are due to mutations that alter the structure of the beta globin chain near its carboxy terminus, producing elongated or truncated beta globin chains. Even though their initial rate of synthesis is normal, these mutant chains combine abnormally with alpha globin to produce highly insoluble hemoglobin dimers or tetramers. The precipitates generate severe inclusion body formation and a phenotype more like severe beta thalassemia. These rare patients require management like patients with beta thalassemia major or intermedia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=see_link&amp;anchor=H26#H26\">",
"     \"Molecular pathology of the thalassemic syndromes\", section on 'Dominant thalassemia trait due to nonsense codons in the final exon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8127371\">",
"    <span class=\"h3\">",
"     Protection against arterial thromboembolic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies and a meta-analysis have indicated that beta thalassemia trait has a protective effect against arterial cardiovascular and cerebrovascular disease in male subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. This beneficial effect has been attributed to low serum cholesterol levels, slight anemia, and microcytosis, with a concomitant decrease in blood viscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. These intriguing hypotheses require further prospective follow-up studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hemoglobin electrophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;On electrophoresis or high performance liquid chromatography (HPLC) in patients with beta thalassemia trait, over 90 percent of the hemoglobin will be hemoglobin A along with an elevation in the hemoglobin A2 value, sometime as high as 7 or 8 percent, and an increase in Hb F in about 50 percent of patients (",
"    <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"mobipreview.htm?17/56/18316\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example, in a study of 444 Chinese individuals with beta thalassemia trait, hemoglobin A2 levels, when measured by HPLC, were in the range of 5.6 &plusmn; 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/69\">",
"     69",
"    </a>",
"    ]. While mean hemoglobin A2 levels were slightly lower in those with both beta thalassemia trait and iron deficiency anemia (5.3 percent), all subjects with both conditions had hemoglobin A2 levels &ge;3.5 percent. While others have agreed that the presence of iron deficiency does not compromise the diagnosis of high hemoglobin A2 beta thalassemia trait [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/70\">",
"     70",
"    </a>",
"    ], this has not been a universal conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some forms of beta thalassemia trait are not associated with an elevated hemoglobin A2 level, such as those with delta-beta or gamma-delta-beta thalassemia trait or when beta thalassemia trait is co-inherited with a delta globin gene mutation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/69,72,73\">",
"     69,72,73",
"    </a>",
"    ]. Therefore, a normal concentration of hemoglobin A2 does not rule out the presence of beta thalassemia trait. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link&amp;anchor=H18#H18\">",
"     \"Structure and function of normal human hemoglobins\", section on 'Hemoglobin A2'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More complex hemoglobin electrophoretic patterns may be seen in patients with beta thalassemia trait who have co-inherited a gene for sickle cell anemia (eg, sickle",
"    <span class=\"nowrap\">",
"     cell/thalassemia)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"mobipreview.htm?17/56/18316\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70184 \" href=\"mobipreview.htm?16/17/16667\">",
"     table 4",
"    </a>",
"    ). These combinations are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H26\">",
"     'Effect of concomitant alpha thalassemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Beta thalassemia intermedia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"beta thalassemia intermedia\" refers to patients with symptomatic beta thalassemia who do not require transfusion during at least the first few years of life, and are able to survive into the second decade of life without chronic hypertransfusion therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This term is losing favor because it fails to address the genetic or clinical mechanisms for the phenotype of intermediate clinical severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/2\">",
"     2",
"    </a>",
"    ]. However, it remains useful to refer to a category of patients who present special challenges in management.",
"   </p>",
"   <p>",
"    The understanding that alpha globin inclusion burden is the predominant driver of clinical severity in patients with beta thalassemia has provided a useful paradigm for understanding some of the factors that contribute to the extraordinary clinical variability of this disease (",
"    <a class=\"graphic graphic_table graphicRef69490 \" href=\"mobipreview.htm?27/53/28507\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/75\">",
"     75",
"    </a>",
"    ]. As an example, some beta thalassemia mutations entirely ablate beta globin synthesis (ie, the beta(0) variants), while others are compatible with the production of up to 35 or 40 percent of the normal output of beta globin (ie, the beta(+) variants). Clearly, compound heterozygosity for a \"severe\" and a \"mild\" mutation, in terms of the degree to which beta-globin production is impaired, should result in a somewhat milder syndrome than homozygosity for a mutation that permits no beta-globin synthesis whatsoever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects with thalassemia intermedia, while they may not require transfusion therapy at all, or as often as those with thalassemia major, have increased absorption of dietary iron, and may ultimately develop signs, symptoms, and complications of iron overload (eg, cardiac dysfunction, end-stage liver disease including hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/76\">",
"     76",
"    </a>",
"    ]). They may also suffer from the complications of chronic hypoxia, such as high cardiac output, increased pulmonary vascular resistance, pulmonary hypertension, and heart failure. As a result, such patients should be monitored frequently for these complications. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7802?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of beta thalassemia\", section on 'Beta thalassemia intermedia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While most patients with thalassemia intermedia do not need regular blood transfusions in order to survive, the stigmata of the disease, including bone marrow expansion, hepatosplenomegaly, and chronic hemolytic anemia are present, even in milder forms of the disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At the milder end of the scale of thalassemia intermedia, some of these patients will undergo normal puberty and survive into adult life. However, they may be subject to a number of complications with advancing age (eg, leg ulcers, thrombosis, extramedullary hematopoiesis, pulmonary hypertension, hypothyroidism, osteoporosis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At the more severe end of the spectrum, children with thalassemia intermedia develop a need for transfusions or splenectomy at earlier times, often at the onset of or during adolescence. This may reflect the increased demands of puberty and the prepubertal growth spurt on the production of red cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients present a therapeutic dilemma, namely, when to institute chronic transfusion therapy with its attendant complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1\">",
"     1",
"    </a>",
"    ]. Delay for the longest possible time is clearly desirable, given the life-long problems associated with transfusion therapy. On the other hand, excessive delay can lead to significant morbidity, similar to that seen in younger children with beta thalassemia major. It is important to realize, however, that progressive iron overload can develop in many of these children, even in the absence of chronic transfusion therapy, requiring consideration for the use of iron chelating agents.",
"   </p>",
"   <p>",
"    As already noted, expansion of the erythroid marrow and accelerated erythroid turnover stimulate iron absorption from the gut, leading to excessive iron accumulation in the body in patients incapable of utilizing the excess iron to manufacture hemoglobin. When these patients develop signs and symptoms of iron overload, they are similar in virtually all respects to that described in beta thalassemia major. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Non-transferrin bound iron'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, in a cross-sectional study of 168 subjects with beta thalassemia intermedia and a mean age of 35 years, their mean liver iron concentration, as determined by magnetic resonance imaging, was 8.4 &plusmn; 6.7 mg",
"    <span class=\"nowrap\">",
"     Fe/g",
"    </span>",
"    dry weight (normal: &lt;2; iron overload: &gt;4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/78\">",
"     78",
"    </a>",
"    ]. After adjusting for age, gender, splenectomy and transfusion status, and laboratory indices, a 1 mg",
"    <span class=\"nowrap\">",
"     Fe/g",
"    </span>",
"    dry weight increase in liver iron concentration was independently and significantly associated with higher odds of thrombosis, pulmonary hypertension, hypothyroidism, osteoporosis, and hypogonadism. While very suggestive of a correlation between liver iron burden and organ damage, such as vasculopathy and endocrinopathy, these results from a cross sectional study require confirmation before being regarded as predictive in individual patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Effect of concomitant alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha thalassemia is common in the same populations in which beta thalassemia is prevalent. Coinheritance of alpha thalassemia trait clearly ameliorates the severity of beta thalassemia, since the reduction in alpha globin synthesis (from the alpha thalassemia component) reduces the burden of alpha globin inclusions (from the beta thalassemia component) without greatly affecting the amount of actual hemoglobin made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21924630\">",
"    <span class=\"h2\">",
"     Effect of fetal hemoglobin levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal hemoglobin (HbF) synthesis also persists to some degree in most patients with symptomatic beta thalassemia. In part, this reflects the tendency of \"erythropoietic stress\" to stimulate HbF production, even in adults. Elevated levels of Hb F also appear to vary in the population via polymorphisms for heterocellular hereditary persistence of fetal hemoglobin.",
"   </p>",
"   <p>",
"    Persistent synthesis of HbF has two beneficial effects: it provides additional oxygen carrying capacity and the gamma globin chain binds some of the free alpha globin, thus reducing alpha globin inclusions. In some ethnic groups and locations, such as Portugal and parts of equatorial Africa, thalassemia also tends to be milder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the effect of HbF levels on 10 measures of morbidity was assessed in 63 untransfused subjects with thalassemia intermedia who had never received HbF induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/81\">",
"     81",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Levels of HbF correlated positively with total hemoglobin and negatively with non-transferrin bound iron.",
"     </li>",
"     <li>",
"      There was a strong negative correlation between the HbF level and the total number of morbidities (eg, extramedullary hematopoiesis, pulmonary hypertension, venous thromboembolism, heart failure, leg ulcers, abnormal liver function, endocrinopathy, osteoporosis).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A HbF threshold of 63.7 percent had 95.5 and 100 percent sensitivity and specificity, respectively, for ensuring the absence of morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Other causes of disease variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although features of the globin genotype in families with thalassemia account for some of the clinical variability encountered in this disorder, much remains to be explained. For example, siblings in some families appear to have identical globin genotypes, yet exhibit rather notable differences in clinical severity or in the prominence of individual manifestations of the disease. There is thus a substantial effort underway to use gene expression profiling, study of single nucleotide polymorphisms, and other technologies in an effort to associate polymorphic variations in other genes with altered clinical phenotype. To date, despite a considerable accumulation of preliminary data, no definitive leads are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link\">",
"     \"Clinical variability in sickle cell anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diagnosis and differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of beta thalassemia minor or intermedia should be entertained in patients of any age with microcytic, hypochromic red cells (",
"    <a class=\"graphic graphic_picture graphicRef77536 \" href=\"mobipreview.htm?14/49/15123\">",
"     picture 3",
"    </a>",
"    ). As the beta thalassemias show considerable heterogeneity, patients may or may not have symptoms referable to anemia, may have variable degrees of splenomegaly and variable degrees of hemolysis.",
"   </p>",
"   <p>",
"    The major differential diagnosis in patients with microcytic, hypochromic red cells includes iron deficiency and the anemia of (chronic) inflammation, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Iron deficiency",
"      </strong>",
"      &mdash; Patients with iron deficiency will have low levels of serum iron and ferritin and increased levels of transferrin (total iron binding capacity). Those with iron deficiency rarely become microcytic (mean corpuscular volume (MCV) &lt;80 fL) until the hematocrit has dropped below 30 percent. The red cell distribution width (RDW) is usually increased and the total red cell count is decreased in concert with the degree of anemia. A cause for blood loss will be obvious in most patients.",
"     </li>",
"     <li>",
"      <strong>",
"       Anemia of inflammation",
"      </strong>",
"      &mdash; Patients with the anemia of chronic inflammation will have low levels of serum iron and transferrin. Levels of ferritin will be normal or increased. An inflammatory, infectious, or malignant disease is usually the underlying cause.",
"     </li>",
"     <li>",
"      <strong>",
"       Thalassemia",
"      </strong>",
"      &mdash; Patients with thalassemia will have normal to increased levels of serum iron and ferritin. Levels of transferrin will be normal or decreased. Patients with beta thalassemia trait almost always have a hematocrit &gt;30 percent, and a mean corpuscular volume (MCV) &lt;75 fL. The RDW tends to be normal. The total red cell count is usually normal to increased in those with beta thalassemia trait, reflecting the presence of an increased number of smaller than normal red cells. At least one of the patient's parents will also be affected. A family history of \"iron deficiency anemia not responding to treatment with iron&rdquo; is common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of a beta thalassemic condition is confirmed on hemoglobin electrophoresis (",
"    <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"mobipreview.htm?17/56/18316\">",
"     table 3",
"    </a>",
"    ). Hemoglobin A will be the major hemoglobin present. Levels of hemoglobin A2 are increased in virtually all patients, while levels of hemoglobin F are increased in about 50 percent of patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/968?source=see_link\">",
"     \"Laboratory diagnosis of the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If hemoglobin S is present on electrophoresis along with hypochromic, microcytic red cells, and iron deficiency is absent, one of the sickle",
"    <span class=\"nowrap\">",
"     cell/thalassemia",
"    </span>",
"    conditions is present (",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"mobipreview.htm?17/56/18316\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70184 \" href=\"mobipreview.htm?16/17/16667\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     THE ALPHA THALASSEMIA SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha thalassemia is due to impaired production of alpha globin chains, leading to a relative excess of beta globin chains. The toxicity of the excess beta globin chains on the red cell membrane skeleton appears to be less than that of the excess partially oxidized alpha globin chains in beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36025?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology of alpha thalassemia\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Nomenclature and diagnostic patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal subject has four functional alpha globin genes, two on each chromosome 16 (ie,",
"    <span class=\"nowrap\">",
"     aa/aa).",
"    </span>",
"    There are four deletional alpha thalassemia syndromes, reflecting the loss of one, two, three, or all four of these alpha chain genes (",
"    <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Alpha thalassemia minima",
"      </strong>",
"      (silent carrier of alpha thalassemia, heterozygosity for alpha (+) thalassemia, heterozygosity for the alpha thalassemia-2 trait) is due to the loss of",
"      <strong>",
"       one",
"      </strong>",
"      of the four alpha globin genes (ie,",
"      <span class=\"nowrap\">",
"       aa/a-).",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Alpha thalassemia minor",
"      </strong>",
"      is due to the loss of",
"      <strong>",
"       two",
"      </strong>",
"      of the four alpha globin genes. This can come about in two different ways, as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Heterozygosity for the alpha thalassemia-1 trait (heterozygosity for alpha (0) thalassemia), in which both alpha genes on one of the two chromosomes have been deleted (ie, cis deletional form,",
"      <span class=\"nowrap\">",
"       aa/--)",
"      </span>",
"     </li>",
"     <li>",
"      Homozygosity for the alpha thalassemia-2 trait (homozygosity for alpha (+) thalassemia), in which one of the alpha genes has been deleted on each of the two chromosomes (ie, trans deletional form,",
"      <span class=\"nowrap\">",
"       a-/a-)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       The deletional form of hemoglobin H disease",
"      </strong>",
"      is due to the loss of",
"      <strong>",
"       three",
"      </strong>",
"      of the four alpha globin loci, due to compound heterozygosity for both the alpha thalassemia-2 trait and the alpha thalassemia-1 trait (ie,",
"      <span class=\"nowrap\">",
"       a-/--).",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Hydrops fetalis with Hb Barts",
"      </strong>",
"      is due to loss of all",
"      <strong>",
"       four",
"      </strong>",
"      alpha globin loci secondary to homozygosity for the alpha thalassemia-1 trait (ie,",
"      <span class=\"nowrap\">",
"       --/--).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of patients with alpha thalassemia, especially in Asia and Africa, have lost alpha globin gene function because of deletion of one, two, three, or all four structural alleles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. However, non-deletion alleles are also common, especially in the Mediterranean area, as are mutations producing highly unstable alpha globin variants that lead to failure to produce intact hemoglobin during erythropoiesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major clinical feature associated with inheritance of alpha thalassemia is the interaction of alpha thalassemia trait with beta globin hemoglobinopathies, including beta thalassemia and sickle cell anemia. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Effect of concomitant alpha thalassemia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link&amp;anchor=H8#H8\">",
"     \"Variant sickle cell syndromes\", section on 'Sickle-alpha thalassemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Alpha thalassemia minima",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha thalassemia minima is essentially asymptomatic. Adult patients with alpha thalassemia minima are not anemic, their red cells are not microcytic, and their hemoglobin electrophoresis pattern is normal. The complete blood count and peripheral smear are usually normal, although very slight hypochromia and microcytosis might be evident by microscopic examination. Alpha thalassemia minima becomes apparent in families usually because individuals carrying this allele can, when mating with a partner carrying the alpha thalassemia-1 allele, give rise to an infant with HbH disease. The diagnosis of alpha thalassemia minima can be reliably made only via DNA analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Alpha thalassemia minor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha thalassemia minor resembles mild beta thalassemia trait. Adult patients with alpha thalassemia minor may have mild anemia, their red cells are hypochromic and microcytic and target cells are present. Hemoglobin electrophoresis pattern is normal. In contrast to patients with beta thalassemia, elevation of HbA2 is not seen in the alpha thalassemias; slight elevations of HbF have been reported.",
"   </p>",
"   <p>",
"    Alpha thalassemia minor in individuals of African origin usually arises from the homozygous state for the alpha-thalassemia-2 allele (ie,",
"    <span class=\"nowrap\">",
"     a-/a-).",
"    </span>",
"    Deletion of both alleles from one chromosome (the \"cis\" deletion) rarely occurs in this population. Moreover, the deletion usually involves the less active of the two normal alpha-globin alleles, so that alpha thalassemia minor",
"    <span class=\"nowrap\">",
"     (a-/a-)",
"    </span>",
"    in this group tends to be milder than alpha thalassemia minor in Asian populations",
"    <span class=\"nowrap\">",
"     (aa/--).",
"    </span>",
"    This diagnosis can be definitively made only through the use of molecular genetic techniques, which are not generally available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Hemoglobin H disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of HbH disease are more severe than those of patients with alpha thalassemia minor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/84\">",
"     84",
"    </a>",
"    ]. Hemoglobin H, composed of four beta chains, forms because the marked impairment in alpha globin production results in accumulation of excess unpaired beta globin chains. In contrast to free alpha globin chains, which are exceptionally insoluble, free beta globin chains are soluble enough to form the homotetrameric HbH. Adult patients have a moderate degree of anemia, their red cells are microcytic, and their hemoglobin electrophoresis pattern shows 5 to 30 percent hemoglobin H (beta-4 tetramers).",
"   </p>",
"   <p>",
"    HbH exhibits a dramatically left-shifted oxygen disassociation curve, such that it is virtually useless for oxygen transport. Moreover, it is rather insoluble, so that it behaves as an unstable hemoglobin during the latter stages of erythropoiesis and during the circulating life span of the red cell. Inclusion body formation during the early stages of erythropoiesis is less prominent because of the somewhat higher solubility of unpaired beta globin, so that ineffective erythropoiesis in most patients with HbH disease is less severe than that seen in beta thalassemia. Rather, these patients suffer from a chronic hemolytic anemia, due to the formation of inclusion bodies in circulating red cells as HbH precipitates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with HbH disease suffer from hemolytic anemia throughout much of gestation and are symptomatic at birth, often presenting with neonatal jaundice and anemia, and occasionally with hydrops fetalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/85\">",
"     85",
"    </a>",
"    ]. This occurs because alpha globin synthesis is required in utero for the production of the major hemoglobin found during late gestation: hemoglobin F",
"    <span class=\"nowrap\">",
"     (alpha2/gamma2).",
"    </span>",
"    Patients with beta thalassemia, on the other hand, do not have these difficulties until a few months after birth, when HbF production (and gamma globin production) decreases markedly and there is a need for increased production of beta globin chains for HbA",
"    <span class=\"nowrap\">",
"     (alpha2/beta2).",
"    </span>",
"   </p>",
"   <p>",
"    Patients",
"    with HbH disease exhibit all of the stigmata of chronic hemolytic anemia, including hepatosplenomegaly, indirect hyperbilirubinemia, elevated LDH, reduced haptoglobin, leg ulcers, and premature biliary tract disease, as described for severe beta thalassemia (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Laboratory findings'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/84,86\">",
"     84,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The skeletal, developmental, and metabolic changes due primarily to ineffective erythropoiesis tend, in general, to be less severe in this patient population for reasons already stated. However, for poorly understood reasons, some of these patients can exhibit clinical phenotypes strongly resembling severe beta thalassemia intermedia or beta thalassemia major. Most patients, however, do not require chronic transfusion support during the first decade of life.",
"   </p>",
"   <p>",
"    The typical patient with HbH disease resembles patients with beta thalassemia intermedia. Even though transfusion support is not necessary early in life, splenectomy or institution of transfusion support during the second or third decade of life is often necessary. Iron overload due to increased iron absorption is also as significant an issue as it is in beta thalassemia intermedia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/84,86,87\">",
"     84,86,87",
"    </a>",
"    ]. Measures to delay the onset of hepatic and cardiac damage due to iron deposition must therefore be employed as in patients with beta thalassemia intermedia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoglobin H is readily oxidized. Thus, patients with HbH disease, as in patients inheriting unstable hemoglobins or glucose-6-phosphate dehydrogenase deficiency, are at risk for exacerbations of their hemolytic process and anemia when exposed to oxidant stressors, such as infection or oxidizing drugs (eg, antimalarials, certain sulfa drugs). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36025?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathophysiology of alpha thalassemia\", section on 'Role of oxidant injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HbH disease patients are also, similar to other patients with chronic hemolytic anemias, particularly susceptible to aplastic or hypoplastic crises by the same mechanisms described for beta thalassemia (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Aplastic crisis'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood film in HbH disease shows hypochromia and microcytosis (",
"    <a class=\"graphic graphic_picture graphicRef80776 \" href=\"mobipreview.htm?19/41/20113\">",
"     picture 4",
"    </a>",
"    ) with readily detectable inclusion bodies, especially if the smear is stained with a supravital dye such as methyl violet or brilliant cresyl blue (",
"    <a class=\"graphic graphic_picture graphicRef77536 \" href=\"mobipreview.htm?14/49/15123\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/89\">",
"     89",
"    </a>",
"    ]. Bone marrow examination reveals erythroid hyperplasia with poorly hemoglobinized erythroblasts carrying inclusion bodies.",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by finding HbH in circulating red cells, in concentrations from 5 to 30 percent, using a number of hemoglobin electrophoretic or chromatographic techniques (",
"    <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50325 \" href=\"mobipreview.htm?7/33/7711\">",
"     figure 1",
"    </a>",
"    ). In addition, Hb Barts (gamma-4), a fast-moving hemoglobin, can be detected in concentrations of about 20 to 40 percent at the time of birth of a child with hemoglobin H disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/84\">",
"     84",
"    </a>",
"    ]. This latter test has been successfully employed in California as a screening test for HbH disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/90\">",
"     90",
"    </a>",
"    ]. DNA-based genotyping is required for precise diagnosis, and is especially important in prenatal testing and genetic counseling (see",
"    <a class=\"local\" href=\"#H40\">",
"     'Genetic counseling and antenatal diagnosis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Acquired hemoglobin H disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin H disease can be acquired during the course of several hematologic malignancies, most notably the myelodysplastic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H4008672#H4008672\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Acquired hemoglobin H disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Hydrops fetalis and hemoglobin Barts",
"    </span>",
"    &nbsp;&mdash;&nbsp;This condition is incompatible with extrauterine life since",
"    <strong>",
"    </strong>",
"    normal neonatal and adult hemoglobins (ie, hemoglobins A, F, and A2) cannot be made and Hb Barts (gamma-4 tetramers) cannot release oxygen to tissues because its affinity for oxygen is at least 10 times greater than that of HbA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36025?source=see_link&amp;anchor=H25#H25\">",
"     \"Pathophysiology of alpha thalassemia\", section on 'Hydrops fetalis and hemoglobin Bart's'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These patients produce no alpha globin, which is essential for the formation of fetal hemoglobin, the predominant hemoglobin normally produced after the first six to eight weeks of gestation. Hb Barts, a homotetramer composed of four gamma globin chains (gamma-4), exhibits an extremely left-shifted oxygen dissociation curve. It fails to deliver any oxygen to tissues, resulting in profound tissue hypoxia. The deficit in oxygen delivery, coupled with anemia due to mechanisms similar to HbH disease, causes massive tissue ischemia in the developing fetus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34393?source=see_link&amp;anchor=H19#H19\">",
"     \"Nonimmune hydrops fetalis\", section on 'Anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hydropic state in the fetus reflects the existence of massive total body edema due to high output heart failure. Fetal death usually occurs during the late second through mid-third trimester of pregnancy. However, occasional live births have been reported, sometimes at full term, following use of intrauterine transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=see_link\">",
"     \"Intrauterine fetal transfusion of red blood cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These infants usually die within a few hours after birth, unless supported with massive total exchange transfusions. Rare infants have survived the perinatal period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/93\">",
"     93",
"    </a>",
"    ] and need to be maintained on a chronic intensive hypertransfusion regimen with iron chelation. However, survival beyond the perinatal period almost never occurs, except in rare circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Mothers of fetuses with hydrops fetalis are at risk for the development of polyhydramnios, and a variety of other obstetrical complications.",
"   </p>",
"   <p>",
"    In populations of African origin, this severe form of alpha thalassemia almost never occurs because the &ldquo;cis&rdquo; deletion, in which both loci are absent from the same chromosome (ie,",
"    <span class=\"nowrap\">",
"     aa/--),",
"    </span>",
"    occurs very rarely. Inheritance of the cis deletion chromosome from each of the two parents, which occurs most commonly in populations of Asian origin, is necessary for development of hydrops fetalis. On the other hand, inheritance of the cis deletion from one parent",
"    <span class=\"nowrap\">",
"     (aa/--)",
"    </span>",
"    and alpha thalassemia-2 trait from the other (ie, either",
"    <span class=\"nowrap\">",
"     a-/a-",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     aa/a-)",
"    </span>",
"    is necessary for the development of HbH disease (ie,",
"    <span class=\"nowrap\">",
"     a-/--).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Hemoglobin Constant Spring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin (Hb) Constant Spring (CS) is a particularly common structural variant associated with alpha thalassemia in Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/83\">",
"     83",
"    </a>",
"    ]. It is always inherited in association with a normal alpha chain (eg,",
"    <span class=\"nowrap\">",
"     aa/aa",
"     <sup>",
"      CS",
"     </sup>",
"     ).",
"    </span>",
"    An additional feature in these patients is the presence of a minor, very slowly migrating abnormal hemoglobin component on hemoglobin electrophoresis; this is the Hb Constant Spring band.",
"   </p>",
"   <p>",
"    The alpha(CS) gene contains a mutation that abolishes the normal translation termination codon, so that polyribosomes \"read through\" the normal translation termination site on alpha(CS) mRNA, translating an additional 31 residues from the normally untranslated 3' extremity of the mRNA, until another in frame termination codon is reached. This \"read through\" process disrupts normal alpha globin mRNA stability, resulting in a highly unstable alpha(CS) mRNA that accumulates to only 1 percent of the normal level. The alpha(CS) allele thus functions as a severe alpha thalassemia gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11049845\">",
"    <span class=\"h3\">",
"     Non-deletional Hemoglobin H disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Co-inheritance of the cis deletional form of alpha thalassemia minor from one parent and hemoglobin Constant Spring from the other (ie,",
"    <span class=\"nowrap\">",
"     --/aa",
"     <sup>",
"      CS",
"     </sup>",
"     )",
"    </span>",
"    results in a form of hemoglobin H disease (eg, non-deletional HbH disease), which is often more severe than that seen in subjects with deletional HbH disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=see_link&amp;anchor=H27#H27\">",
"     \"Molecular pathology of the thalassemic syndromes\", section on 'Failed translation termination: Hb constant spring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha thalassemia minima and alpha thalassemia minor require no specific therapy. Inappropriate use of iron should be avoided in patients with detectable hypochromia and microcytosis; proper diagnosis and distinction of these patients from patients with iron deficiency is crucial.",
"   </p>",
"   <p>",
"    Individuals carrying alpha thalassemia trait alleles require especially careful genetic counseling, given the complex patterns of inheritance that could affect the clinical phenotype of their offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/1,83\">",
"     1,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=see_link&amp;anchor=H19#H19\">",
"     \"Mean corpuscular volume\", section on 'Causes of microcytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with HbH disease parallels in many respects the approach described for patients with beta thalassemia intermedia. Because of the tendency of HbH to suffer oxidative damage, close monitoring of the blood count and possible transfusional intervention may be required during periods of oxidant stress, such as infection or exposure to oxidant drugs. Patients must be monitored carefully for signs that institution of chronic transfusion or iron chelation support are needed, especially during the second and third decades of life. A role for bone marrow transplantation in the treatment of HbH disease has not yet been established. Fetal hemoglobin manipulation plays no role in this disorder, and no effective means of gene therapy has been developed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7802?source=see_link\">",
"     \"Treatment of beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hydrops fetalis with hemoglobin Barts is, as noted above, almost always lethal in utero. The possibility for survival of these fetuses by institution of chronic total exchange transfusional support exists, but is not practical and not usually recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. However, combinations of transfusion, iron chelation, and hematopoietic cell transplantation have allowed a small number of these children to survive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/92,94,95\">",
"     92,94,95",
"    </a>",
"    ]. Because of the high risk of maternal morbidity, early consideration of therapeutic termination of pregnancy is an issue that must be discussed with mothers at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     GENETIC COUNSELING AND ANTENATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families in which a patient with heterozygous or homozygous thalassemia is discovered require intensive education and genetic counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Beta thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the beta globin gene exists as a single copy, the odds of two parents, each carrying beta thalassemia trait, giving rise to a child with homozygous beta thalassemia are one in four, since the gene follows straightforward Mendelian rules of inheritance. The odds of their child having heterozygous thalassemia (thalassemia trait) are one in two, and the odds are one in four that the child's hemoglobin profile will be normal.",
"   </p>",
"   <p>",
"    Mothers with heterozygous thalassemia require particularly close monitoring during pregnancy because of the occasional incidence of especially severe physiologic anemia of pregnancy. Screening of the family for beta thalassemia trait can usually be accomplished through a combination of a routine CBC, with particular attention being paid to measurement of the mean corpuscular volume (MCV), as well as results of a hemoglobin electrophoresis, including the level of Hb A2. A characteristic smear exhibiting hypochromia and microcytosis is clearly helpful. If microcytosis is encountered, iron deficiency should be ruled out, especially if the hematocrit is less than 30 to 33 percent.",
"   </p>",
"   <p>",
"    Couples at risk for giving birth to a child with homozygous thalassemia should be apprised of the availability of antenatal diagnosis by direct gene analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/97\">",
"     97",
"    </a>",
"    ]. A small chorionic villus biopsy sample, or amniocytes from a routine amniocentesis provide adequate DNA for comprehensive globin gene analysis. The fact that thalassemia mutations have been thoroughly characterized and categorized within individual populations allows for nearly unambiguous diagnosis of homozygous thalassemia, heterozygous thalassemia, compound heterozygous states, and normal hemoglobin genotypes by use of PCR amplification and allele-specific oligonucleotide hybridization probes designed to detect the most prevalent mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although these methods require referral to a laboratory equipped with the appropriate technology, the procedures can routinely be done by these facilities with a rapid turnaround time. Hematology divisions at most academic medical centers in the Western world are familiar with ways to access these reference labs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=see_link&amp;anchor=H8#H8\">",
"     \"Prenatal testing for the hemoglobinopathies and thalassemias\", section on 'Testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Families in whom a fetus homozygous for beta thalassemia is identified face the difficult choice as to whether or not to undergo elective termination of pregnancy. One study has raised the possibility of an alternative to pregnancy termination. When there are family members available who are HLA compatible with the fetus, early hematopoietic cell transplantation appears to be efficacious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/98\">",
"     98",
"    </a>",
"    ]. This is a highly individualized decision that must be made in light of a thorough discussion of the known facts. The considerable burden of disease morbidity and the elaborate therapies required must be weighed against the potential for long-term survival with a reasonable quality of life. Individual moral, ethical, and religious views must be taken into account during this discussion.",
"   </p>",
"   <p>",
"    In certain regions, such as Cyprus, Sardinia, Northern Italy, and parts of Greece, the introduction of DNA-based antenatal diagnosis and genetic counseling has led to a nearly complete eradication of new cases of severe beta thalassemia. In other areas of the world, the impact has been less dramatic but still significant. Genetic counseling and antenatal diagnosis should be attempted only in collaboration with genetic counselors familiar with the hemoglobinopathies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41783?source=see_link\">",
"     \"Community public health issues and the thalassemic syndromes: Lessons from other countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pre-implantation genetic testing, by which the genotype of the fetus can be ascertained from polar bodies created during ovulation, without damage to the potential fertilized egg, is a rapidly emerging technology. This approach has a clear potential for application to families at risk to conceive a child with severe thalassemia. At the present time, this method is prohibitively expensive and competently performed in only a few centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics of alpha thalassemia are somewhat more complex because of the duplicated nature of the alpha globin genes on chromosome 16. Since uncomplicated alpha thalassemia trait is frequently asymptomatic and barely detectable, prospective identification of families at risk is less likely.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals of African descent are rarely at risk for giving birth to infants with severe forms of alpha thalassemia. Counseling to make individuals aware of the condition is usually adequate.",
"     </li>",
"     <li>",
"      More intensive counseling is needed if the individual partners are non-African individuals from alpha thalassemia endemic areas, in whom there is the risk of having a fetus with hydrops fetalis or hemoglobin H disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=see_link\">",
"       \"Fetal blood sampling\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Hemoglobin H disease or hydrops fetalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families in which HbH or hydrops fetalis has previously occurred are clearly at risk of giving birth to additional infants with these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/13/38106/abstract/84\">",
"     84",
"    </a>",
"    ]. The principles of genetic counseling and antenatal diagnosis that should be followed are similar to those outlined above for beta thalassemia. Early monitoring of pregnancies at risk for the presence of a hydropic fetus is important, because of the increased risk for polyhydramnios and other obstetrical complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=see_link\">",
"     \"Polyhydramnios\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/14/7394?source=see_link\">",
"       \"Patient information: Thalassemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11049855\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major hemoglobin in adults is hemoglobin A, consisting of one pair of alpha globin chains and one pair of beta globin chains. Globin chain synthesis is very tightly controlled, such that the ratio of production of alpha to non-alpha chains is 1.00 &plusmn; 0.05. Thalassemia refers to a spectrum of diseases characterized by reduced or absent production alpha or beta globin chains, disrupting this closely-regulated ratio.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20826087\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood in thalassemia demonstrates hypochromic, microcytic red cells, a picture often confused with iron deficiency. Routine laboratory tests (complete blood count, red cell indices, iron studies) will serve to differentiate these two disorders from one another. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Diagnosis and differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11049863\">",
"    <span class=\"h2\">",
"     Beta thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major forms of beta thalassemia, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Beta thalassemia minor",
"      </strong>",
"      &mdash; These subjects carry one normal beta globin allele and one beta globin thalassemic allele. The vast majority are asymptomatic. On electrophoresis, over 90 percent of the hemoglobin will be hemoglobin A along with an elevation in the hemoglobin A2 value, and an increase in Hb F in about 50 percent of patients (",
"      <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64715 \" href=\"mobipreview.htm?17/56/18316\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Beta thalassemia minor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Beta thalassemia intermedia",
"      </strong>",
"      &mdash; These subjects are compound heterozygotes for two different beta globin chain mutations and have a disease that is intermediate in severity between beta thalassemia minor and beta thalassemia major. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Beta thalassemia intermedia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Beta thalassemia major",
"      </strong>",
"      &mdash; These severely affected subjects are homozygous for mutations associated with absent (or very severely reduced) production of beta chains. The diagnosis is usually made at around 6 to 12 months of age due to the presence of pallor, irritability, growth retardation, abdominal swelling due to hepatosplenomegaly, and jaundice. The laboratory examination shows severe hemolytic anemia with markedly abnormal hypochromic, microcytic red cells (",
"      <a class=\"graphic graphic_picture graphicRef76666 \" href=\"mobipreview.htm?26/29/27089\">",
"       picture 1",
"      </a>",
"      ). The diagnosis is confirmed on hemoglobin electrophoresis (",
"      <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"       table 1",
"      </a>",
"      ). Hemoglobin A is absent or very severely reduced; only hemoglobins F and A2 are present. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Beta thalassemia major'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11050084\">",
"    <span class=\"h2\">",
"     Alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal individual has a complement of four alpha globin chain genes. There are four major forms of alpha thalassemia, due to loss of one, two, three, or four of these genes, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Alpha thalassemia minima",
"      </strong>",
"      : These subjects have inherited three normal alpha globin chain genes, are asymptomatic, and have normal blood counts and red blood cell indices. The diagnosis of alpha thalassemia minima can be reliably made only via DNA analysis. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Alpha thalassemia minima'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Alpha thalassemia trait",
"      </strong>",
"      : These subjects have inherited two normal alpha globin chain genes. Adults may have mild anemia, their red cells are hypochromic and microcytic and target cells are present. Hemoglobin electrophoresis pattern is normal. Elevation of HbA2 is not seen in the alpha thalassemias; slight elevations of HbF have been reported. The diagnosis of alpha thalassemia trait can be reliably made only via DNA analysis. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Alpha thalassemia minor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Hemoglobin H disease",
"      </strong>",
"      : These subjects have inherited only one functional alpha globin chain gene and are symptomatic at birth, with neonatal jaundice and life-long hemolytic anemia. The diagnosis is confirmed by finding hemoglobin H, a tetramer of beta globin chains, in circulating red cells (",
"      <a class=\"graphic graphic_table graphicRef50393 \" href=\"mobipreview.htm?41/24/42380\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef50325 \" href=\"mobipreview.htm?7/33/7711\">",
"       figure 1",
"      </a>",
"      ). Hemoglobin Barts (a tetramer of gamma globin chains) can be detected at the time of birth of a child with hemoglobin H disease. Hemoglobin H disease can also be acquired in some patients with myeloid malignancies. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Hemoglobin H disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Hydrops fetalis and hemoglobin Barts",
"      </strong>",
"      : These subjects have inherited no alpha globin chain genes. This condition is generally incompatible with extrauterine life. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Hydrops fetalis and hemoglobin Barts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Forget BG. Thalassemia syndromes. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/2\">",
"      Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/3\">",
"      Adams JG 3rd, Coleman MB. Structural hemoglobin variants that produce the phenotype of thalassemia. Semin Hematol 1990; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     Forget BG, Pearson HA. Hemoglobin synthesis and the thalassemias. In: Blood: Principles and Practice of Hematology, Handin RI, Lux SE, Stoesel TP (Eds), JB Lippincott, Philadelphia 1995. p.1525.",
"    </li>",
"    <li>",
"     Schwartz E, Benz EJ Jr. Thalassemia syndromes. In: Smith's Blood Diseases of Infancy and Childhood, 6th ed, Miller DR, Baehner RL (Eds), CV Mosby, St. Louis 1989. p.428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/6\">",
"      Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006; 6:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/7\">",
"      Rahav G, Volach V, Shapiro M, et al. Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol 2006; 133:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/8\">",
"      Cunningham MJ, Macklin EA, Neufeld EJ, et al. Complications of beta-thalassemia major in North America. Blood 2004; 104:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/9\">",
"      Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/10\">",
"      Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/11\">",
"      Basu S, Kumar A. Hair-on-end appearance in radiograph of skull and facial bones in a case of beta thalassaemia. Br J Haematol 2009; 144:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/12\">",
"      Haidar R, Mhaidli H, Musallam KM, Taher AT. The spine in &beta;-thalassemia syndromes. Spine (Phila Pa 1976) 2012; 37:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/13\">",
"      Vichinsky EP. The morbidity of bone disease in thalassemia. Ann N Y Acad Sci 1998; 850:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/14\">",
"      Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003; 123:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/15\">",
"      Engkakul P, Mahachoklertwattana P, Jaovisidha S, et al. Unrecognized vertebral fractures in adolescents and young adults with thalassemia syndromes. J Pediatr Hematol Oncol 2013; 35:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/16\">",
"      Perrotta S, Cappellini MD, Bertoldo F, et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000; 111:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/17\">",
"      Dresner Pollack R, Rachmilewitz E, Blumenfeld A, et al. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000; 111:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/18\">",
"      Ferrara M, Matarese SM, Francese M, et al. Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia. Br J Haematol 2002; 117:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/19\">",
"      Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001; 112:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/20\">",
"      Bielinski BK, Darbyshire PJ, Mathers L, et al. Impact of disordered puberty on bone density in beta-thalassaemia major. Br J Haematol 2003; 120:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/21\">",
"      Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Clin Endocrinol (Oxf) 1995; 42:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/22\">",
"      Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004; 127:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/23\">",
"      Tsay J, Yang Z, Ross FP, et al. Bone loss caused by iron overload in a murine model: importance of oxidative stress. Blood 2010; 116:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/24\">",
"      Chan YL, Li CK, Pang LM, Chik KW. Desferrioxamine-induced long bone changes in thalassaemic patients - radiographic features, prevalence and relations with growth. Clin Radiol 2000; 55:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/25\">",
"      Naselli A, Vignolo M, Di Battista E, et al. Long-term follow-up of skeletal dysplasia in thalassaemia major. J Pediatr Endocrinol Metab 1998; 11 Suppl 3:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/26\">",
"      Papanikolaou G, Tzilianos M, Christakis JI, et al. Hepcidin in iron overload disorders. Blood 2005; 105:4103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/27\">",
"      Weizer-Stern O, Adamsky K, Amariglio N, et al. Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol 2006; 135:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/28\">",
"      Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/29\">",
"      Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/30\">",
"      Premawardhena A, Fisher CA, Fathiu F, et al. Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia. Lancet 2001; 357:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/31\">",
"      Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/32\">",
"      Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/33\">",
"      Taher AT, Musallam KM, Nasreddine W, et al. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010; 8:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/34\">",
"      Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/35\">",
"      Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/36\">",
"      Noetzli LJ, Mittelman SD, Watanabe RM, et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/37\">",
"      Farmaki K, Angelopoulos N, Anagnostopoulos G, et al. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major. Br J Haematol 2006; 134:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/38\">",
"      Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 2009; 146:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/39\">",
"      Kremastinos DT, Tsetsos GA, Tsiapras DP, et al. Heart failure in beta thalassemia: a 5-year follow-up study. Am J Med 2001; 111:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/40\">",
"      Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta-thalassemia syndromes: a decade of progress. Am J Med 2005; 118:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/41\">",
"      Hahalis G, Manolis AS, Gerasimidou I, et al. Right ventricular diastolic function in beta-thalassemia major: echocardiographic and clinical correlates. Am Heart J 2001; 141:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/42\">",
"      Detterich J, Noetzli L, Dorey F, et al. Electrocardiographic consequences of cardiac iron overload in thalassemia major. Am J Hematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/43\">",
"      Detchaporn P, Kukongviriyapan U, Prawan A, et al. Altered vascular function, arterial stiffness, and antioxidant gene responses in pediatric thalassemia patients. Pediatr Cardiol 2012; 33:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/44\">",
"      Ferrara M, Matarese SM, Francese M, et al. Role of apolipoprotein E (APOE) polymorphism on left cardiac failure in homozygous beta thalassaemic patients. Br J Haematol 2001; 114:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/45\">",
"      Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996; 14:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/46\">",
"      Origa R, Satta S, Matta G, Galanello R. Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major. Br J Haematol 2008; 142:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/47\">",
"      Wood JC, Claster S, Carson S, et al. Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major. Br J Haematol 2008; 141:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/48\">",
"      Pepe A, Positano V, Capra M, et al. Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart 2009; 95:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/49\">",
"      Piga A, Longo F, Musallam KM, et al. Left ventricular noncompaction in patients with &beta;-thalassemia: uncovering a previously unrecognized abnormality. Am J Hematol 2012; 87:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/50\">",
"      Sohn EY, Kato R, Noetzli LJ, et al. Exercise performance in thalassemia major: Correlation with cardiac iron burden. Am J Hematol 2013; 88:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/51\">",
"      Hahalis G, Manolis AS, Apostolopoulos D, et al. Right ventricular cardiomyopathy in beta-thalassaemia major. Eur Heart J 2002; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/52\">",
"      Hershko C, Cappellini MD, Galanello R, et al. Purging iron from the heart. Br J Haematol 2004; 125:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/53\">",
"      Sohn EY, Noetzli LJ, Gera A, et al. Pulmonary function in thalassaemia major and its correlation with body iron stores. Br J Haematol 2011; 155:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/54\">",
"      Tam DH, Farber HW. Pulmonary hypertension and beta-thalassemia major: report of a case, its treatment, and a review of the literature. Am J Hematol 2006; 81:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/55\">",
"      Singer ST, Kuypers FA, Styles L, et al. Pulmonary hypertension in thalassemia: association with platelet activation and hypercoagulable state. Am J Hematol 2006; 81:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/56\">",
"      Vij R, Machado RF. Pulmonary complications of hemoglobinopathies. Chest 2010; 138:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/57\">",
"      Morris CR, Kim HY, Trachtenberg F, et al. Risk factors and mortality associated with an elevated tricuspid regurgitant jet velocity measured by Doppler-echocardiography in thalassemia: a Thalassemia Clinical Research Network report. Blood 2011; 118:3794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/58\">",
"      Haines D, Martin M, Carson S, et al. Pain in thalassaemia: the effects of age on pain frequency and severity. Br J Haematol 2013; 160:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/59\">",
"      Dragean CA, Duquesne L, Theate I, et al. Extramedullary haemopoiesis and spinal cord compression. Lancet 2011; 377:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/60\">",
"      Danjou F, Anni F, Perseu L, et al. Genetic modifiers of &beta;-thalassemia and clinical severity as assessed by age at first transfusion. Haematologica 2012; 97:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/61\">",
"      Tassiopoulos T, Rombos Y, Konstantopoulos K, et al. Spleen size in beta-thalassaemia heterozygotes. Haematologia (Budap) 1995; 26:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/62\">",
"      Karimi M, Bagheri MH, Tahmtan M, et al. Prevalence of hepatosplenomegaly in beta thalassemia minor subjects in Iran. Eur J Radiol 2009; 69:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/63\">",
"      Premawardhena A, Arambepola M, Katugaha N, Weatherall DJ. Is the beta thalassaemia trait of clinical importance? Br J Haematol 2008; 141:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/64\">",
"      Sheiner E, Levy A, Yerushalmi R, Katz M. Beta-thalassemia minor during pregnancy. Obstet Gynecol 2004; 103:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/65\">",
"      Gallerani M, Scapoli C, Cicognani I, et al. Thalassaemia trait and myocardial infarction: low infarction incidence in male subjects confirmed. J Intern Med 1991; 230:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/66\">",
"      Dentali F, Romualdi E, Ageno W, et al. Thalassemia trait and arterial thromboembolic events: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2011; 9:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/67\">",
"      Maioli M, Pettinato S, Cherchi GM, et al. Plasma lipids in beta-thalassemia minor. Atherosclerosis 1989; 75:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/68\">",
"      Tassiopoulos T, Stamatelos G, Zakopoulos N, et al. Low incidence of acute myocardial infarction in beta-thalassaemia trait carriers. Haematologia (Budap) 1995; 26:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/69\">",
"      Verhovsek M, So CC, O'Shea T, et al. Is HbA2 level a reliable diagnostic measurement for &beta;-thalassemia trait in people with iron deficiency? Am J Hematol 2012; 87:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/70\">",
"      Passarello C, Giambona A, Cannata M, et al. Iron deficiency does not compromise the diagnosis of high HbA(2) &beta; thalassemia trait. Haematologica 2012; 97:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/71\">",
"      Kattamis C, Lagos P, Metaxotou-Mavromati A, Matsaniotis N. Serum iron and unsaturated iron-binding capacity in the -thalassaemia trait: their relation to the levels of haemoglobins A, A 2 , and F. J Med Genet 1972; 9:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/72\">",
"      Fucharoen S, Fucharoen G, Sanchaisuriya K, Pengjam Y. Molecular analysis of a thai beta-thalassaemia heterozygote with normal haemoglobin A2 level: implication for population screening. Ann Clin Biochem 2002; 39:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/73\">",
"      Galanello R, Barella S, Ideo A, et al. Genotype of subjects with borderline hemoglobin A2 levels: implication for beta-thalassemia carrier screening. Am J Hematol 1994; 46:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/74\">",
"      Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/75\">",
"      Chang YP, Littera R, Garau R, et al. The role of heterocellular hereditary persistence of fetal haemoglobin in beta(0)-thalassaemia intermedia. Br J Haematol 2001; 114:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/76\">",
"      Maakaron JE, Musallam KM, Ayache JB, et al. A liver mass in an iron-overloaded thalassaemia intermedia patient. Br J Haematol 2013; 161:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/77\">",
"      Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-na&iuml;ve patients with thalassaemia intermedia. Br J Haematol 2010; 150:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/78\">",
"      Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with &beta; thalassemia intermedia. Haematologica 2011; 96:1605.",
"     </a>",
"    </li>",
"    <li>",
"     Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic and Clinical Aspects, WB Saunders, Philadelphia 1986.",
"    </li>",
"    <li>",
"     Weatherall DJ. The thalessemias. In: Molecular Basis of Blood Diseases, 2nd ed, Stamatoyannopoulos G, Nienhuis AW, Majerus PW (Eds), WB Saunders, Philadelphia 1994. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/81\">",
"      Musallam KM, Sankaran VG, Cappellini MD, et al. Fetal hemoglobin levels and morbidity in untransfused patients with &beta;-thalassemia intermedia. Blood 2012; 119:364.",
"     </a>",
"    </li>",
"    <li>",
"     Steinberg MH, Benz EJ Jr. Pathobiology of the human erythrocyte and its hemoglobins. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.356.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/83\">",
"      Steinberg MH. Management of sickle cell disease. N Engl J Med 1999; 340:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/84\">",
"      Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003; 101:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/85\">",
"      Lorey F, Charoenkwan P, Witkowska HE, et al. Hb H hydrops foetalis syndrome: a case report and review of literature. Br J Haematol 2001; 115:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/86\">",
"      Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med 2000; 343:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/87\">",
"      Origa R, Sollaino MC, Giagu N, et al. Clinical and molecular analysis of haemoglobin H disease in Sardinia: haematological, obstetric and cardiac aspects in patients with different genotypes. Br J Haematol 2007; 136:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/88\">",
"      Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol 2006; 133:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/89\">",
"      Pan LL, Eng HL, Kuo CY, et al. Usefulness of brilliant cresyl blue staining as an auxiliary method of screening for alpha-thalassemia. J Lab Clin Med 2005; 145:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/90\">",
"      Lorey F, Cunningham G, Vichinsky EP, et al. Universal newborn screening for Hb H disease in California. Genet Test 2001; 5:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/91\">",
"      Carr S, Rubin L, Dixon D, et al. Intrauterine therapy for homozygous alpha-thalassemia. Obstet Gynecol 1995; 85:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/92\">",
"      Naqvi J, Marrow W, Nisbet-Brown E, et al. Normal development of an infant with homozygous alpha thalassemia (abstract). Blood 1997; 90(suppl 1):132a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/93\">",
"      Lee SY, Chow CB, Li CK, Chiu MC. Outcome of intensive care of homozygous alpha-thalassaemia without prior intra-uterine therapy. J Paediatr Child Health 2007; 43:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/94\">",
"      Singer ST, Styles L, Bojanowski J, et al. Changing outcome of homozygous alpha-thalassemia: cautious optimism. J Pediatr Hematol Oncol 2000; 22:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/95\">",
"      Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 2005; 116:e818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/96\">",
"      Lal A, Goldrich ML, Haines DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011; 364:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/97\">",
"      Sutcharitchan P, Embury SH. Advances in molecular diagnosis of inherited hemoglobin disorders. Curr Opin Hematol 1996; 3:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/13/38106/abstract/98\">",
"      Orofino MG, Argiolu F, Sanna MA, et al. Fetal HLA typing in beta thalassaemia: implications for haemopoietic stem-cell transplantation. Lancet 2003; 362:41.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7116 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.12-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38106=[""].join("\n");
var outline_f37_13_38106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11049855\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BETA THALASSEMIA MAJOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Skeletal changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Liver and gallbladder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Kidneys",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Endocrine and metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cardiopulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Aplastic crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19407982\">",
"      - Chronic pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Red blood cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Iron studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9655434\">",
"      - Other laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4178107\">",
"      Extramedullary hematopoiesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Hemoglobin electrophoresis patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CLINICAL HETEROGENEITY OF BETA THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Beta thalassemia minor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8127371\">",
"      - Protection against arterial thromboembolic events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hemoglobin electrophoresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Beta thalassemia intermedia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Effect of concomitant alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21924630\">",
"      Effect of fetal hemoglobin levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Other causes of disease variability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diagnosis and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      THE ALPHA THALASSEMIA SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Nomenclature and diagnostic patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Alpha thalassemia minima",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Alpha thalassemia minor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Hemoglobin H disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Acquired hemoglobin H disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Hydrops fetalis and hemoglobin Barts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Hemoglobin Constant Spring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11049845\">",
"      - Non-deletional Hemoglobin H disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      GENETIC COUNSELING AND ANTENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Hemoglobin H disease or hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11049855\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20826087\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11049863\">",
"      Beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11050084\">",
"      Alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7116\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7116|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/13/35025\" title=\"diagnostic image 1\">",
"      Extramed hematopoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7116|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/33/7711\" title=\"figure 1\">",
"      Electrophoresis hgb H",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7116|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/29/27089\" title=\"picture 1\">",
"      Beta thalassemia intermedia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/23/30071\" title=\"picture 2\">",
"      Beta thalassemia trait",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/49/15123\" title=\"picture 3\">",
"      Hgb H inclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/41/20113\" title=\"picture 4\">",
"      Hemoglobin H disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7116|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/24/42380\" title=\"table 1\">",
"      Lab findings thalassemias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/53/28507\" title=\"table 2\">",
"      Beta thal intermedia variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/56/18316\" title=\"table 3\">",
"      Hgb electrophoresis patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/17/16667\" title=\"table 4\">",
"      Sickle trait alpha thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/24/1416?source=related_link\">",
"      Asymptomatic hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41783?source=related_link\">",
"      Community public health issues and the thalassemic syndromes: Lessons from other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5529?source=related_link\">",
"      Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/51/41784?source=related_link\">",
"      Isolated left ventricular noncompaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/968?source=related_link\">",
"      Laboratory diagnosis of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=related_link\">",
"      Molecular pathology of the thalassemic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/53/3929?source=related_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/14/7394?source=related_link\">",
"      Patient information: Thalassemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4808?source=related_link\">",
"      Polyhydramnios",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/26/24999?source=related_link\">",
"      Prenatal testing for the hemoglobinopathies and thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_13_38107="Reducing absorption";
var content_f37_13_38107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Steps to take to minimize lead absorption in your family",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Make sure that your children wash their hands and face before eating and sleeping.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Prevent your children from eating things other than food (eg, dirt, paint).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Make sure that all surfaces (floors, countertops, tabletops, etc) have been thoroughly cleaned with a detergent. This is especially important for toddlers since they crawl and lay on the floor and frequently put their hands in their mouths.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. If your home was built prior to 1977, it is extremely important to remove any flaking or peeling paint in the house, since older homes frequently were painted with lead-based paint. Hire or consult a professional certified in lead paint abatement. Painting over lead-based paint, or applying wallpaper, are only temporary ways to control exposure, and are not acceptable means of control. Protective equipment and respirators must be worn in the removal of lead-based paint from walls and woodwork.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Make sure that your children receive the recommended daily allowance of multivitamins with iron. They should have well-balanced diets that include a combination of fruits, vegetables, grains, protein, and dairy products.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Do not use herbal or folk medicine (these may contain lead).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. If you are not sure if your pottery has a lead glaze, use it only for decoration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Store food in glass, plastic, or stainless steel containers, not in open cans.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Use water from the cold tap for cooking and drinking. Let it run for several minutes before collecting for use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Be careful to keep materials for hobbies, such as those used for making ceramics or stained glass, away from children and areas where they spend time.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38107=[""].join("\n");
var outline_f37_13_38107=null;
var title_f37_13_38108="PSI Step 2";
var content_f37_13_38108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pneumonia Severity Index Step 2: risk factors and assigned points",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Demographic factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age for a man",
"       </td>",
"       <td>",
"        Age (in years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age for a woman",
"       </td>",
"       <td>",
"        Age (in years) - 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nursing home resident",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Coexisting illnesses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neoplastic disease (active)",
"       </td>",
"       <td>",
"        +30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic liver disease",
"       </td>",
"       <td>",
"        +20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heart failure",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cerebrovascular disease",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic renal disease",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Physical examination findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Altered mental status",
"       </td>",
"       <td>",
"        +20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory rate &ge;30/minute",
"       </td>",
"       <td>",
"        +20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systolic blood pressure &lt;90 mmHg",
"       </td>",
"       <td>",
"        +20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temperature &lt;35&deg;C or &ge;40&deg;C",
"       </td>",
"       <td>",
"        +15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulse &ge;125 beats/minute",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Laboratory and radiographic findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Arterial pH &lt;7.35",
"       </td>",
"       <td>",
"        +30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blood urea nitrogen &ge;30 mg/dL (11 mmol/L)",
"       </td>",
"       <td>",
"        +20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium &lt;130 mmol/L",
"       </td>",
"       <td>",
"        +20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose &ge;250 mg/dL (14 mmol/L)",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hematocrit &lt;30 percent",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Partial pressure of arterial oxygen &lt;60 mmHg*",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleural effusion on chest x-ray",
"       </td>",
"       <td>",
"        +10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Or an oxygen saturation of &lt;90 percent on pulse oximetry.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Fine, MJ, Auble, TE, Yealy, DM, et al. N Engl J Med 1997; 336:243.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38108=[""].join("\n");
var outline_f37_13_38108=null;
var title_f37_13_38109="Plasma AAT after IV replacement";
var content_f37_13_38109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Efficacy of weekly infusions of alpha-1 antitrypsin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serum alpha-1 antitrypsin (AAT) levels by immunodiffusion after once weekly administration of 60 mg/kg of active AAT to patients with the ZZ homozygous form of AAT deficiency. The dashed line represents the protective threshold. Weekly infusions (arrows) maintained the serum A1AT levels above this threshold. Values are in commercial standard units of mg/dL; the true standard levels in &micro;mol/L can be&nbsp;estimated by dividing the&nbsp;immunodiffusion value by 7.3.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hubbard RC, Crystal RG. Am J Med 1988; 84(Suppl 6A):52.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38109=[""].join("\n");
var outline_f37_13_38109=null;
var title_f37_13_38110="Flow fraction and solute saturation";
var content_f37_13_38110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F76066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F76066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Flow fraction and solute saturation in hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 380px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data reproduced with permission from: NxStage Medical, Inc. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38110=[""].join("\n");
var outline_f37_13_38110=null;
var title_f37_13_38111="Hand expression PI";
var content_f37_13_38111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Hand method to release breast milk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hold your hand in a c-shape, with your thumb on top. Press your thumb gently on your breast straight back into the chest. Then, roll your thumb and fingers toward the nipple. Breast milk should come out of the nipple. Keep doing this as you move your hand around the whole breast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_13_38111=[""].join("\n");
var outline_f37_13_38111=null;
